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ABSTRACT
The initial aim of this research was to discover and characterise new members of the 
G-protein linked receptor (GPLR) superfamily. There is an abundance of molecules 
which elicit a physiological response in the central nervous system (CNS) but have not 
yet had their mechanism elucidated. Because of recent work in this area there have 
been many new GPLRs discovered corresponding to many of these potential ligands 
and this area of research remains a rapidly expanding area of great interest in medical 
and physiological research.
Using sequence homology the receptors were grouped and degenerate primers were 
designed towards motifs specific to certain groups. These primers were then used to 
amplify sequences via the polymerase chain reaction (PCR) which could then be 
characterised.
The dopamine receptors are a subgroup of the GPLR superfamily containing five main 
members (D1 - D5) all related by sequence homology and their recognition of 
dopamine as the major ligand. They are of particular interest because they are the 
primary targets of drugs used in the treatment of psychomotor disorders (eg 
Parkinson’s disease); however the reason for the range of the members with their 
different affinities for dopamine and different distributions within tissues still remains 
to be discovered.
This project aims to isolate members of this family by PCR and investigate their 
pharmacological properties in relation to each other.
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SECTION A
CHAPTER 1 
INTRODUCTION
Section A: Introduction - Chapter 1
Research into novel G Protein Linked Receptors
G-protein linked receptors (GPLRs) are crucial components of intercellular 
communication and important targets for drug development. The work described 
in this thesis was aimed at:
a) the discovery of novel GPLRs, and
b) the investigation of the molecular biology of specific drug interactions 
on a particular subset of GPLRs, the dopamine D2-like receptors
Therefore it is necessary to outline both the general properties and importance of 
GPLRs, and to describe the specific features of dopamine receptor biology and 
pharmacology.
Communication between cells and external factors is vital for the cells to respond 
in the appropriate way to allow development, co-ordinate growth, differentiation, 
perception, adaptation and ultimately survival of the organism. For this 
communication to occur there has to be a link between the exterior and interior of 
the cell to allow information to be relayed through the biological surface membrane 
which surrounds each cell. This transfer of information can be both by the 
physical movement of a substance in either direction, by diffusion for gases such 
as oxygen and carbon dioxide or via more complex systems, such as ion channels 
and surface receptors. Such highly specialised transmembrane signalling systems, 
along with a vast number of specific messenger molecules eliciting specific 
responses, enables the immense and complex functioning of the central nervous 
system (CNS).
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1.11 Ion Channels
Ion channels are protein channels spanning membranes, which allow specific ion 
types (eg K+ or Na+) to pass through in a direction determined by their 
electrochemical gradient. Therefore, unlike diffusion, their action is controlled 
and the channels may be either open or closed depending upon triggers such as a 
change in voltage (voltage-sensitive channel), or a signal created by the binding of 
a ligand to an adjacent receptor molecule (chemically activated channel).
Ion channels are necessary because the lipid bilayer of the cell membrane has a 
high electrical resistance; therefore charged particles such as ions require a special 
passage which allows rapid transfer and give neurons the property of excitability 
(Barker etal, 1991).
1.12 Receptors
'Cell surface receptors are primary targets for pharmacological interference with 
physiological processes' (Burbach & Meijer, 1992); they are membrane spanning 
proteins which are components of a signal transduction system. The receptor 
receives extracellular signals, by the binding of a specific ligand, and relays the 
signal through the membrane (probably by a conformational change) to an 
intracellular component which effects a cascade of events, in response to the initial 
stimulus; therefore the receptor also amplifies and integrates extracellular signals 
(Dohlman etal, 1991).
Nearly all receptors and their subtypes are expressed in the brain and this is 
thought to provide the cells with a greater potential adaptive function for CNS 
information handling capabilities (Schofield et al, 1990). CNS receptors are 
situated mainly in the post and pre-synaptic membranes and can be classified into 
three main families according to the components of their signal transduction
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mechanism, however their classification is becoming more difficult as the range 
increases with the discovery of new members. The main classes are:
1) receptors with an intrinsic ligand-gated ion channel (eg nicotinic 
acetylcholine receptors)
2 ) those containing an intracellular enzymatic domain (eg insulin receptors)
3) those coupled to a guanine nucleotide-binding regulatory protein (G- 
protein) which in turn triggers the appropriate second messenger system or 
ion channel (Burbach & Meijer, 1992).
This scientific study focuses on the latter group of G-protein linked receptors 
(GPLR). This is a fast expanding superfamily of receptors found as different 
populations in most tissues of most organisms from viruses and bacteria to 
humans. They are of great significance in the elucidation of CNS function and 
control.
1 .2  Drug Development
GPLRs are involved in the transduction of many diverse extracellular signals 
including light, odorants, biogenic amines (products of cellular metabolism) and 
peptides. They consequently are of great interest from the view of drug 
development for major human disorders including those of the digestive system, 
heart and circulatory system, and of the central nervous system (CNS) (Dohlman 
etal, 1991).
Discovery of new receptor subtypes and specific ligand tests have become the 
basis of drug development. In the past few years this area has expanded greatly, 
especially on the molecular front. This opens up the possibility of great advances 
in the development of drugs for the associated physiological diseases. The 
increasing speed of discovery of new receptors and the increase in understanding
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of their functions and interactions illustrate the impact of molecular research in this 
field. Technical advances have allowed the pharmacology, biochemistry and 
molecular genetics of the whole of mechanism of signal transduction and its 
associated effector processes to be studied.
It has been discovered that the involvement of GPLR in disease aetiology can be 
direct when sequence mutations cause the receptor to be constitutively active. An 
example of this is a somatic mutation in the thyrotropin receptor which causes 
constitutive stimulation of adenylyl cyclase and produces hyperfunctioning thyroid 
adenomas leading to hyperthyroidism. This occurs because the mutation is at a 
region of association with the G protein (Gs) and seems to eliminate the 
desensitisation mechanism. The receptors therefore are acting as proto-oncogenes 
producing excess cAMP which stimulates function and growth in the thyroid 
tissues (Parma etal, 1993).
Alternatively the receptor may not be the direct cause of illness but acts as a 
convenient point for drug intervention as with the treatment of Parkinson's 
Disease with L-Dopa.
Those GPLR found in the CNS are of particular interest in the study and treatment 
of neurological and psychiatric disorders such as Parkinsonism, Alzheimer's 
Disease and schizophrenia. The cloning of these receptors is an important advance 
in improving existing and developing new drug synthesis programs and is vital in 
discovering the extent of CNS involvement in the way the drugs have their action.
1 .3  History Of G-Protein Linked Receptor Research
The field of receptor research has evolved from the early work of people such as 
Ahlquist (1948), who first divided the adrenergic receptors into pharmacological 
subtypes. During recent years great advances have been made, with the cloning of
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increasing numbers of new receptors and additional subtypes of previously 
discovered receptors. Subtypes are defined as those members of a receptor family 
with significant structural and sequence homology but differences in the coupled 
effector pathway and ligand binding pharmacological profiles (Schofield et al.
1990). As new subtypes are detected, the number and size of subclasses in the 
GPLR superfamily increases, in some cases leading to new groups being defined, 
for example the 'VIP-like' class, (including the secretin, bombesin, and VIP 
(vassoactive intestinal peptide) receptors). This increase in number can cause 
problems with nomenclature and classification.
Now that the sequences of many members of the GPLR superfamily have been 
obtained, the DNA directed approach is the principal area of new advances. 
Cross-species screening has revealed equivalent receptor genes in different species 
and new related receptors are constantly being discovered using degenerate oligos 
for conserved regions in the transmembrane (TM) regions (Libert et al, 1989). 
Originally the technique of library screening was sufficient to uncover relatives 
however PCR has become increasingly important in uncovering those receptors 
present at very low levels in tissue (Burbach & Meijer, 1992).
Two receptors of the GPL type which have been of particular significance in the 
study of this superfamily, are rhodopsin and the p-adrenergic receptors (p-AR). 
Rhodopsin mediates conversion of light energy into a neurochemical signal 
(phototransduction). It is synthesised only in the retinal rod cells, at very high 
concentrations, which has facilitated its purification and subsequent 
characterisation. The bovine gene was cloned first in 1983 followed by the human 
gene the following year (Nathans & Hogness, 1984). Analysis of the sequence 
revealed seven stretches of hydrophobic amino acids representing possible 
membrane-spanning domains. This hypothesis was derived using the hydropathy 
analysis of Kyte and Dolittle (1982), which indicated a very similar profile to that
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of bacteriorhodopsin - a non-G-protein linked membrane proton pump protein 
from Halobacterium halobium. This protein structure had previously been 
determined by image reconstruction from electron microscopy and found to 
contain seven a-helices spanning the lipid bilayer (Henderson et al, 1990). 
Proteolytic mapping of rhodopsin and p2-adrenoceptor supports this topography 
(Ovinnikov, 1982) and although still the subject of controversy due to the lack of 
structural evidence for other GPLR this structure has become a characteristic of 
GPLRs (Hoflack etal, 1994), (Figure 1.3, p6 a).
1.31 Adrenoceptors as Model Receptors
The adrenoceptors (AR) have been studied as the model system for the 
mechanisms of GPLRs since the first of their class, the mammalian p2- 
adrenoceptor (P2-AR), was cloned and found to be homologous to rhodopsin, 
relatively early on (Dixon et al, 1986). It has since been particularly useful for 
relating structural information to biological function.
The previous attempts to clone these receptors had encountered difficulty, due to 
the problem of purification. p-AR are only present at very low concentrations in 
most mammalian tissues (-0.001% mRNA) which has been a difficulty common 
in all GPLR studies (Lefkowitz et al, 1983). This has now been overcome by 
advanced techniques such as polymerase chain reaction (PCR).
Initially, the production of cAMP had been demonstrated to be controlled by the 
catecholamine neurotransmitters adrenaline and noradrenaline binding to receptors 
distinct from the effector enzyme adenylyl cyclase (Robison et al, 1967). A third 
component of the system was discovered when the requirement of guanine 
triphosphate (GTP) was observed for hormonal activation of adenylyl cyclase, in 
vitro (Rodbell eta l, 1980) and subsequently an adenylyl cyclase-stimulatory, 
GTP-binding protein (Gs) was purified and cloned (Gilman, 1987). Prior to
6
Figure L.3 Proposed membrane topography of G-protein linked receptors.
Sites marked a-g indicate proposed interaction sites for ligand binding 
to B-adrenergic receptors (table 1.7a).
l ipid
b i l a y e r
COOH
Key : a - asparagine 79
b - asparagine 113 
c - serine 165 
d - serine 204 
e - serine 207 
f - phenylalanine 290 
g - tyrosine 326
|  - glycosylation 
@ N6 & N15
> - palmytolation @ C341
* * * - regions involved in
G-protein coupling
The putative disulphide bridge between cysteine residues on E l and E2 
is shown as are the glycosylation sites on the N-terminus (N6 & N15) and the 
palmytolation site on the C-terminus (C341)
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cloning the receptors involved had already been identified and subdivided into a ,  
pi and p2 types, using ligand binding studies (Lands etal, 1967).
Today there are nine distinct cloned AR subtypes, six alpha and three beta, alike in 
sequence homology but pharmacologically discrete. Research has revealed a great 
deal about their signal transduction mechanisms which can be applied through 
structural homology to GPLR in general.
The pi and p2 adrenoceptors were the first GPLR to have their signalling pathway 
elucidated (Kobilka etal; 1987; Frielle etal, 1987), from the involvement of the 
stimulatory G-protein intermediary, to the coupling to the second 
messenger/effector system adenylate cyclase which brings about a cascade of 
further events including cAMP dependant phosphorylation of many target proteins 
(Summers & McMartin, 1993).
1 .4  G -Protein In teractions and Second M essenger Systems 
Kobilka et al (1988) produced chimeras from a 2 & p2 adrenoceptors to study 
receptor-G-protein interactions. The receptors respectively inhibit (via GO and 
stimulate (via Gs) adenylyl cyclase but are both activated by adrenaline. By 
studying the ligand binding and effector activating properties of these chimeras 
within cell systems, structural domains were deduced, determining the specificity 
of ligand binding and effector coupling.
The results showed that the 5th and 6 th TM domains, the 3rd cytoplasmic loop 
and the C terminus contained specificity for the Gs coupling to the p2 
adrenoceptor, confirming that G-protein interaction with the receptor is complex 
and can not be isolated to one particular domain, preventing allocation of specific 
G-protein interactions by identification of specific receptor consensus sequences.
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The present knowledge of the transmembrane signalling system indicates the 
following situation:
1) a receptor spanning the cell surface membrane
2) a G-protein situated on the inside surface of the membrane and able to 
interact with both the receptor and effector
3) an effector/second messenger system - eg adenylyl cyclase, phospholipase 
C, ion channels or other enzymes such as cGMP phosphodiesterase (as in 
the case of rhodopsin) (Dohlman etal, 1991).
All three peptides in the pathway are membrane associated. Binding of the 
extracellular agonist turns the intracellular face of the receptor into a catalyst that 
can dock with the G-protein and promote the exchange of cytoplasmic GTP for the 
GDP usually bound to the G-protein at rest. (Stemweis & Pang, 1990; Hille,
1992).
Following the discovery from adrenergic receptor research that control of cAMP 
production was due to the binding of extracellular catecholamines to a receptor 
discreet from adenylyl cyclase, it was found that receptor signal transduction was 
regulated by GTP (Rodbell et al, 1971). This initial work was performed on 
hormone receptors and was the first indication of the existence of G-proteins. 
Now it is recognised that the action of many stimuli including odorants, photons, 
cytokines, peptides, neurotransmitters and even sensory stimuli is mediated by 
receptor signal transduction pathway involving G-proteins.
Since the cloning of the first G protein (Gs), which stimulates the adenylyl cyclase 
system (Gilman, 1987), many forms of G-proteins have been discovered. They 
fall into several groups as classified by their a  subunit:
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a) Gs - stimulates adenylyl cyclase and regulates calcium channels
b) Gi and G0 - affect several secondary messenger systems including 
inhibition of adenylyl cyclase, stimulation of cGMP phosphodiesterase and 
regulation of ion channels
c) Gq- stimulates phospholipase C
Unstimulated, the G complex is a stable heterotrimer of three subunits (a,p  & y) 
which dissociates into two parts when GDP is replaced. The a-GTP moiety 
associates with the effector (eg adenylyl cyclase, phospholipase C) and influences 
second messenger production (eg cAMP, inositol phosphate (IP3)). The Py moiety 
also acts as a signal for different effector subtypes, in the case of rhodopsin 
triggering an alternative primary effector for rhodopsin (Stemweis & Pang,
1990).
The point at which the receptor couples to the G protein is amplificatory and 
pleiotropic. Many G protein molecules of the same species are stimulated by the 
receptor (when bound to an agonist) and multiple systems are subsequently 
affected. However, different receptors have the capability to bind to several 
different species of G-protein in certain orders of selectivity depending upon their 
primary sequence, secondary structure and host cell environment (Watson & 
Arkinstall, 1994).
The a , p and y subunits of G proteins are encoded by separate genes. To date 
there are at least 17 a , 4p and 6 y genes, with more products possibly produced by 
alternative splicing (Simonetal, 1991). The greatest diversity is found in the a  
subunit group, which is expected as this subunit performs the physical interaction 
with the receptor. This subunit also contains an integral GTPase activity and 
canries the GDP moiety associated when the G-protein is at rest.
9
Section A: Introduction - Chapter 1
The receptor, when stimulated by agonist binding, physically couples to the a  
subunit of the appropriate heterotrimeric G-protein. This triggers the exchange of 
bound GDP for cytoplasmic GTP raising the G-protein momentarily to an 
activated state. Whilst activated the a  subunit dissociates from the receptor and 
from the p and y subunits which remain as one unit, and these then regulate 
effector activities. The a  subunit's innate GTPase activity hydrolyses the GTP, 
returning the subunit to the inactive state allowing reassociation with the py unit. 
Antagonist binding does not trigger the exchange of GDP to GTP and hence does 
not trigger signal transduction (Hille, 1992).
1 .5  Receptor Topology
The problem in obtaining a 3D model of any of the GPLR superfamily is that due 
to their low abundance and membrane association. Manipulation is difficult and it 
has not been possible to generate ordered 2D and 3D structures from the proteins 
or to carry out X-ray crystallographic analysis. This however has been performed 
for bacteriorhodopsin (Henderson et al, 1990), an integral membrane protein 
which is a light-driven proton pump from the prokaryote Halobacteriumhalobium. 
Although not G-protein linked, this protein bears a functional resemblance to the 
mammalian membrane bound photoreceptor rhodopsin (they are both involved in 
photoisomerization of a covalently linked retinal chromophore) and a 3D folding 
pattern identical to that predicted for rhodopsin and other GPLR (Savarese & 
Fraser, 1992). Through further structural studies a topological model for 
bacteriorhodopsin was established, which could be applied to rhodopsin and in 
turn to GPLR in general (Ovchinnikov etal, 1979 & 1982).
Much of the current structural information has been deduced from rhodopsin and 
P-adrenergic receptors and applied to the many other members of the family using 
hydrophobicity profiles (Lentes et al, 1993) and primary sequence homology 
analysis (Dixon et al, 1986). However, there have been other modelling
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approaches using amino acid side chain interaction energies (Roper et al, 1994) 
and computer generated 3D models (Hibert et al, 1991; Probst et al, 1992; 
Baldwin, 1993) using combined sequence and structural information. All 
methods result in the same general structural conclusions:
1) The general structure consists of 7 segments of 20-28 hydrophobic amino 
acids, which are predicted to form a-helical structures.
2) These a-helices are arranged through the lipid bilayer and linked by 3 
extracellular and 3 intracellular loops of residues.
3) The a-helices are orientated so that polar residues, conserved residues and 
any residues known to be involved in ligand binding, are located towards 
the inner core of the model, so a 'binding-pocket' is formed.
4) The N terminus of the protein lies to the exterior of the cell membrane and 
the C terminus to the interior (cytoplasmic side).
However they differ in the finer details of helical arrangement (Donnelly et al, 
1994).
It is important that work continues into verifying bacteriorhodopsin as a template 
for GPLR modelling as this is crucial in understanding ligand binding and 
rationalising drug design (Hoflack et al, 1994). Some controversy over the 
validity of bacteriorhodopsin appears to be regarding the differences in electron 
diffraction projection maps for bovine rhodopsin and bacteriorhodopsin (Hibert et 
al, 1993). This confirms that both proteins have seven transmembrane a-helices, 
but that they may not have the same topology. However the situation appears to 
be explained by differences in packaging of the helices and the angles with which 
they penetrate the membrane (Baldwin, 1993; Hoflack et al, 1994). Also it has 
been discovered that bacteriorhodopsin has different crystal forms depending on
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the crystallisation conditions, which affects the protein packaging and may explain 
the differences in projection maps (Schertler etal, 1993).
A further general feature is the mechanism of signal transduction, elucidated by 
work on the p2-adrenoreceptor (O'Dowd et al, 1989; Summers & McMartin,
1993). Members of the GPLR superfamily have been shown to be analogous to 
these model receptors in both structure and function.
1 .6  Evolution
The conservation of amino acid sequence and domain organisation suggests that 
these mechanistically related receptors have evolved by gene duplication from a 
common ancestral gene. The existence of so many genes for this information 
handling capacity indicates the biological importance of their function for 
evolutionary survival and species adaptation presumably by increasing the 
information handing capacities of tissues. This adaptive system offers the greatest 
flexibility for the vast heterogeneity of receptor subtypes (Schofield etal, 1990).
Many of the genes encoding GPLR have been mapped in both rodents, and more 
recently humans, and the results show that the loci are well dispersed throughout 
the genome. Interspecific backcross analysis was used and the data was used to 
predict human chromosomal locations based on linkage homologies identified 
between human and mouse. Even close family members are at distant loci, for 
example the dopamine receptors were mapped to human chromosomes 11 (D2 & 
D4), 3 (D3), 4 (D5) and 5 (Di) (Wilkie etal, 1993).
It is known that basic cellular transmitters and their receptors developed very early 
phylogenetically (Walker & Holden-Dye, 1989). Subsequent evolution of many 
more receptor subtypes was required as the nervous system became more 
complex. To explore the relationship among the GPLR superfamily, a
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phylogenetic tree has been constructed using nucleotide sequence information, 
which suggests that two of the major groups the opsin and catecholamine 
receptors diverged from a common ancestor over 1 billion years ago (Yokoyama et 
al, 1989) and the fact that these receptors are present in such a wide range of 
species including yeasts, indicates the importance of their function.
There are two mechanisms by which the superfamily could evolved to such a size 
and complexity. Duplication of existing genes appears to be likely (Onho, 1970) 
and is indicated by the relative preservation of intron location, which tend to be 
between TM domains. The D2-like dopamine receptors are a good example of 
this, but there is also positional conservation to a lesser extent between this group 
and the tachykinins (Probst etal, 1992). The second mechanism is retroposition, 
as most of the receptor genes are intronless, indicating that they arose through 
reverse transcription of mRNA and incorporation into the genome (Brosius etal,
1991). However, convergent evolution is also evident as some receptors show no 
sequence relation to others (eg the secretin/VIP group).
Alternative splicing is also involved to a lesser extent in producing separate 
receptor isoforms. An example of this is the D2 receptor gene which produces a 
splice variant lacking 29 amino acids of the third cytoplasmic loop (D2 Short and 
D2iong> see below), (Grandy etal, 1989).
1.7 Associating Structure to Function
With respect to amino acid sequence the transmembrane domains have been found 
to be the most conserved regions and the remaining loops and termini more 
divergent. Together with the structural information available this has led to 
investigation of various receptor structure/function relationships (Attwood et al,
1991).
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From a comparison of different areas of coding sequences it appears that genes 
from different receptor classes are subject to different selective pressures. For 
example the two groups adrenergic and muscarinic acetylcholinic receptors have 
some shared conservation especially in the transmembrane domain sequences, but 
also different patterns of conservation within their own groups involving the loop 
regions (Burbach & Meijer 1992). The same occurrence has been recorded for 
neuropeptide GPLR, when sub-grouped as secretin/VIP-like and neurokinin-like 
receptors.
For ease of comparison the amino acid sequences have generally been divided into 
domains E l-3 (the three extracellular loops), 11-3 (the three intracellular loops), 
TM1-7 (the seven transmembrane a-helices) and the C (carboxy, internal) and N 
(amino, external) termini. This overcomes the difficulties caused by differences in 
the length of receptor sequences, allowing for a more accurate alignment.
1.71 Transmembrane Domains
Even though these are the most conserved domains the degree of homology 
depends on how closely receptors are related. A study comparing the P2-AR and 
muscarinic receptors revealed that the most conserved regions within these 
domains were those nearest to the cytoplasmic side of the membrane. This may be 
due to interactions with common cytoplasmic effectors, ie G proteins which have 
highly conserved structures. The extracellular sides are less conserved, and as the 
ligand interaction is likely here, this may possibly be due to the individual ligand 
binding profiles (Dohlman etal, 1988).
A great deal of work has been done by many groups on sequence conservation 
and this has identified a variety of conserved residues specific to different 
subclasses, which are possibly involved in ligand binding. (Strader et al, 1994; 
Probst etal, 1992) (Tables 1.7a & 1.7b).
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Several proline residues are conserved in TM4, 5, 6  and 7 between many groups 
within the GPLR superfamily. These residues aren’t commonly found in a  
helices as they cause kinks to the structure. It is expected that such conservation 
indicates an involvement in the tertiary structure required for functional activity. 
Brandi & Deber (1986) proposed that they may be responsible for conformational 
changes, triggered by ligand binding, whilst Applebury & Hargrave (1986) 
suggest that the bent helices may interlock to create a ligand accommodating 
pocket.
The transmembrane domains are demarcated by positively charged residues at the 
internal surface. This is common in membrane integrated proteins and may 
determine the correct orientation of the protein in the membrane and secure it there 
(O'Dowd etal, 1989).
1 .7 2  Intra and Extracellular Loops
The loops of residues linking the transmembrane regions of the GPLRs have 
variable lengths between receptor types, however the functions they perform seem 
to be conserved. The extracellular loops appear not to contain residues directly 
associated with ligand binding, but rather have a conformational role. Most 
receptors contain conserved cysteine residues in the extracellular loops E l & E2 
which form a disulphide bond essential for the correct interaction of ligands 
(Dixon etal, 1987). (See '1.8 Structural Modifications')
On the intracellular side of the receptor all three loops, along with the C terminus, 
are responsible for the G-protein interaction. Charged residues have been 
identified in several receptors at the membrane proximal regions of loop 12 (in the 
highly conserved DRY sequence) and 13 which when mutated reduce dramatically 
G-protein coupling. These sites along with other residues in the C terminus and 
TM2 and 6  permit the complex association to the G-protein (Probst et al, 1992).
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Putative phosphorylation sites have also been discovered on 13, which are 
thought to be utilised in the process of desensitisation (O'Dowd etal, 1989).
1.73 Terminal Regions
There appears to be no general functional role for the amino terminus as it lacks 
homology in sequence of length. It has been suggested that it may be an 
uncleaved signal sequence (Singer et al, 1987) and may protect this end form 
proteolytic attack due to its possession of putative glycosylation sites.
The C terminus is thought to be involved in modulation of receptor sensitivity, in 
response to the intensity or frequency of stimulation. This is known as 
desensitisation and is a negative feedback regulation of receptor function involving 
a rapid reduction in response to continuation of the same stimulus, displayed by all 
characterised GPLRs (Dohlman et al, 1991). There are two forms of 
desensitisation. The homologous mechanism involves a single receptor molecule 
which becomes modified by phosphorylation at the serine and threonine sites on 
the C terminus (Thompson & Findlay, 1984) and the binding of inhibitory 
proteins to decrease activity. In extreme cases of prolonged agonist exposure the 
receptor may be 'down-regulated' where it is endocytosed from the membrane and 
destroyed. Heterologous desensitisation is thought to be a more general 
mechanism, initiated by the over stimulated second messenger (eg cAMP initiates 
desensitisation of adenylyl cyclase systems), (Perkins, 1991). The result of both 
mechanisms is attenuation of the G protein coupling stage of the pathway and 
mutational work on the TM7 adjacent region of the C terminus indicates it as an 
interaction site for the G protein (Ostrowski etal, 1992).
A significant number of serine and threonine residues in the C terminus of most 
GPLRs are substrates for specific phosphorylases, the protein kinases PKC and 
PKA, which act when the receptor is stimulated (Benovic et al, 1986). Mutants
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for these residues have been shown to eliminate desensitisation but there is still 
argument against the theory as the pattern of conservation in this region is poor. 
(O'Dowd etal, 1989; Dohlman etal, 1987)
1.74 Chimeric Experiments and Ligand Binding
This approach has become more popular for the study of these functionally 
complex molecules, as conclusions can be drawn from qualitative changes in 
receptor function such as acquisition of new functions that can be correlated with 
specific protein sequences. The mutagenesis approach provides more limited 
information as the end result is loss of function however it can be used to pin­
point the involvement of an area as small as one residue. Substitution mutagenesis 
also has be carefully evaluated as the result depends greatly on the nature of the 
replacement residue.
The structure receptors when modelled on bacteriorhodopsin appear to form a 
hydrophobic 'pocket' which would allow ligand binding (Baldwin, 1993).
Ligand interaction sites occuring within TM regions of receptors provides more 
evidence for a binding 'pocket'. These conserved residues, when mutated, affect 
ligand binding and signal transduction (see Table 1.7a, pl7a).
Although certain receptors are used as models when investigating certain aspects 
such as ligand binding it should be noted that this does not always give a realistic 
view not least because of the range of different ligands involved (Neve & Wiens,
1995). This is particularly obvious in the case of peptide receptors.
The proposed models for ligand binding in different classes of GPLR all take into 
account charged and aromatic residues within the 'pocket' and propose an 
interaction of ligand to receptor which could form a network of aromatic-aromatic
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Table L 7a Key sites fo r  ligand interaction with biogenic amine binding GPLRs
Receptor TM Residue Structure Function
Rhodopsin TM3 G lull3 side-chain counterion for Schiff base
TM7 Lys296 E-amino group side-chain
Schiff base formation 
with rhodopsin
P-adrenoceptor 
a
TM2 Asp79b agonist efficacy, transduction of signal
TM3 A spll3c side-chain counterion for ligand binding
TM4 Seri 65 OH side-chain ligand binding sited
TM5 Ser204e
Ser204
OH side-chain H-bond formation for agonists and signal 
transduction
TM6 Phe290e stabilizes aromatic ring of catecholamine ligands
TM7 Asn312 side-chain phenoxypropanolamine antagonist binding sitef
TM4
&
TM5
binding pocket multiple residue interactions determining 
agonist specificity s
E>2 dopamine TM2 Asp 80 ligand binding and signal transduction1
TM3 A spll4 ligand binding site
TM5 Seri 94 
Seri 97
H-bond formation for 
agonists and signal 
transduction
TM6 Leu387
Phe389
Phe390
conformational change 
for signal transduction
TM7 Phe411 signal transduction
[Reviewed in Strader etal 1994]
a p-adrenoceptor is a model receptor for all biogenic amine GPLRs and members of the GPLR 
family in general
b a corresponding aspartic acid residue occurs in all biogenic amine receptors and has been 
shown in several to have the same function (eg a-AR, muscarinic, histamine)
c most GPLRs have this highly conserved residue which has been shown to have the same 
function in many (eg a-AR, angiotensin, 5HT2, NK1, D2)
d this residue is hypothesised to have this function as it mutation results in processing error 
and non-expression
e these residues are conserved in all catecholamine receptor which suggests co-evolution with 
the ligands
f conserved in biogenic amine receptors which bind phenoxypropanolamine antagonists with 
high affinity
§ region determined by chimeric work - no single residue determined specificity
1 Neve et al, 1991
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and hydrogen bonding interactions possibly leading to the proposed 
conformational change (Trumpp-Kallmeyer etal 1994).
Work on the tachykinin receptors (neuropeptides) has discovered that binding for 
peptide receptors appears to be much more complex.
1.75 Peptide Receptors
The size of ligands for this group of receptors is generally much larger than for the 
biogenic amines. Some peptides can be up to 40 residues in size (eg glucagon) 
and therefore modelling suggests that binding can not be supported by TM 
interactions alone (Strader eta l, 1994). Mutagenic and chimeric studies have 
revealed that extracellular regions are involved, including the N terminus (Regoli, 
etal 1989) and all three extracellular loops (Fong et al, 1992). Research has been 
unable to pinpoint interaction sites to individual residues in many areas. The 
discovery that the neurokinin peptides occur as different conformations when in 
solution has lead to the hypothesis that selectivity may be determined by the the 
degree of conformational compatability between each peptide and the binding 
pocket of the receptor (Savian et al, 1992). Some individual residues involved 
have been discovered both in the extracellular domains and in the TM regions. 
However the situation is further complicated by the seperate but overlapping 
binding sites for peptide agonists and non-peptide antagonists. The peptide 
agonists have essential residues for binding in TM2, TM7 and E l, 2 & 3 whilst 
antagonist binding sites occur in TM4, 5 & 6  (Table 1.7b, p i 8 a).
1.8 Structural modifications
There are several biochemical modifications which are important in defining and 
controlling receptor function:
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Table 1.7b Key sites fo r  ligand interaction with peptide binding GPLRs based 
__________ on NK1 receptor work ______________________________
Receptor Residue/Region Function
NK l 1 (substance P) f x g l m -n h 2
N-terminus
required for agonist activity in all 
tachykinin receptors
Asn23
Gln24
Phe25
Asn96
Hisl08
El
E2
required for high affinity 
endogenous agonist binding 2 
(no individual residues show this 
effect)
Asn85 3 
Asn89 
Tyr92
TM2
agonist binding via 
H-bonds
Tyr287 TM7 agonist & antagonist binding
Glu784 
Tyr205
TM2 
TM5
agonist binding, essential for 
receptor activation
Vail 16 
Ile290
TM3
TM7
responsible for conformation of 
non-peptide antagonist 
binding pocket
Gin165 
His 197 
His265 
Tyr287
TM4
TM5
TM6
TM7
binding sites for non-peptide 
antagonists
Exterior ends of 
TM5&TM6
important for non-peptide 
antagonist binding
[Reviewed in Strader etal 1994]
1 NK1 (substance P receptor) is a model receptor for all tachykinin and most 
other peptide GPLRs (eg CCK and angiotensin)
2 this indicates that the situation for peptide receptors is more complex than for 
biogenic amine receptors with some regions having functions which can not be 
assigned to individual residues
3 conserved in NK1,2 & 3 receptors
4 conserved as glutamic acid/aspartic acid and tyrosine/phenylalanine in many 
GPLRs
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1.81 Glycosylation
G-protein linked receptors contain putative glycosylation sites usually in the N 
terminal region but they may also be present in the carboxy terminus. These sites 
are consensus sequences containing asparagine residues which may become 
glycosylated. Work on the p2-adrenergic receptor showed that endoglycosidase 
treatment decreased its molecular weight from 65kDa to the expected 49kDa 
confirming that the protein was glycosylated (Rands et al, 1990). It was also 
shown that of the 4 sites in hamster P2-AR the 2 in the N-terminus were utilised 
and glycosylated whilst the 2 in the C-terminus were not (Dohlman et al, 19872) . 
Removal of glycosylation does not affect ligand binding of function of receptors 
but may be involved in determining the distribution of the receptor, or its level of 
expression (Saverese & Fraser, 1992). However disruption of glycosylation can 
be detrimental in some cases. Retinitis pigmentosa is a retinal degenerative disease 
caused by a mutation causing destruction of a glycosylation site in rhodopsin 
(Sung etal, 1991).
1.82 Palmitoylation
Most GPLR have one or more cysteine residue in the C-terminal region. The 
single residue present in p2-AR has been show to covalently bind palmitate, 
which may insert into the lipid bilayer forming a small fourth cytoplasmic loop. 
Site directed mutagenesis of this cysteine residue interferes with coupling of the 
receptor to its associated G-protein (Gs), (O'Dowd etal, 19892).
1.83 Disulphide Bridges
Yet another conserved feature of GPLR is the presence of two further cysteine 
residues at conserved sites on the first and second extracellular loops (El & E2). 
In rhodopsin it has been biochemically demonstrated that these form a disulphide 
bond ('bridge') which is necessary for arranging the receptor in the correct 3D
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conformation (Kamik & Khorana, 1990). Dixon (1987) also demonstrated that 
ligand interactions in P2-AR are disturbed by mutagenesis of these residues.
1.84 Phosphorylation
As mentioned previously GPLR can be negatively controlled by phosphorylation 
in the process of desensitisation, where G-protein coupling is disrupted. The 
phosphorylation occurs as consensus sites rich in serine and threonine which are 
targets for protein kinases such as PKC and PKA. These sites have been found 
on all of the three cytoplasmic loops as well as the C terminus which may point to 
multiple interaction sites for G-protein coupling.
1 .9  Aims of Research
The superfamily of GPLRs is increasing in size rapidly as new members and sub­
groups are discovered. They are being uncovered via various pathways - 
homology to existing, cloned GPLR is being taken advantage of, with cDNA 
library screening (VanTol etal, 1991) and more extensively PCR is being used to 
discover further members of existing sub-groups (Libert etal, 1989).
In addition, receptor pharmacology has been used to uncover totally new sub- 
types of GPLR, which do not appear to be related to other groups by sequence 
homology but are transmembrane receptors baring all of the topological 
characteristics of GPLR. An example of this is the secretin receptor (Ishihara et 
d , 1991) which was isolated by direct expression cloning.
This project aims to discover new members of the neuropeptide receptor sub­
family using the property of sequence homology to existing receptors. 
Degenerate primer PCR will be used. This approach has previously been used 
successfully by several groups to extend receptor sub-groups, for example
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Zastawny etal, (1994) discovered further members of the opioid sub-group in this 
way.
A selection of published peptide sequences for known neuropeptide receptor 
sequences will be taken and sub-divided by peptide sequence homology, then the 
degenerate primer sequences created from the consensus’ of these sub-groups. 
This will allow design of primers with a limited degeneracy, retaining a certain 
degree of specificity for the sub-group.
If this approach is successful and new members are discovered these will be 
cloned and further characterised both molecularly and pharmacologically.
A particular area of interest for the discovery of new receptors are the ligands they 
bind and the binding process, which is important for the understanding of 
physiological processes and the development of drugs to treat disorders involving 
GPLRs.
An area that particularly interests me is the selectivity of binding which a receptor 
has for a specific drug, and the difference in selectivity between receptors which 
differ very little in peptide sequence, such as the tachykinin receptors. As all of 
the evidence indicates that the receptors have the same intrinsic topological 
structure, therefore indicating that the alteration in selectivity must be due to the 
residue differences either directly or via a conformational change.
To investigate this, it is hoped that any new receptor cloned will have high enough 
homology to an existing member of it’s sub-group (from which the degenerate 
primers towards it were designed) to create functional chimeric molecules from the 
pair. Chimeras for different regions of the receptors could be expressed and tested 
pharmacologically for binding specificity, in comparison with the pharmacological
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profiles of the uncombined receptors, and in this way a binding profile for the new 
receptor could be built up, along with information about the regions important for 
its ligand interaction and specificity.
It is hoped that the chimeras will be created using a PCR method involving 
recombinant primers along with both receptors as templates. This technique has 
successfully been used by England et d  (1991) to produce m l muscarinic/D2 
dopamine receptor chimeras.
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SEQUENCE ANALYSIS
2 .0  Sequence Analysis Of G-Protein Linked Receptors
In order to design degenerate PCR primers, with the aim of amplifying novel 
neuropeptide receptors, it was necessary to analyse a selection of neuropeptide 
receptor amino acid sequences to see if they could be further sub-grouped 
according to peptide sequence homology. The peptide sequence was used, as 
residue differences and similarities are more obvious and also the degeneracy can 
be designed with mouse codon bias (as the PCR template is mouse cDNA).
The sequences were randomly selected from those published on the GenEMBL 
database at that time (http://www2.ncbi.nlm.nih.gov/genbank). Eighteen 
sequences in total were chosen with the proviso that they were all neuropeptide 
binding GPLRs and that they were derived from rodents if possible, as the 
template for PCR was prepared from mouse brain tissue. Unfortunately, at this 
time, it was impossible to obtain the whole range of receptors from the mouse 
however, the selection was narrowed to human, and rodent sequences, which 
have reasonable homology.
Table 2.11 Neuropeptide receptors analysed for sequence homology
Receptor Species Accession N°
thyrotropin releasing hormone mouse M59811
bombesin mouse M61000
NK-1 mouse X62934
somatostatin mouse M91000
neurotensin rat P20789
6 -opioid rat L07271
parathyroid hormone rat M77184
secretin rat X59132
NK-2 rat M31838
bradykinin rat X69681
cholecystokinin rat X01032
endothelinB human M74921
calcitonin human L00587
angiotensin human M93394
NK-3 human M89473
neuropeptide Y human M84755
vasoactive intestinal peptide human L13288
N-formyl peptide human M60627
2 .1  Classification of Receptors
The advent of computer software to analyse sequence data has proved 
revolutionary in molecular genetics as now huge amounts of data can be compared 
and regions of sequence conservation which may be important to function or 
structure can be discovered and subsequently examined experimentally. Also 
established motif patterns (eg promoters, zinc fingers etc.) can be recognised 
allowing ease of elucidation of the function of a newly discovered gene or protein.
Analysis of this type has helped to elucidate the molecular structure of the GPLRs 
(G-protein linked receptors) and has been important in determining the relationship 
between different members of the superfamily, establishing their evolutionary and 
functional relationships.
The University of Wisconsin Genetic Computer Group Software package (GCG) 
contains many useful molecular analysis programs. Some of these were used to 
create multiple sequence alignments of various neuropeptide receptor amino acid 
sequences. The peptide sequences were chosen as these allow a more clear 
comparison of the differences or similarities between receptors at a structural level, 
as this affects ligand interactions and receptors are usually classified according to 
their ligand binding character.
At present a certain group of GPLRs may be allocated into different subset 
depending on which properties of the receptor are considered. For example this 
may be its major ligand type (eg catecholamines, peptides, hormones etc), its 
physiological effects or tissue specificity, conservation of structural features or 
sequence motifs or by sequence homology, leading to confusion and overlap 
between subgroups of GPLRs.
Much of the early confusion arose because of the naming system, whereby one 
receptor could have two or even three names, depending upon the number of 
groups which cloned it. For example the neurokinin-1 receptor (NK-1R) was 
known until relatively recently as the substance P or neurokinin A receptor and the 
bombesin receptor was also known as the gastrin releasing hormone receptor 
(Watson & Arkinstall, 1994).
The situation has now been clarified by the intervention of the International Union 
of Pharmacology (IUPHAR), a committee producing an annual supplement in the 
journal Trends in Pharmacology, reviewing and classifying receptors according to 
a standard nomenclature.
The analysis in this study compares the entire peptide sequence of several 
neuropeptide receptors allowing allocation of receptors into subsets by sequence 
homology. This type of analysis is useful from a molecular point of view and is 
important in the study of evolutionary relationships. Several homology studies on 
GPLRs have only analysed the transmembrane (TM) regions of the receptor 
sequence in order to eliminate the variation in length between receptors. This 
variation can occur both in the terminal and loop regions of the proteins and 
therefore could cause problems when trying to align two receptor sequences of 
different lengths. The multiple sequence alignment program on GCG, 'PILEUP' 
allows for this variation, producing the overall best alignment by introducing gaps 
into shorter sequences at positions calculated to give the least disruption and shift 
the sequence to the best alignment with its longer counterpart; it also allows for 
varying termini lengths.
2 .2  Computer Analysis
The peptide sequences of 18 neuropeptide receptors were obtained from the 
GenEMBL database and converted into open-reading frame peptide sequences
using TRANSLATE (Wisconsin GCG). These were entered into the ‘PILEUP’ 
program which produced a multiple sequence alignment using the progressive, 
pairwise alignment method of Feng and Doolittle (1990). These sequences were 
chosen as a selection of neuropeptide receptor sequences on the GenEMBL 
database at the time of analysis. Translation to amino acid sequence was 
necessary in some cases, as many were not present on the SwissPROT database.
The method 'clusters' most alike sequences to create a dendrogram which is not 
phylogenetic but determines the likeness of sequences to each other and directs the 
order in which sequences are aligned. A total pairwise alignment of the sequences 
is then produced starting with the two sequences with highest homology, 
proceeding to next most homologous sequence and so on until all sequences have 
been aligned. The final output alignment therefore displays a multiple sequence 
alignment with the most similar sequences adjacent to each other.
The total alignment of all of the receptor sequences studied allowed the sequences 
to be subgrouped according to their 'pairwise similarity score' and aligned into a 
multiple sequence file. The program ‘PRETTY’ could then used to derive a 
consensus from the alignment and display it below.
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2 .3  Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a powerful technique which amplifies a 
specific sequence from an initial low concentration in a complex mixture (Mullis et 
d , 1987). Its success relies upon the careful design of experimental primers and 
calculation amplification conditions.
2 . 31  Experimental Design
The primers are the most crucial part of the technique as they are the key to 
detecting and amplifying the target sequence. It is important that each primer in 
the pair is designed with equal care as amplification will only occur when these 
two independent probes hybridise specifically and close enough to specify a target 
sequence. There are some general rules on the design of primer pairs:
primers should contain at least 15 bases of homology
the Tms of the primer pair should be balanced and ideally lie between
55-80°C
the last three 3' bases of the primers should be totally homologous to the 
target sequence
the primers should have little or no complementarity to each other at the 3' 
ends to avoid primer-dimer formation (Innis & Gelfand, 1990)
Once designed the primer sequences were checked to confirm homology to the 
target sequences on the correct coding strand using the GCG program 
‘BESTFIT’. Also the primer sequences were checked to avoid homology between 
opposite members of each primer pair or palindromic/secondary structures within 
the primers. Secondary structures were checked for using the ‘FOLD’ program 
on GCG (Eberhardt, 1992).
2.311 Degenerate PCR
The situation becomes more complicated with the use of degenerate primers as the 
reaction must be specific enough to amplify related sequences without being 
indiscriminate. When an oligonucleotide is designed from an amino acid 
sequence, the occurrence of several codons for each residue means that a mixture 
of nucleotide sequences of the same length are created. These primers are useful 
for detecting the gene of a novel peptide or to amplify new genes, related to those 
from which the primers are designed.
Degenerate PCR has been successfully used in several cases to discover new 
members of the GPLR family. A typical example this is shown by the discovery 
of a somatostatin receptor by O'Carroll etal (1992) using degenerate PCR primers 
based on conserved regions of other related receptors, on a rat pituitary cDNA 
library. The method relies on the structural conservation of the different receptors 
in the GPLR family. The seven transmembrane domains offer regions of 
sequence conservation which can be aligned to provide an amino acid motif 
particular to a subgroup of receptors; these regions can then be used for degenerate 
primer design specifically towards that group. Therefore primer pairs are 
commonly designed towards the most highly conserved regions at an easily 
amplified interval from each other, eg TM domains 3 & 7 or 2 & 6  (O'Carroll et 
d , 1992). Amplified products can then be sequenced and libraries probed using 
any putative novel receptor sequences, to isolate full length cDNAs.
As primer design is more complicated them in non-degenerate PCR, there are 
further steps which may be taken to reduce primer complexity and hence increase 
specificity. In this experiment the specificity was increased by designing primers 
with a low degeneracy (below 516-fold). This was done by avoiding peptide 
regions containing amino acids with high codon usage and by using mammalian 
codon bias (Maruyama etal, 1986). Also the substitution of the nucleotide inosine
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(which will pair with any base) at points where there is four-fold base 
redundancy, was used to reduce overall degeneracy (Compton, 1990). 
Degeneracy specifically at the 3’ end of the primers was avoided where possible, 
as a mismatch in this region can impede extension of the primer (McPherson etal, 
1990)
The primers were designed towards TM3 & TM7 because these regions have 
successfully been used by other groups and produce an easily amplifiable 
fragment («500-600bp), which is long enough to contain many of the major 
ligand binding residues (Figure 1.3, p6 a) and the 13 loop which is likely to contain 
any variation in G-protein linkage residues.
The 3’ region of homology was designed to be >15 nucleotides so that the primer 
could accurately anneal but a Kpnl restriction site could be incorporated into a 
non-homologous 5’ end. Using the program ‘MAP’ on GCG, it was shown that 
Kpnl did not cut within the template receptors but will cut near the ends of DNA 
fragments.
2 . 32  Technical Considerations
The other major element in PCR is the template. It is possible to use either a 
preconstructed library (usually cDNA) or uncloned single stranded cDNA. The 
important fact is to be sure that the template complex contains the target sequence. 
In this experiment cortex and striatum RNAs were extracted and reverse 
transcribed. It was know that within brain regions all of the receptors used to 
design the primers were represented and there was evidence of further subtypes 
(Watson & Arkinstall, 1994).
2 . 33  Reaction Composition
Once the primers were made it was important to optimise the conditions for 
amplification. There are certain guidelines, but optimisation of a new set of 
primers requires much trial and error. Factors to consider include mainly primer 
& Mg2 + concentration and annealing temperatures:
• primer concentration should be 100-200pM ; too high a concentration leads to 
mispriming
• the annealing temperature should be around 5-10°C below the Tm (melting 
temperature) of the primer pair
• magnesium ion concentration should be between 0.5-2.5mM; concentration 
can affect primer annealing, primer-dimer formation and enzyme activity and 
fidelity
deoxynucleotide triphosphates have to be at equal concentrations between 2 0 - 
200pM; for ease a 2mM stock mix of all four nucleotide was used, care was 
taken to avoid multiple freeze-thaws as this can reduce efficiency.
Taq concentration should be between 1-2.5 units/lOOpl reaction; too high a 
concentration causes accumulation of non-specific products
2 . 3 4  Amplification
There are three main steps:
a) Denaturation
Heating the template DNA to around 95°C for about 30 seconds is usually 
sufficient to denature duplexes to single strands ready for the next primer 
annealing step, any longer will lead to loss of enzyme activity. A ‘hot-start’ (94- 
96°C for l-2mins) was incorporated into to the reaction prior to the first cycle. 
The Taq enzyme is added when the high temperature is reached in order to prevent 
extension of early non-specific primer hybridisations which could seriously reduce 
specificity.
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b) Annealing
Conditions required for annealing of primers to the template depend upon the 
nature of the primer and it advisable to optimise the reaction for a particular pair of 
primers by trying different annealing temperatures, and varying Mg2+, primer and 
enzyme concentrations (Wages & Fowler, 1993). A guide annealing temperature 
is 5°C below the Tm of the primers. At temperatures between 55 & 72°C with 
average primer concentrations (200pM) annealing should only require a few 
seconds (Innis & Gelfand, 1990). Increasing the annealing temperature increases 
the stringency and therefore the specificity of the reaction.
c) Extension
This is dependant upon the length and concentration of the target sequence. The 
usual temperature is 72°C as this has been shown to give the most efficient primer 
extension (Innis etal, 1988). One minute at this temperature is sufficient for a 
distance of up to 2  kb, but longer times are usually used to allow for low template 
concentrations.
Cycle number is also important. After a certain number of cycles (specific to the 
reaction) the exponential reaction stops and the amount of product plateaus. The 
problem with continued cycling after this point is that the level of non-specific 
products continues to increase (Wages & Fowler, 1993). It is suggested that 25- 
40 cycles should be used depending upon initial target molecule concentration, 
more than 40 cycles should be avoided for the above reason and also because even 
a single copy template should be amplified in 40 cycles.
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RESULTS
2 .4  Sequence Analysis
From the analysis of the amino acid sequences the neuropeptide receptors were 
assigned to groups according to a homology value determined using 'PILEUP'. 
This is a score of homology between each pair of receptors in every combination, 
with higher scores indicating greater homology up to a value of 1 .0  which shows 
total homology.
Tables 2.41 to 2.45 (p34 & 35) show the sub-grouping according to peptide 
sequence analysis at TM domains 1-3 & 6-7. Domains 4 and 5 show much lower 
levels of homology and therefore have been omitted as it is difficult to define 
groups from these regions. Table 2.46 (p35) shows the sub grouping according 
to entire length sequence comparisons.
The sub grouping within the tables is determined by the homology of each peptide 
sequence for each other sequence, as derived by the ‘PILEUP’ application 
(Wisconsin GCG) and shown in Table 2.40, p32a.
The results of grouping at different TM domains (Tables 2.41 - 2.45, p34 - 35) 
show that the sub-group which a receptor falls into differs, depending upon which 
region is being examined. In some studies receptors have been assigned to sub­
groups according to their homology only at TM regions, however, these results 
show that in this case it is more reasonable to assign grouping by sequence 
analysis of the entire reading frame so that the ambiguity of grouping by TM 
region sequences is eliminated.
In Table 2.46, as expected some established groups appear such as the tachykinins 
(group ii) and the ‘secretin-like’ receptors (group i). However there are some
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unexpected results.
Chang etal (1993) suggest that the ‘secretin’ subgroup also includes the bombesin 
and VIP receptors, as they show by peptide sequence analysis. However, in this 
analysis no such grouping was obvious, even at TM regions.
The actual sequence alignments for each group as determined in Table 2.46 are 
shown in Appendix II. If these figures are studied it can be seen how the 
consensus sequence varies from group to group in each case providing a unique 
peptide sequence specific for that group. From these sequences PCR primers 
were designed, with the aim of discovering new receptors which would cluster, 
by sequence, with that sub-group.
By initially selecting groups with high homology (high pairwise alignment scores) 
and choosing regions in the consensus which are highly conserved and unique to 
that sub-group, primers can be designed which are selective for that group and 
with the introduction of limited degeneracy also capable o f amplifying related 
receptors with similar sequence conservation.
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Table 2.41 Receptors grouped by homology at TM 1
i ii iii iv
parathyroid
hormone
secretin
calcitonin
neurokinin 1 
neurokinin 2 
neurokinin 3 
bombesin
neurotensin 
endothelin B 
cholecystokinin 
neuropeptide Y 
N-formyl peptide 
angiotensin 2 
biadykinin 3
vasoactive
intestinal
peptide
6 opioid
somatostatin
thyrotropin 
releasing hormone
Table 2.42 Receptors grouped by homology at TM 2
i ii iii iv V
parathyroid
hormone
secretin
calcitonin
neurokinin 1 
neurokinin 2 
neurokinin 3
neurotensin
thyrotropin
releasing
hormone
endothelin B
cholecystokinin
bombesin
neuropeptide Y
N-formyl
peptide
angiotensin 2
bradykinin 3
vasoactive
intestinal
peptide
6 opioid
somatostatin
Table 2.43 Receptors grouped by homology at TM 3
i ii iii iv V
parathyroid
hormone
secretin
calcitonin
neurokinin 1
neurokinin 2
neurokinin 3
thyrotropin
releasing
hormone
neurotensin bombesin 
endothelin B 
cholecystokinin 
neuropeptide Y
N-formyl
peptide
angiotensin 2
bradykinin 3
vasoactive
intestinal
peptide
6 opioid
somatostatin
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Table 2.44 Receptors grouped by homology at TM6
i ii iii iv V
parathyroid
hormone
secretin
calcitonin
neurokinin 1
neurokinin 2
neurokinin 3
thyrotropin 
releasing hormone
neurotensin
6 opioid
bombesin 
endothelin B 
cholecystokinin 
neuropeptide Y
N-formyl
peptide
angiotensin 2
bradykinin 3
vasoactive 
intestinal peptide
somatostatin
Table 2.45 Receptors grouped by homology at TM7
i ii iii iv V vi
secretin
calcitonin
parathyroid
hormone
neurokinin 1 
neurokinin 2 
neurokinin 3
neurotensin
neuropeptide Y
thyrotropin
releasing
hormone
bombesin 
endothelin B 
cholecystokinin
angiotensin 2
bradykinin 3
N-formyl
peptide
6 opioid
somatostatin
vasoactive
intestinal
peptide
Table 2.46 Receptors grouped by overall homology
i ii iii iv V vi
secretin
calcitonin
parathyroid
hormone
neurokinin 1 
neurokinin 2 
neurokinin 3
neurotensin
neuropeptide Y
thyrotropin
releasing
hormone
bombesin
cholecystokinin
endothelin
angiotensin 2
bradykinin 3
N-formyl
peptide
6 opioid
somatostatin
vasoactive
intestinal
peptide
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2 .5  Polymerase Chain Reaction
Tables 2.51-2.54 show the sequences of the primers designed as a result of the 
sequence analysis work, and Tables 2.55 & 2.56 the thermal cycling conditions 
that they were used at. Figure 2.50 & 2.51 (p36a-d) show the primer alignments.
These particular receptor groups were chosen as they were the most distinctive 
sets from the entire sequence comparison, always clustering together, and this 
close sequence homology allowed the design of degenerate primers with minimal 
complexity, so that they retained some specificity.
Table 2.51 Mouse neurokinin-1 receptor control primers
primer
name
5' primer sequence 3' length
bp
TM Tm sense
MNK1-3 tatCgCggtaccTGCAAGTTTCACAATTCTTCCC 35 3 66°C sense
MNK1-7 tatCgCggtaccCCACATGCTGGCCAGGTAGACCT 35 7 74°C anti
Table 2.52 Tachykinin group degenerate primers, based on the alignment o f 
____________ sequences in Table 2.46, group ii__________________________
primer
name
5’ primer sequence 3' length
bp
TM degeneracy Tm
TACH-3 tatCgCggtaccGCY STSTTCGYCW S YATTTACTC 35 3 27 = 128 64-70°C
TACH-7 talcgcggt accCCAIAWTS KIGCCAR RATS ACCT 35 7 26 = 64 58-62°C
Table 2.53 Rat parathyroid hormone receptor control primers
primer
name
5’ primer sequence 3' length
bp
TM Tm sense
PATH-3 tatCgCggtaccAACTACTACTGGATTCTGGTGGAG 36 3 70°C sense
PATH-7 tatCgCggtaccGCCTGCACCTCACCATTGCAGAA 36 7 72°C anti
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Figure 2.50 Alignment of mouse tachykinin receptors showing the sites at
which the primers were designed.
l  50
n k l     TTGCTGC CTTGCCCGCC AAAATGGATA ACGTCCTTCC
nk2 AGACCCTGTG TTCCAGGCCC AGGATCAGCC ATGGGGGCCC ACGCCAGCGT
n k3 ATCACTGAGT GGCTTGCGCT CCAGGCTGGC AACTTCTCCT CCGCGCTGGG
100
n k l  TGTGGACTCT GATCTCTTCC CCAACACCTC CACCAACACT TCTGAGTCTA
nk2 TACCGACACC AACATCTTGT CTGGCCTTGA GAGTAACGCA ACAGGCGTTA
n k3 CTTGCCAGTG ACATCCCAGG CACCTTCCCA AGTCCGGGAC AACCTGACGA
1 5 0
n k l  ACCAGTTTGT GCAACCTACC TGGCAAATTG TCCTTTGGGC AGCCGCCTAT
nk2 CAGCCTTCTC TATGCCTGGC TGGCAGCTGG CGCTATGGGC CACAGCCTAC
n k 3 ACCAGTTCGT GCAGCCCTCC TGGCGAATCG CGCTCTGGTC GCTGGCCTAT
200
n k l  ACGGTCATCG TGGTGACTTC CGTGGTGGGC AACGTAGTGG TGATATGGAT
nk2 CTGGCCCTGG TGCTGGTGGC TGTAACAGGC AACGCCACAG TCATCTGGAT
nk3 GGCTTAGTGG TGGCGGTGGC AGTCTTCGGA AACCTCATCG TTATTTGGAT
TM1
2 5 0
n k l  CATTTTGGCC CACAAGAGAA TGAGGACAGT GACCAATTAT TTCCTGGTGA
nk2 CATTCTGGCC CATGAGAGAA TGCGCACGGT CACCAACTAT TTCATCATCA
n k 3 CATCTTGGCC CACAAGCGCA TGAGGACCGT CACCAACTAT TTCCTGGTAA
3 0 0
n k l  ACCTGGCCTT CGCTGAGGCC TGCATGGCTG CATTCAATAC AGTGGTGAAC
nk2 ACCTGGCCTT GGCAGACCTC TGCATGGCGG CCTTCAATGC CACCTTCAAC
n k 3 ACCTGGCTTT CTCCGACGCC TCCGTGGCTG CCTTCAACAC CTTGGTCAAT
TM2
3 5 0
n k l  TTCACCTACG CAGTCCACAA CGTGTGGTAC TACGGCCTCT TTTACTGCAA
nk2 TTCATCTATG CCAGTCACAA CATCTGGTAC TTCGGCAGCA CCTTCTGCTA
n k 3 TTCATCTATG GTGTTCACAG CGAGTGGTAC TTTGGCGCCA ACTACTGCCG
m n k l-3  4 0 0
n k l  GTTTCACAAC TTCTTCCCCA TTGCTGCTCT CTTCGCCAGT ATCTACTCCA
n k2 CTTCCAGAAC CTCTTTCCTG TCACAGCCAT GTTCGTCAGC ATCTACTCCA
nk3 CTTCCAGAAC TTCTTTCCCA TCACAGCGGT GTTTGCCAGC ATCTACTCTA
TM3 t a c h - 3
4 5 0
n k l  TGACAGCTGT GGCCTTTGAC AGATACATGG CCATCATCCA CCCTCTTCAG
nk2 TGACCGCCAT CGCCGCTGAC AGGTACATGG CCATTGTCCA CCCTTTCCAG
n k 3 TGACAGCCAT TGCAGTGGAC AGGTATATGG CCATTATCGA TCCTTTGAAA
5 0 0
n k l  CCCCGGCTGT CGGCCACTGC TACCAAAGTG GTCATCTTTG TCATCTGGGT
nk2 CCACGGCTCT CCGCCCCCAG CACCAAGGCG GTTATTGCTG TCATCTGGCT
nk3 CCCAGACTAT CTGCCACAGC CACTAAGATT GTCATCGGAA GTATTTGGAT
5 5 0
n k l  CCTGGCTCTC CTGCTGGCCT TTCCACAGGG CTACTACTCC ACCACAGAGA
nk2 GGTAGCCCTG GCTCTCGCCT CCCCACAATG TTTCTACTCC ACCATCACTG
n k3 TTTGGCATTT CTACTTGCCT TCCCTCAATG TCTTTATTCC AAAATAAAAG
TM4
600
n k l CCATGCCCAG CAGAGTAGTG TGCATGATAG AGTGGCCAGA ACATCCCAAC
nk2 TGGACCAGGG GGCCACCAAG TGTGTGGTGG CCTGGCCCAA TGACAACGGA
n k 3 TCATGCCAGG CCGTACCCTT TGCTATGTGC AGTGGCCAGA AGGTCCCAAG
6 5 0
n k l AGGACTTAC G AGAAAGCGTA CCACATCTGT GTGACTGTGC TGATCTACTT
nk2 GGCAAGATGC TCCTACTGTA TCATCTGGTG GTGTTTGTCC TCATCTACTT
n k3 CAACATTTC. ............ ACGTA CCACATCATT GTTATCATCC TGGTGTACTG
7 0 0
n k l CCTGCCTCTG CTGGTGATTG GCTATGCATA CACTGTGGTA GGGATTACAC
nk2 CCTGCCTCTA GTGGTGATGT TTGCAGCTTA CAGTGTCATT GGCCTCACAC
nk3 TTTCCCATTG CTCATCATGG GTGTCACCTA CACCATCGTT GGAATTACTC
TM5
7 5 0
n k l TGTGGGCCAG TGAGATCCCC GGTGAC. . . T CCTCTGACCG TTACCATGAG
nk2 TGTGGAAACG CGCCGTACCC AGACACCAGG CTCATGGAGC TAACCTGCGC
nk3 TCTGGGGAGG AGAGATCCTA GGAGAC• • • A CCTGTGACAA GTACCATGAG
8 0 0
n k l CAAGTCTCTG CCAAGCGCAA GGTGGTCAAA ATGATGATCG TGGTTGTGTG
nk2 CATCTACAGG C CAAGAAGAA GTTTGTGAAG GCCATGGTAC TGGTGGTGGT
nk3 CAGCTTAAGG CTAAACGAAA GGTTGTAAAA ATGATGATTA TTGTGGTGGT
8 5 0
n k l TACCTTCGCC ATCTGCTGGC TGCCCTTCCA CATCTTCTTC CTCCTGCCCT
nk2 GACATTTGCC ATCTGCTGGC TGCCCTACCA CCTCTACTTC ATCCTGGGGA
n k3 GACATTTGCC ATCTGCTGGC TACCCTACCA TGTGTATTTC ATTCTCACTG
TM6
9 0 0
n k l ACATCAACCC AGATCTCTAC CTTAAGAAGT TCATCCAGCA GGTCTACCTG
nk2 CCTTCCAAGA GGACATCTAC TACCGCAAGT TTATCCAGCA GGTCTACCTG
n k3 CGATCTACCA ACAGTTAAAC AGGTGGAAAT ACATCCAGCA GGTCTACCTG
ta c h -7
m n k l-7 95<
n k l GCCAGCATGT GGCTGGCCAT GAGTTCTACC ATGTACAAC C CCATCATCTA
nk2 GCACTCTTCT GGCTGGCCAT GAGTTCCACC ATGTACAAC C CCATCATTTA
n k3 GCTAGCTTCT GGCTGGCCAT GAGCTCAACC ATGTACAACC CCATCATCTA
TM7
1 0 0 0
n k l CTGCTGCCTC AATGACAGGT TCCGTCTGGG CTTCAAGCAT GCCTTTCGCT
nk2 TTGCTGCCTT AACCACAGGT TTCGCTCTGG ATTCCGGCTT GCTTTCCGGT
n k3 CTGCTGTTTG AACAAAAGAT TTCGTGCAGG CTTCAAGAGA GCATTTCGCT
1 0 5 0
n k l GCTGCCCTTT CATCAGTGCT GGTGATTATG AGGGGCTGGA AATGAAATCC
nk2 GCTGCCCCTG GGGGACACCA ACCGAGGAAG ACAGGCTGGA GCTGACCCAC
n k3 GGTGTCCTTT CATCCAAGTC TCCAGCTACG ATGAGCTGGA GCTCAAGACC
1 1 0 0
n k l ACCCGATACC TCCAGACCCA GAGCAGCGTG TACAAGGTCA GCCGCCTGGA
nk2 ACTCCGTCCA TCTCCAGGAG AGTCAACCGG TGTCACACCA AGGAGACTTT
n k3 ACCAGGTTTC ATCCCACACG GCAGCCA------
1 1 5 0
n k l GACCACCATC TCCACTGTGG TGGGAGCCCA TGAAGATGAG CCAGAGGAAG
nk2
n k3
GTTCATGACA GGGGATATGA CCCACTCTGA GGCTACCAAT GGGCAGGTTG
TM domains are labelled and indicated by a single underline. 
Primers are labelled and indicated by a double underline.
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Figure 2.5 OS’ Rat parathyroid hormone receptor sequence showing the
points at which the primers align.
— ATGGGGGC CGCCCGGATC GCACCCAGCC
29 TGGCGCTCCT ACTCTGCTGC CCAGTGCTCA GCTCCGCATA TGCGCTGGTG
79 GATGCGGACG ATGTCTTTAC CAAAGAGGAA CAGATTTTCC TGCTGCACCG
1 2 9 TGCCCAGGCG CAATGTGACA AGCTGCTCAA GGAAGTTCTG CACACAGCAG
1 7 9 CCAACATAAT GGAGTCAGAC AAGGGCTGGA CACCAGCATC TACGTCAGGG
2 2 9 AAGCCCAGGA AAGAGAAGGC ATCGGGAAAG TTCTACCCTG AGTCTAAAGA
2 7 9 GAACAAGGAC GTGCCCACCG GCAGCAGGCG CAGAGGGCGT CCCTGTCTGC
3 2 9 CCGAGTGGGA CAACATCGTT TGCTGGCCAT TAGGGGCACC AGGTGAAGTG
3 7 9 GTGGCAGTAC CTTGTCCCGA TTACATTTAT GACTTCAATC ACAAAGGC CA
4 2 9 TGCCTACAGA CGCTGTGACC GCAATGGCAG CTGGGAGGTG GTTCCAGGGC
4 7 9 ACAACCGGAC GTGGGCCAAC TACAGCGAGT GCCTCAAGTT CATGACCAAT
5 2 9 GAGACGCGGG AACGGGAGGT ATTTGACCGC CTAGGCATGA TCTACACCGT
57 9 GGGATACTCC ATGTCTCTCG CCTCCCTCAC GGTGGCTGTG CTCATCCTGG
6 2 9 CCTATTTTAG GCGGCTGCAC
TM1
TGCACGCGCA ACTACATCCA CATGCACATG
6 7 9 TTCCTGTCGT TTATGCTGCG CGCCGCGAGC ATCTTCGTGA AGGACGCTGT
7 2 9 GCTCTACTCT GGCTTCACGC
TM2
TGGATGAGGC CGAGCGCCTC ACAGAGGAAG
7 7 9 AGTTGCACAT CATCGCGCAG GTGCCACCTC CGCCGGCCGC TGCCGCCGTA
8 2 9 GGCTACGCTG GCTGCCGCGT GGCGGTGACC TTCTTCCTCT ACTTCCTGGC
8 7 9 TACCAACTAC TACTGGATTC TGGTGGAGGG GCTGTACTTG CACAGCCTCA
9 2 9 TCTTCATGGC
p ath -3
CTTTTTCTCA
TM3
GAGAAGAAGT ACCTGTGGGG CTTCACCATC
9 7 9 TTTGGCTGGG GTCTACCGGC TGTCTTCGTG GCTGTGTGGG TCGGTGTCAG
1 0 2 9 AGCAACCTTG GCCAACACTG
TM4
GGTGCTGGGA TCTGAGCTCC GGGCACAAGA
1 0 7 9 AGTGGATCAT CCAGGTGCCC ATCCTGGCAT CTGTTGTGCT CAACTTCATC
1 1 2 9 CTTTTTATCA ACATCATCCG
TM5
GGTGCTTGCC ACTAAGCTTC GGGAGAC CAA
1 1 7 9 TGCGGGCCGG TGTGACACCA GGCAGCAGTA CCGGAAGCTG CTCAGGTCCA
1 2 2 9 CGTTGGTGCT CGTGCCGCTC TTTGGTGTCC ACTACACCGT CTTCATGGCC
1 2 7 9 TTGCCGTACA CCGAGGTCTC
TM6
AGGGACATTG TGGCAGATCC AGATGCATTA
1 3 2 9 TGAGATGCTC TTCAACTCCT TCCAGGGATT TTTTGTTGCC ATCATATACT
TM7
1 3 7 9 GTTTCTGCAA TGGTGAGGTG CAGGCAGAGA TTAGGAAGTC ATGGAGCCGC
p ath -7
1 4 2 9 TGGACACTGG CGTTGGACTT CAAGCGCAAA GCACGAAGTG GGAGTAGCAG
1 4 7 9 CTACAGCTAT GGCCCAATGG TGTCTCACAC GAGTGTGACC AATGTGGGCC
1 5 2 9 CCCGTGCAGG ACTCAGCCTC CCCCTCAGCC CCCGCCTGCC TCCTGCCACT
1 5 7 9 ACCAATGGCC ACTCCCAGCT GCCTGGCCAT GCCAAGCCAG GGGCTCCAGC
1 6 2 9 CACTGAGACT GAAACCCTAC CAGTCACTAT GGCGGTTCCC AAGGAC GATG
1 6 7 9 GATTCCTTAA CGGCTCCTGC TCAGGCCTGG ATGAGGAGGC CTCCGGGTCT
1 7 2 9 GCGCGGCCGC CTCCATTGTT GCAGGAAGAA TGGGAAACAG TCATG----------
Tm domains are labelled and indicated by a single underline 
Primers are labelled and souble underlined
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Table 2.54 Secretin group degenerate primers, based on the alignment o f 
____________ sequences in Table 2.46, group i_______ ______ _
primer
name
5' primer sequence 3' length
bp
TM degeneracy Tm
SEC-3 tatCgCggtaccAACTAYKIMTGGMTICTSKKKG 34 3 2» = 256 56-66°C
SEC-7 tatcgcggt accUGS ACCTCIY Y RTTIM RGAA 33 7 2^ = 64 58-62°C
Key: TM -transmembrane domain
Tm -melting temperature 
degeneracy -number of different unique primer sequences present
lower case -non-homologous sequence, bold type indicates Kpnl site
uppercase -homologous sequence, bold type indicates degeneracy
Codes for nucleotide sequence degeneracy :-
M = A or C R = A or G W = A orT  S = G o rC  K = G or T 
Y = C or T D = A, G or T H = A ,C o rT  N = A ,C ,G o rT
Tables 2.55-2.56 Thermal cycling conditions
2.55 Amplification using mouse NK-1 receptor control primers
temperature 94°C 94°C 60° C 72°C 4°C
time (minutes) 1 1 2 3 storage
30 cycles
2.56 Amplification using degenerate tachykinin receptor primers
temperature 94°C 94°C 55°C 72°C 4°C
time (minutes) 1 1 2 3 storage
30 cycles
For the parathyroid hormone receptor (PHR) control primers and degenerate 
secretin group primers, various annealing temperatures ranging from 50-65°C 
were tried but they failed to amplify the correct product. In the case of the 
degenerate primers no products were obtained. Therefore the work was 
concentrated on the NK-1 receptor primers and the degenerate tachykinin receptor 
primers.
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The control primers were non-degenerate primer pairs of approximately equivalent 
size and position as the degenerate pairs, but designed towards one member of a 
group in each case (ie the NK-1 and PH receptors). It was hoped that the use of 
these primers would allow reaction conditions to be optimised before introducing 
the added complication of degeneracy.
2.6 PCR Results
PCR reactions were carried out as in the ‘Methods’ Chapter 8 , section 8 .6 , p96. 
Figure 2.61 shows the result of an initial optimisation experiment. No 
amplification occurred as the annealing temperature was too high and also the 
concentrations of primer used were 10 fold too high. Reaction conditions were 
altered accordingly. The Figure also shows lOng of striatal template cDNA which 
appears to span a good size range and not be degraded.
In Figure 2.62 (p38b) the template was tested using an established, successful 
primer pair. Primers for the a-subunit of the GABAa receptor gene (designed by 
Dr D Livingstone) were used, at the conditions in Table 2.56 (p37), as a positive 
control amplifying a 480bp product.
Figure 2.63 (p38c) displays the result of successful amplification with the NK-1 
receptor control primers, at the thermal cycling conditions indicated. The product 
was of the correct size («563bp) and cloning and sequencing confirmed its 
identity. The use of the GABAa primers here shows the difference between the 
striatal and cortex template, with the striatal template giving a much stronger band, 
reflecting the relative mRNA abundance.
Once reaction conditions had been established using the control primers the 
degenerate primers were used with the same conditions but at successively lower 
temperatures. At 55°C a small amount of product was visible of about 550bp, a
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Figure 2.61 Optimising reaction conditions: Assessing primer concentration 
and confirmation of cDNA product.
1.6 kb
Key to lanes 1 250ng lkb marker (Gibco BRL)
2 neurokinin-1 primers at 2pM on mouse striatal cDNA
3 neurokinin-1 primers at 1 pM on mouse cortex cDNA
4 2pl striatal cD N A ( 10 ng)
Products were electrophoresed on a 1 % agarose gel at 50V for 1 hour
PCR Programme
94 C - 1 min
66 C - 2 min x 30 cycles 
72 C - 3 min
Figure 2.62 Confirmation o f template quality and reaction conditions: 
Specific amplification of GABAa u-subunit fragment by 
GAB A Ad specific primers
1.6 kb 
1.0 kb
500 bp 
400 bp 
300 bp
1 2 3 4 5
Key to lanes 1 250ng 1 kb marker (Gibco BRL)
2 GABAau primers on mouse striatal cDNA
3 GABAacx primers on mouse striatal cDNA
4 GABAau primers on mouse cortex cDNA
5 GABAau primers with no template (negative control
Products were electrophoresed on a 1 % agarose gel at 50V for 1 hour
PCR Programme 95 C - 4 min
n
95 C - 1 min
55 C - 2 min x 30 cycles 
72°C - 2 min
II
4 C soak
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Figure 2.63 Positive PCR controls at optimised conditions: products
produced by primers designed towards the mouse neurokinin-1
receptor and the a-subunit of the GABAa receptor gene.
1.0 kb
500bp 
400 bp
Key to lanes 1 250ng lkb marker (Gibco BRL)
2 neurokinin-1 primers on mouse striatal cDNA
3 neurokinin-1 primers on mouse cortex cDNA
4 GABAau primers on mouse striatal cDNA
5 GABAau primers on GABAa(i clone DNA
6 G A B A au  primers on mouse cortex cDNA
Products were electrophoresed on a 1 % agarose gel at 50 volts for 1 hour
PCR Programme 94°C - 1 min
60 C - 2 min x 30 cycles
72°C - 3 min
Expected product sizes neurokinin-1 fragment 563 bp
GABAa fragment 480 bp
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Figure 2.64 Products of PCR using the neurokinin-1 control and degenerae 
tachykinin primer pairs with striatal cDNA template.
1.0 kb
500 bp
400 bp 
300 bp
Key to lanes 1 250ng lkb marker (Gibco BRL)
2 neurokinin-1 primers on mouse striatal cDNA
3 tachykinin primers on mouse striatal cDNA
4 tachykinin primers on mouse striatal cDNA (second round 
PCR products)
5 tachykinin primers with no template (negative control)
PCR Programme 94 C - 1 min
n
94°C - 1 mm
55 C - 2 min x 30 cycles 
72°C - 2 min
ii
4 C soak
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second round at the same conditions using 1 jul of the first reaction produced a 
stronger band (Figure 2.64, p38d). The reaction produced three major products 
of approximately 800, 550 and 350bp which were individually cloned and 
sequenced (Chapter 8 ). Very few clones were obtained for the larger and smaller 
bands, and sequencing did not produce anything related to the tachykinin 
receptors. The larger product matched the database sequence for the Prp gene from 
the Golden Syrian hamster (GenEMBL, accession no. J02686) whilst the 
sequence from smaller product matched that from the mouse PAP homologous 
protein gene (GenEMBL, accession no. D13509), (Figures 2.66 & 2.67, p41a). 
These non-specific products probably arose due to the degenerate nature of the 
primers allowing these genes to be amplified.
The product at ~550bp proved to be the NK-1 receptor (Figure 2.68, p41b) and 
no new receptors were isolated.
2.65 Lack of novel products using tachykinin degenerate primers
The PCR reactions were repeated many times at lower annealing temperatures 
however no new products were obtained. These preliminary experiments suggest 
that either there are no close relatives of the tachykinin receptors or that the primers 
used could not detect them. Nevertheless, the general technology was shown to 
work well with the technique amplifying original members of the group.
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3 .0  D iscussion  
Sequence analysis
From the Tables 2.41-2.45 (p34 -35) showing grouping of neuropeptide receptors 
according to peptide sequence, it can be seen that the homology at transmembrane 
domain seven (TM7) (Table 2.45, p35) best represents the overall homology 
between these peptide receptors (Table 2.46, p35), but that the other 
transmembrane regions give different results.
It appears that further towards the 3’ end of the sequence there are more group 
distinguishing motifs. At TM1 the sequences divide into only 4 main groups, at 
TM2, TM3 & TM5 they can be distinguished into 5 groups and TM7 sequences 
split the receptors into 6  groups. Six groups can also be defined from the analysis 
of the whole sequences. Also the group allocation varies between TM domains, eg 
for the thyrotropin releasing hormone receptor (TRH). It groups with the 
somatostatin, VIP and 6 -opioid receptors at TM1, with neurotensin at TM2, and 
the tachykinin receptors at TM3 & 6 . however, the overall homology agrees with 
the grouping at TM7 along with the neurotensin and neuropeptide Y receptors.
This result suggests that analysing the homology at the TM regions alone could 
give a false impression of the subgroups within the neuropeptide receptor family.
The results here contrast with previous classification; for example Chang et al 
(1993) suggest that the ‘secretin’ subgroup also includes the bombesin and VIP 
receptors, as they show by peptide sequence analysis. However, in this analysis 
no such grouping was obvious, even at TM regions. This could possibly be 
explained if Chang et d  used only a few sequences in their comparison. A 
reasonable amount of homology exists between all GPLRs, no matter how 
distantly related, and therefore any selection of GPLRs once aligned will have
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some points of homology. However, the study of a larger range of receptor 
sequences using alignment and statistical analysis of the homology actually 
indicates a different, and perhaps more accurate conclusion of the true sub-groups.
To allocate groups by sequence homology seems a reasonable system. The 
groups indicate evolutionary relationships, as those with a higher degree of 
sequence homology are more likely to have diverged from a more recent common 
ancestor than those with less homology. Also those groups which have little or no 
sequence homology, but have structural homology as members of the GPLR 
superfamily, may have convergently evolved.
This study illustrates a simple an definitive method of receptor subgroup allocation 
by amino acid sequence homology.
2 .7  Polymerase Chain Reaction
The amplification of the control fragments had a limited success. In the case of the 
neurokinin-1 receptor (NK-1 R) the primers were successful. The reaction was 
able to be optimised and the product cloned and confirmed by sequence analysis. 
This optimisation was aided by the use of a positive control primer pair towards 
the GABAa receptor, previously designed and successfully used by Dr David 
Livingstone.
Once it had been confirmed that the NK-1 receptor had been amplified, equivalent 
conditions were used for the degenerate primers for this group of receptors 
(TACH-3 & TACH-7). Initially this produced a very low level of product which 
may have been due to the successful primer species being at a lower concentration 
in the population of primers. However, a second round of PCR using the initial 
product as template produced three individual products. One appeared to be the 
same size as the NK-1R product (563bp); the second larger at about 800bp and the
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Figure 2.71 Alignment o f large PCR product to Golden Syrian Hamster
Prp gene (J02686), result o f a ‘Fasta’ search on GCG.
The sequences have 83.4% identity over a 175 bp overlap
60 70 80 90 100
Seqrta CA— CT-CGC-ACTGTTGG— AAGGCGATCGGTGCGGG-CTCTTCGCGATT— GCAGCTG
I I  I I  I I I  M I N I M  I 1 1 1 1 I I I I I I I 1 1 I I  I I 1 1 1 1 I I  I I I  l l l l l l
Hamprp CAGGCTGCGCAACTG1TGGGAAGGGCGATCGGTGCGGGGCTCTTCGCTATTAGCCAGCTG 
4720 4730 4740 4750 4760 4770
110 120 130 140 150 160
Seqrta GCGAAA-GGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCA
l l l l l l  I I  I I  I I I  I I  I I I I I  I I  I I  I I I  I I I  I I I  I I M i l l  I I I I I  I I I I I I I I I I I
Hamprp GCGAAAGGGGGATGTGCTGTAAGGCGATTAAGTTGGGCAACGCTAGGGTTTTCCCAGTGA 
4780 4790 4800 4810 4820  4830
170 180 190 200 210 220
Seqrta CGACG-TGTAAAACGACGGCCAGTGAGCTGCGTAATACGACTCACTATAGGGCGAATTGG
M i l l  I I I I I 1 1 I I 1 1 1 I I I I I 1 1
Hamprp CGACGTTGTAAAACGACGGCCAGTG 
4840 4850 4860
Figure 2.72 Alignment o f small PCR product to mouse PAP homologous 
protein gene (D13509 ), result o f a ‘Fasta ’ search on GCG. 
The sequences have 87.1 % identity over a 155 bp overlap
30 40 50 60 70 80
Seqrta AGGCCACAGCTGTGATGGAGTACATGCAGACGAACACGGCGGTAC-CCAATTCGCCCTAT
I I I I I I  I I  I I I I I I I I I I I I  I I I
Mmpapl CCGGGGGATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAATTCGCCCTAT 
570 580 590 600 610 620
90 100 110 120 130
Seqrta AGTGAGTCGTATTACGCAGCTCACTGGCCGTCGTTTTAC-ACGTCGTGACTGGGAAAACC
I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
Mmpap 1 AGTGAGTCGTATTA— GAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACC 
630 640 650 660 670 680
140 150 160 170 180 190
Seqrta CTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCTTTCGCCAGCT GGAATCG
I I  I I  I I I  I I I  I I I I I I I  I I I I I  I I I I  I I  I I I I I I I I I I I I I I I I  I I I I I I I  I
Mmpapl CTGGCGTTACCCAACTTAATCGCCTT GCACATCCCCTTTCGCCAGCTGGGGTAATAG
690 700 710 720 730 740
200 210 220 230 240 250
Seqrta CGAAGAGCCCGCACCGATCGCCTTCCAACAGTGCGAGTGAATGGAATGAATGTAGCGTTA
M i l l
Mmpapl CGAAG
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Figure 2.68 Alignment o f the 563bp PCR product to NK-1 receptor gene.
The sequences have 100% identity over their entire length.
Seqsta
10 20 
GGTGGTCAAAATGATGATCGTGGTTGTGT
Mmsubp TTACCATGAGCAAGTCTCTGCCAAGCGCAAGGTGGTCAAAATGATGATCGTGGTTGTGT
730 740 750 760 770 780
30 40 50 60 70 80
Seqsta GTACCTTCGCGATCTGCTGGCTGCCCTTCCACATCTTCTTCCTCCTGCCCTACATCAACC
Mmsubp GTACCTTCGCGATCTGCTGGGTGCCCTTGGAGATCTTCTTCCTCCTGCCCTACATGAACC
790 800 810 820 830 840
90 100 110 120 130 140
Seqsta CAGATCTCTACCTTAAGAAGTTCATCCAGCAGGTCTACCTGGCCAGCATGTGGCGGGC
Mmsubp CAGATCTCTACCTTAAGAAGTTCATCCAGCAGGTCTACCTGGCCAGGATGTGGGTGGG
850 860 870 880 890 900
150
Seqsta CATGAGTT
Mmsubp GATGACTTTCTA 
910
third smaller at approximately 350bp.
On further analysis the sequences revealed that the 563bp product was indeed NK- 
1R (Figure 2.73, p41b) but the other two products were not related to tachykinin 
receptors. The larger product matched the database sequence for the Prp gene 
from the Golden Syrian hamster (GenEMBL, accession no. J02686) whilst the 
sequence from smaller product matched that from the mouse PAP homologous 
protein gene (GenEMBL, accession no. D13509), (Figures 2.71 & 2.72, p41a). 
These non-specific products probably arose due to the degenerate nature of the 
primers and also the high number of cycles created by performing a secondary 
round of PCR (Innis & Gelfand, 1990).
As these primers had given these initially promising results, the next step was to 
alter the conditions so as to increase the probability of amplifying a related 
receptor. To use slower ramping times between the annealing and extension 
temperatures and to perform the initial 2-5 cycles at a low nonstringent annealing 
temperature. These conditions should allow a greater proportion of the population 
degenerate of primers to anneal, therefore yeilding a greater number of products, 
which when screened could include a new tachykinin receptor group member 
(Compton, 1990).
Work on this optimisation was started, however, being an MSc project with a 
limited time-span it was decided to shift the focus of to an area which would give 
guaranteed results. The Eh-like dopamine receptors were of considerable interest 
to my industrial sponsors and therefore it was decided to concentrate on this group 
by cloning and further characterising these receptors.
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At the time that this research began this was a rapidly expanding area with 
evidence for many GPLR receptors as yet uncloned. Although research has 
advanced greatly since this time, the work contained in this project is still of 
interest and use in currect research. The method of sub-grouping receptors by 
sequence and subsequently using the consensus produced for degenerate primer 
design has great potential in the discovery of new GPLRs.
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Investigation of Dopamine D2 S Receptors
The cationic amine dopamine is an intermediate in the biosynthetic pathway of the 
neurotransmitters adrenaline and noradrenaline, it is also an important 
neurotransmitter itself although it is much less widely distributed in brain tissue. 
Dopamine neurons lack the enzyme dopamine (3-hydroxylase and therefore 
dopamine is the final product of the pathway.
Figure 4.01 Synthesis o f Dopamine
In the central nervous system (CNS) dopamine is involved in the control of motor, 
cognitive, affective and neuroendocrine processes and in the peripheral nervous 
system dopamine regulates hormone synthesis and secretion, vascular tone and 
renal function.
Dopaminergic systems are of particular interest because of their role in the 
aetiology and management of various disorders such as the motor disorders, 
Parkinson's disease and Huntington's disease. Both involve nigrostriatal 
degeneration and an alteration in dopamine neurotransmission, decreased in 
Parkinsonism leading to rigidity, tremor and hypokinesia and in Huntington's an 
increase causing severe involuntary movements.
transmitted
Tyrosine taken up l-DOPA DoPa— > DOPAMINE  > across
synapse 
to D receptors
into neuron decarboxylase
Dopamine-p-
hydroxylase
NORADRENALIN
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In the mesolimbic system which is involved with cognitive and emotional 
responses, dopamine also acts as a neurotransmitter and it is believed that it may 
be involved with the etiology of schizophrenia although there has been no 
evidence of altered transmission.
Most dopamine in the brain is located in the nigrostriatal pathway and the axons 
extending into the striatum, it is also found to varying extents in the nucleus 
accumbens, hypthalamus, pituitary gland, olfactory bulb and retina. In the 
periphery it is present in some sympathetic neurons, mainly in the kidney.
4.1 Dopamine Receptors
Initial research concluded that the effects of dopamine could be accounted for by 
the existence of two receptor subtypes which were named the Di and D2 dopamine 
receptors (Kebabian & Caine, 1979). Recent developments however have 
demonstrated that the family is larger, with six distinct dopamine receptor 
subtypes isolated at present and indications of further, as yet unidentified 
members.
4.11 D2 -like Receptors
The rat D2 receptor was the first member cloned (Bunzow et al, 1988) and was 
confirmed as possessing the functional properties originally predicted by Sasaki &
Sato (1987) of coupling inhibitorally to adenylate cyclase. In addition the high 
affinity for benzamides and low affinity for benzazepines discovered by Stoof & 
Kebabian (1984) was shown to conform (Albert etal, 1990).
The D2 dopamine receptor is typical of the classic GPLR structure however it has 
been found to exist in two forms derived from the same gene by alternative 
splicing (Dal Toso etal, 1989). The long form (D21J  contains an additional 29 
amino acids in the third cytoplasmic loop and has slight pharmacological
45
Section B: Introduction - Chapter 4
differences from the short form (E>2 s)- The major difference so far reported is that 
E>2S inhibits adenylyl cyclase to a greater extent (Dal Toso et al, 1989). The long 
form predominates in rodents and the short in humans.
Additional 'I^-like' receptors were subsequently cloned, D3 (Sokoloff etal, 1990; 
Giros et al, 1990) and D4 (Van Tol etal, 1991). Both bind the benzamide and 
butyrophenone ligands as D2 does but also possess distinguishing 
pharmacological characteristics. Structurally they are also similar, having a classic 
GPLR arrangement, with short C terminal and long 13 loops, characteristic of 
GPLRs which are coupled to Gi leading to inhibition of adenylyl cyclase and Ca2+ 
channels and activation of K+ channels.
Subsequently, a second spliced isoform of the D3 receptor has been isolated and 
also many variants of the human D4 receptor. The D4 receptor varies at the third 
cytoplasmic loop region and was the first catecholamine receptor to be discovered 
with polymorphic variation involving the repeat of a 48 base pair sequence from 
two to seven times (D4 .2 , D4.3 etc.), in human populations. Each has a different 
pharmacological profile for spiperone and clozapine binding (Van Tol et al, 1992). 
The fact that this gene shows polymorphism has implications for neuropsychiatric 
disease (such as schizophrenia) as other occurances of repeated sequences have 
been implicated in disease (eg fragile X syndrome and myotonic dystrophy).
4.12 Di-Like Receptors
Using strategies based on the nucleotide sequence of the cloned E>2 receptor 
several groups discovered other slightly less homologous dopamine receptors. 
The first of these was named the Di receptor as it conformed well to the expected 
second messenger coupling and pharmacological properties of the classical Di 
described by Kebabian & Caine 1979. Structurally this receptor also had the 
GPLR topology, with 40-45%  homology at the residue level to D2 , it also had
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homology to the p-adrenergic and 5HT receptors. (Dearry etal, 1990; Monsma et 
al, 1990; Sunhara etal, 1990; Zhou etal, 1990). The coupling of this receptor to 
the adenylyl cyclase system was found to be stimulatory via coupling to the Gs 
protein.
Subsequently other Di-like dopamine receptors were cloned and characterised 
from rat and human (Sunhara etal, 1991; Tiberi et al, 1991). They shared a high 
TM residue identity of -80% with the Di receptor, the same coupling to Gs and 
also the absence of introns within their coding regions, as with the Di receptor 
gene. They have patterns of mRNA in the same regions as Di but at a lOx lower 
level of expression but also a high level of expression in the hippocampus, 
anterior pretectal nuclei and mammalian nuclei (Tiberi etal, 1991) unlike Di.
Problems with inconsistent nomenclature have lead these Di-like receptors to be 
known as D5 or less confusingly Dig with Di being renamed D ia  (Tiberi et al, 
1991).
4.2 Importance Of Dopamine Receptor Research
The discovery of new dopamine receptors has been due to the use of molecular 
biology making it possible to define distinct receptor subtypes previously 
indistinguishable by biochemical and pharmacological properties. Difficulties 
such as large variances in the expression of different subtypes and individual 
expression patterns made further biochemical discovery difficult. However, 
pharmacology has been vital in providing the initial essential evidence for the 
existence of such receptors and points to evidence for additional dopamine 
receptor subtypes.
4.3 Dopamine Receptor Pharmacology
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Assessing the binding affinities of certain compounds for receptors is usually 
performed using radioligands in saturation and competition assays, this is fine for 
antagonists which block the action of the receptor, however agonists (which 
stimulate action) are more complex to assess. In tissue, the receptor can be in 
either of two states, high or low affinity for the agonist. Low affinity receptors 
are not linked to a G protein, whereas high affinity are which is though to give a 
conformational change making the receptor more receptive to agonist binding. 
This situation must be mimicked in vitro to give a true measurement of agonist 
binding and this is done by the addition of GTP and Mg2+ ions, which causes the 
receptors to dissociate from linked G proteins leaving all in a standard low affinity 
state.
4.31 Dj-Iike Receptor Pharmacology
As mentioned previously the Di and D5 receptors share high amino acid homology 
in the TM domains and as these regions are thought to be involved in ligand 
binding it therefore follows that these receptors have a very similar ligand binding 
profile. They both have a high affinity forbenzazepines (eg SKF 38393, a partial 
agonist and SCH 23390 an antagonist) and low affinity for butyrophenones (eg 
spiperone and halperidol). However there are presently only two notable binding 
differences, dopamine has a tenfold greater affinity for D5 (Tiberi et al, 1991; 
Sunahara et al, 1991) and the antagonists (+) butaclamol and SKF83566 have 
greater affinity for Di (Gingrich & Caron, 1993).
4.32 D2 -Like Receptor Pharmacology
Of the three full length receptors, D4 has the most distinctive pharmacological 
profile, as would be expected as it also has the most differences in sequence at the 
TM regions.
A general shared characteristic, in contrast to the Di-like receptors, is that they 
each have a high affinity for butyrophenones and a low affinity for some
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benzazepines (eg SKF 38393. However, D2 and D3 have relatively high affinity 
for raclopride (another benzazepine) whereas D4 has a much lower affinity. An 
antagonist which appears to have selectively higher affinity for D4 is clozapine. 
There is much debate about whether this is true, but it remains the only selective 
ligand for separating the E>2-like group members (Van Tol et d , 1991). This 
information is summarised in Table 4.321.
Table 4.321 Lfy-Like Selective Ligands
Receptor => D 2L d 3 E>4
Selective Ligands
Agonists N-0437
bromocriptine
7-OH-DPAT*
quinperole
quinerolane
none
Antagonists (+) butaclamol 
YM091512 
domperidone 
haloperidol 
remoxipride
all D2 ligands but 
with lower affinity 
eg remoxipride 
binds with ~1 0 0 x 
less affinity
clozapine 
(binds with a lOx 
higher affinity than 
for D2/3)
Radiolabels [3H]-spiperone 
(also binds 5HT) 
[3H]-YM091512 
[125j]_rodosulpiride
[3H]-YM091512
[3H]-7-OH-DPAT
[3H]-YM091512
[3H]-clozapine
* 7-hydroxy-N,N-di-n-propyl-2-aminotetralin
4.4 Antipsychotic Drugs
The discovery of dopamine receptors was due to research into the mechanism of 
antipsychotic drugs (Seeman & Van Tol, 1994). It was shown using active and 
inactive enantiomers (eg + & - butaclamol), that neuroleptics (antipsychotics) 
specifically blocked dopamine receptors (Seeman et al, 1975). Now that these 
receptors have been cloned, this is facilitating the discovery of selective drugs for 
the treatment of diseases of the motor and cognition systems such as Parkinson's 
disease (dopaminergic degeneration), Huntington's chorea, and schizophrenia 
(type I, due to dopaminergic overactivity) (Seeman, 1987).
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All neuroleptics except clozapine have been shown to occupy >60% of D2 
receptors under therapeutic conditions, however clozapine occupies only 2 0 % 
(Karbe, 1991). Clozapine is an antipsychotic drug used in the treatment of type I 
schizophrenia, proposed to involve overactivity in dopaminergic systems in the 
CNS. Evidence for this includes the increase in density of the D2 and D3 
receptors by 10% and D4 by 600% (Seeman etal, 1993). Clozapine is classed as 
an atypical antipsychotic because it doesn't cause the Parkinson's-like side effects, 
which appear with other antipsychotic drug treatments. This is thought to be 
because the D4 receptor is present at low levels in the basal ganglia (where the 
degeneration of the dopaminergic systems of Parkinson's sufferers occurs), and 
higher levels in the limbic system associated with the dopaminergic system 
overaction, (nigrostriatal, mesolimbic and mesocortical dopaminergic pathways 
are involved) (Watson & Arkinstall, 1994).
4 .5  Aims of Research
This section of work arose from the need to persue a line of research with 
guaranteed results within the time-span of an MSc project. Although section A 
involved an interesting and valid area of research it was covering new ground and 
may not have produced satisfactory results within the given time. Therefore, it 
was decided, along with my CASE sponsors ‘Syntex Ltd.’ that the area of 
research should be altered slightly.
As they had a particular interest in the D2-like dopamine receptors it was decided 
that this should be the area of focus.
The aim was to clone two of the D2-like dopamine receptors, then to express them 
and perform ligand-binding assays, to build up a pharmacological profile. It was 
then hoped that chimera between the two could be created (as mentioned in section
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A, 1.9) to investigate the molecular basis of the differential pharmacology of 
receptor type. Ideally E>2 and D3 receptors would be used as these share the most 
homology, differing at very few residues for the same species and are therefore 
more suitable for chimera design.
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52Cloning of the short-form mouse D2 receptor
5.1 Background
Rodents, particularly rats and mice are frequently used in molecular 
experimentation, both for general research into molecular biology and also for 
specific species research to discover their unique biology and the similarities and 
differences in relation to other species. This has lead to a spectrum of similarities 
to humans being discovered and utilised, particularly in the field of molecular 
biology. They are utilised as models for the human systems with which they 
share homology and the results have become more applicable to humans as strains 
have been developed with certain physical and genetic characteristics to facilitate 
their use. Ethically, some of the most useful molecular genetic experiments such 
as transgenic work can not be performed on human subjects, the use of laboratory 
animal such as mice allows research in this ground breaking area.
Mouse and rat receptor genes share a relatively high homology with the human 
sequences (Figure 5.11, p52a), and as mouse brain tissue is readily available in 
the laboratory, it was decided to isolate and study the D2 dopamine receptor from 
mouse striatal tissue, where this receptor is relatively abundant. At the time of this 
work only the long form (D2L) of this mouse receptor was available from the 
GenEMBL database. So sequence from both ends of the ORF (open reading 
frame) was used to design PCR primers as the short isoform of the receptor is a 
splice variant and therefore will also be amplified by the same primers.
The total length of the mouse D2 long isoform is 1419bp (444 aa) and the short 
form is 1332bp (415 aa) with a 87bp (29 aa) fragment being spliced from the long 
isoform between 723bp and 811 bp at the RNA level.
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Figure 5.11 Alignment of the mouse, rat and human dopamine D2 receptor
peptide sequences (long isoforms), showing the high level of 
homology. Differences in sequence are indicated in bold type.
1 50
m o u se  t a a g g a a v r g  c g g s w k p r a a  g a f s g p g r p m  a * r a v p p s g p  tapMDPLNLS
r a t  .a a g g a a v r g  c g g s w k p p a a  g a f s g p g r h m  a * r a v p p s g p  tapMDPLNLS
hum an ........................................................................................................ w p p s r s  talM DPLNLS
51 100
m o u se  WYDDDLERQN WSRPFNGSEG KADRPHYNYY AMLLTLLIFI IVFGNVLVCM
r a t  WYDDDLERQN WSRPFNGSEG KADRPHYNYY AMLLTLLIFI IVFGNVLVCM
hum an WYDDDLERQN WSRPFNGSDG KADRPHYNYY ATLLTLLIAV IVFGNVLVCM
1 0 1  15 0
m o u se  AVSREKALQT TTNYLIVSLA VADLLVATLV MPWWYLEW GEWKFSRIHC
r a t  AVSREKALQT TTNYLIVSLA VADLLVATLV MPWWYLEW GDWKFSRIHC
hum an AVSREKALQT TTNYLIVSLA VADLLVATLV MPWWYLEW GEWKFSRIHC
151  2 0 0
m o u se  DIFVTLDVMM CTASILNLCA ISIDRYTAVA MPMLYNTRYS SKRRVTVMIA
r a t  DIFVTLDVMM CTASILNLCA ISIDRYTAVA MPMLYNTRYS SKRRVTVMIA
hum an DIFVTLDVMM CTASILNLCA ISIDRYTAVA MPMLYNTRYS SKRRVTVMIS
2 0 1  2 5 0
m o u se  IVWVLSFTIS CPLLFGLNNT DQNECIIANP A FW Y SSIV S FYVPFIVTLL
r a t  IVWVLSFTIS CPLLFRLNNT DQGECIIANP A FW Y SSIV S FYVPFIVTLL
hum an IVWVLSFTIS CPLLFGLNNA DQNECIIANP A F W Y SSIV S FYVPFIVTLL
2 5 1  3 0 0
m o u se  VYIKIYIVLR KRRKRVNTKR SSRAFRANLK TPLKGNCTHP EDMKLCTVIM
r a t  VYIKIYIVLR KRRKRVNTKR SSRAFRANLK TPLKGNCTHP EDMKLCTVIM
hum an VYIKIYIVLR RRRKRVNTKR SSRAFRAHLR APLKGNCTHP EDMKLCTVIM
301  3 5 0
m o u se  KSNGSFPVNR RRMDAARRAQ ELEMEMLSST SPPERTRYSP IPPSHHQLTL
r a t  KSNGSFPVNR RRMDAARRAQ ELEMEMLSST SPPERTRYSP IPPSHHQLTL
hum an KSNGSFPVNR RRVEAARRAQ ELEMEMLSST SPPERTRYSP IPPSHHQLTL
35 1  4 0 0
m o u se  PDPSHHGLHS NPDSPAKPEK NGHAKIVNPR IAKFFEIQTM PNGKTRTSLK
r a t  PDPSHHGLHS NPDSPAKPEK NGHAKIVNPR IAKFFEIQTM PNGKTRTSLK
hum an PDPSHHGLHS TPDSPAKPEK NGHAK.DHPKIAKIFEIQTM PNGKTRTSLK
40 1  4 5 0
m o u se  TMSRRKLSQQ KEKKATQMLA IVLGVFIICW LPFFITH ILN IHCDCNIPPV
r a t  TMSRRKLSQQ KEKKATQMLA IVLGVFIICW LPFFITH ILN IHCDCNIPPV
hum an TMSRRKLSQQ KEKKATQMLA IVLGVFIICW LPFFITHILN IHCDCNIPPV
451
m o u se  LYSAFTWLGY VNSAVNPIIY TTFNIEFRKA FMKILHC*
r a t  LYSAFTWLGY VNSAVNPIIY TTFNIEFRKA FMKILHC*
hum an LYSAFTWLGY VNSAVNPIIY TTFNIEFRKA FLKILHC*
52a
Section B: Cloning of D2S receptor - Chapter 5
5.2 Experimental Design
5.21 Overview
Total RNA was isolated from mouse striatal tissue and first strand cDNA was 
synthesised from this. The cDNA was then used as a template for nested PCR. 
The initial round of PCR was performed using a pair of primers designed using 
the sequences immediately 5' and 3' of the D2L receptor open-reading frame 
(ORF) sequence (GenEMBL x55674). Then a second round of PCR was 
performed on the first round product using a second, inner pair of primers 
designed to encompass the 5' and 3' ends of the D2L receptor ORF sequence, with 
restriction enzyme sites incorporated at the primers’ 5' ends.
Products of the expected size from the second round of PCR, were purified and 
cloned into the T-vector ’pT7Blue(R)' (Novagen) where the identity of each clone 
was determined initially by restriction and those which appeared correct sequenced 
using United States Biochemical 'Sequenase 2.0' (T7 DNA Polymerase). When 
a D2 clone was confirmed it was subcloned into 'pcDNA3' a mammalian 
expression vector (Invitrogen) and its orientation confirmed by restriction digest.
5.22 Polymerase Chain Reaction (PCR)
Nested primers were designed involving two separate pairs of primers. Pair A 
corresponded to sequence outside of the open reading frame (ORF) of the D2L 
sequence (GenEMBL), while pair B corresponded to sequence at either end of the 
ORF (see Figures 5.221 & 5.222, p52a & 53a).
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Figure 5.221 Mouse E>2l  dopamine receptor nucleotide (GenBank X55674,
Montmayeuretal, 1991) and amino acid sequence showing primer 
sites, the area spliced from the short isoform and restriction 
sites utilised for identification of the clone.
B
a  a a q a q c c q t q c c a c c c a q t q q c c c c
m A l
H
I
actqccccaATGGATCCACTGAACCTGTCCTGGTACGATGATGATCTGGAGAGGCAGAAC 
B1 M D P L N L S W Y D D D L E R Q N
5 2 TGGAGCCGGCCCTTCAATGGGTCCGAAGGGAAGGCAGACAGGCCCCACTACAACTACTAT 
1 8 W S R P F N G S E G K A D R P H Y N Y Y
1 1 2  GCCATGCTGCTCACCCTCCTCATCTTTATCATCGTCTTTGGCAATGTGCTGGTGTGCATG 
3 8 A M L L T L L  I  F I  I V F G N V L V C M
17 2  GCTGTATCACGAGAGAAGGCTTTGCAGACCACCACCAACTACCTGATAGTCAGCCTCGCT 
5 8 A V S R E K A L Q T T T N Y L I V S L A
2 3 2  GTGGCCGATCTTCTGGTGGCCACACTGGTTATGCCCTGGGTCGTCTATCTGGAGGTGGTG 
7 8 V A D L L V A T L V M P W V V Y L E V V
2 9 2  GGTGAGTGGAAATTCAGCAGGATTCACTGTGACATCTTTGTCACTCTGGATGTCATGATG 
9 8 G E W K F S R I H C D I F V T L D V M M
P
v
u
3 5 2  TGCACAGCAAGCATCTTGAACCTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCC 
1 1 8  C T A S  I L N L C A I  S I  D R Y T A V A
4 1 2  ATGCCTATGTTGTATAACACACGCTACAGCTCCAAGCGCCGAGTTACTGTCATGATCGCC 
1 3 8  M P M L Y N T R Y S S K R R V T V M I A
4 7 2  ATTGTCTGGGTCCTGTCCTTCACCATCTCTTGCCCACTGCTCTTTGGACTCAACAACACA 
1 5 8  I V W V L S F T I S C P L L F G L N N T
5 3 2  GACCAGAATGAGTGTATCATTGCCAACCCTGCCTTCGTGGTCTACTCCTCCATCGTCTCG 
1 7 8  D Q N E C  I  I A N P A F V V Y S S  I V  S
5 9 2  TTCTACGTGCCCTTCATCGTCACCCTGCTGGTCTATATCAAAATCTACATCGTTCTCCGC 
1 9 8  F Y V P F I V T L L V Y I K I Y I V L R
6 5 2  AAGC GTC GGAAGC GGGTCAACAC CAAGCGTAGCAGC C GAGC TTTCAGAGC CAAC C TGAAG 
2 1 8  K R R K R V N T K R S  S R A F R A N L K
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7 1 2  ACACCACTCAAGGGCAACTGTACCCACCCTGAGGACATGAAACTCTGCACCGTTATCATG 
2 3 8  T P L K G N C T H P E D M K L C T V I M
S
a
c
7 7 2  AAGTCTAATGGGAGTTTCCCAGTGAACAGGCGGAGAATGGATGCTGCCCGCCGAGCTCAG 
2 5 8  K S N G S F P V N R R R M  D A A R R A Q
8 3 2  GAGCTGGAAATGGAGATGCTGTCAAGCACCAGCCCCCCAGAGAGGACCCGGTATAGCCCC 
2 7 8  E L E M E M L S S T S P P E R T R Y S P
8 9 2  ATCCCTCCCAGTCACCACCAGCTCACTCTCCCCGATCCATCCCACCACGGTCTACATAGC 
2 9 8  I P P S H H Q L T L P D P S H H G L H S
9 5 2  AACCCTGACAGTCCTGCCAAACCAGAAAAGAATGGGCATGCCAAGATTGTCAATCCCAGG 
3 1 8  N P D S P A K P E K N G H A K I V N P R
1 0 1 2  ATTGCCAAGTTCTTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTTAAG 
3 3 8  I A K F F E I Q T M P N G K T R T S L K
1 0 7 2  ACGATGAGC C GCAGGAAGCTCTC C CAGCAGAAGGAGAAGAAAGCCACTCAGATGCTTGC C 
3 5 8  T M S R R K L S Q Q K E  K K A T Q M L A
1 1 3 2  ATTGTTCTTGGTGTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACGCACATCCTGAAT 
3 7 8  I V L G V F I  I C W L P F F I T H I L N
1 1 9 2  ATACACTGTGACTGCAACATCCCACCAGTCCTCTACAGCGCCTTCACATGGCTGGGCTAT 
3 9 8  I H C D C N I P P V L Y S A F T W L G Y
1 2 5 2  GTCAACAGTGCCGTGAACCCCATCATCTATACCACCTTCAACATTGAGTTCCGCAAGGCC 
4 1 8  V N S A V N P  I  I Y T T F N I E F R K A
1 3 1 2  TTCATGAAGATCCTGCACTGCt q a q t c t q c c c c t t q c c t g c a c a q c a q c t q c t t q c c q c c  
4 3 8  F M K I L H C *  A 2
B2
t c c c t q c c t a q q c a q
The PCR primer sites are double underlined and labelled A1/A2 and B1/B2. The 87bp 
region underlined from 723bp shows the region spliced to form the short isoform. The 
five underlined 2 0 mers show the position of sequencing primers used to sequnce the 
clone in both directions over its entire length.
Enzymes that cut - BamHI @ 3 bp ORF length - 1332 bp = 444 aa
PvuII @ 404 bp 
SacI @ 828 bp 
(EcoRI does not cut)
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Figure 5.222 Schematic diagram showing position of nested primers fo r
amplification ofD2s
5' - Al -> I- B1 -> <-B2-l <- A2 - 3'
r  ORF 1
Table 5.223 Sequence o f nested D2 receptor PCR primers
primer
Primer Nucleotide Sequence 
5’ y
Length
(bp)
Tm
(°C)
Sense
Al AGAGCCGTGCCACCCAGTGG 2 2 6 8 Sense
A2 CCTAGGCAGGGAGGCGGCAA 2 2 6 8 Anti
B1 C GCG ’ A AT T CTGCCCC A ATGGATCC ACTGA A 30 64 Sense
B2 GCGG ’ A A T T C gcagtgcag gatcttcatg aag 30 6 6 Anti
Table 5.224 PCR reaction conditions
Primary PCR Secondary PCR Duration
Hot-start 94°C 94°C 1 min
Denaturation 94°C 94°C 45 sec
Annealing x30 57°C 55°C 1 min
Extension 72°C 72°C 2  min
Soak 4°C 4°C indefinite
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Figure 5.221 shows the exact position of primer annealing to the dopamine D2 
receptor sequence and this is illustrated schematically in Figure 5.222. The actual 
primer sequences are displayed in Table 5.223 (p54) where it can be seen that the 
outer pair (Al & A2) are totally homologous to sequences 5’ & 3’ of the mouse 
D2 dopamine receptor. Whereas the inner primers (B1 & B2) have total 
homology to the sequence at the 3’ end but have non-homologous 5’ ends which 
include EcoRI restriction sites to aid cloning.
The design of the primers took into account several basic factors in order to 
optimise their action. Because each pair was totally matched to the D2 receptor 
sequence over at least 15 nucleotides to increase the probability of unique 
homologous priming, a non-homologous 5’ end could be added to the inner 
primers without affecting their priming ability. The Tms (melting temperatures) 
were balanced within a pair so that both primers annealed at around the same 
temperature. The 3’ ends were designed to be non-homologous to each other to 
prevent primer-dimer formation and attempts were made to keep the G/C content 
to below 60% to avoid problems with secondary structures.
The reaction conditions were also designed to help prevent mis-priming by using 
hot-start PCR and short ramping times and the nested nature of the primers 
significantly increased the sensitivity of the reaction (McPherson et al, 1990). The 
reaction components and concentrations are shown in Methods (Chapter 8).
5.23 Cloning and Sequencing
PCR products from the second round of thermal cycling were run on a 1% 
agarose gel and the DNA collected using NA45 paper (Schleider & Schuell) as 
described in Chapter 8 .
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The pT7Blue(R) T-vector (R & D Systems) was used to clone the products, as it 
is specifically designed for the cloning of DNA fragments produced by PCR. Taq 
DNA polymerase leaves single 3' A-nucleotide overhangs on the reaction products 
(Clark, 1988). The vector has been digested with EcoRl and single 3' dT 
residues added at each end, allowing direct ligation of the PCR product, but 
preventing self-ligation.
After ligation and transformation (Methods, Chapter 8 ) individual clones were 
selected and restricted using the enzymes BamHl, SacI, PvuII and EcoRI which 
permit positive identification of a dopamine D2 receptor clone and determine its 
orientation within the vector.
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5.3  Results
5.31 Polymerase Chain Reaction
The results of the PCR reaction are displayed in Figure 5.311 (p58). Reactions 
using cortex cDNA as a template were unsuccessful, however striatal cDNA 
produced four definite bands at approximately 1.3, 0.7, 0.4 and 0.3kb. The 
expected length of the long D2 isoform is 1332bp and the short form 1245bp, 
therefore the largest band (which also had the strongest intensity) was collected.
5.32 Cloning and restriction
Figure 5.321 (p59) is a schematic diagram of the T-vector pT7Blue(R) containing 
the desired D2 receptor clone. It illustrates how the restriction enzymes previously 
mentioned can be used to identify correct inserts.
Table 5.322 Restriction fragment sizes produced by digesting either D2 receptor
isoform cloned into pT7Blue(R) with different enzymes
Positive Orientation (bp) Negative Orientation (bp)
C>2S D2L D2S D2L
EcoRI 1258 1345 1258 1345
2899 2899 2899 2899
BamHI 1251 1338 23 23
2906 2906 4134 4221
SacI 449 536 780 867
3708 3708 3377 3377
PvuII 967 1054 1011 1098
581 581 537 537
2609 2609 2609 2609
The above table predicts the approximate size of fragments obtained from 
digestion of mouse D2 dopamine receptors in pT7Blue. Figure 5.323 (p60) 
shows the restriction digest result from a clone which appears to contain a P 2 
receptor in the correct orientation. This clone was selected and sequenced.
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Figure 5.311 Product of second round PCR using the nested dopamine D2 S 
receptor prim er pairs with mouse striatal cDNA template.
1.6 kb
1.0 kb
500 bp
2 3 4 5 6 7
Key to lanes 1 Second round PCR of striatal cDNA using nested D2 
primers
2 First round PCR of striatal cDNA using outer D2 primers
3 Same as lane 1 after collection of larger band sizes using 
NA45 paper
4 250ng lkb marker (Gibco BRL)
5 Second round PCR of cortex cDNA using nested D2 
primers
6 Zero template
7 First round PCR of cortex cDNA using outer D2 
primers
PCR Programme 94°C - 1 min
94°C - 45 sec
57 C - 1 min x 30 cycles 
72°C - 2 min
4°C soak
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BamHI
pT7Blue(R)
Hindlll
BspM
Sphl
S s e 8 3 8 7
P st l
Sail
A cc l
Hindi
Xbal
Spel
Ndel
BamHI
A v a l
S m al
Kpnl
S ac i
EcoRI
f1 origin
Figure 5.321 Mouse C>2 s (short isoform) dopamine receptor ligated into 
pT7Blue(R) T-cloning vector, 4.2kb (R & D Systems).
From the map it can be seen how the use of selected restriction 
enzymes {BamHI, Saci, PvuII and EcoRI) can be used to confirm 
the insert and to determine its orientation within the vector.
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Figure 5.323 Identification of a Do receptor clone in the plasmid vector pT7
(R & D Systems) by restriction fragment length polymorphism.
Key to lanes
Products were 
Product sizes
1.6 kb
1.0 kb
1 2 3 4 5 6 7 8 9
1 &6 E co R I  digestion
2 & 7 Bam HI digestion
3 & 8 Pvu II digestion
4 & 9 S a c i  digestion
5 250ng lkb marker (Gibco BRL)
electrophoresed on a 1% agarose gel at 50 volts for 1 hour
1 -  3000 & 1300 bp
2 * 3000 & 1300 bp
3 * 2500, 1000 & 600 bp
4 * 3800 & 550 bp
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Figure 5.331 Alignment of mouse C>2 s dopamine receptor short isoform 
sequence1, determined by dideoxy DNA sequencing, to 
published mouse D2L receptor2 (x55674, Montmayeur etal, '91)
1ctgccccaATGGATCCACTGAACCTGTCCTGGTACGATGATGATCTGGAGAGGCAGAAC 51  
2 CtgccccaATGGATCCACTGAACCTGTCCTGGTACGATGATGATCTGGAGAGGCAGAAC
TGGAGCCGGCCCTTCAATGGGTCCGAAGGGAAGGCAGACAGGCCCCACTACAACTACTAT 1 1 1  
TGGAGCCGGCCCTTCAATGGGTCCGAAGGGAAGGCAGACAGGCCCCACTACAACTACTAT
GCCATGCTGCTCACCCTCCTCATCTTTATCATCGTCTTTGGCAATGTGCTGGTGTGCATG 17 1  
GCCATGCTGCTCACCCTCCTCATCTTTATCATCGTCTTTGGCAATGTGCTGGTGTGCATG
GCTGTATCACGAGAGAAGGCTTTGCAGACCACCACCAACTACCTGATAGTCAGCCTCGCT 2 3 1  
GCTGTATCACGAGAGAAGGCTTTGCAGACCACCACCAACTACCTGATAGTCAGCCTCGCT
GTGGCCGATCTTCTGGTGGCCACACTGGTTATGCCCTGGGTCGTCTATCTGGAGGTGGTG 2 9 1  
GTGGCCGATCTTCTGGTGGCCACACTGGTTATGCCCTGGGTCGTCTATCTGGAGGTGGTG
GGTGAGTGGAAATTCAGCAGGATTCACTGTGACATCTTTGTCACTCTGGATGTCATGATG 3 5 1  
GGTGAGTGGAAATTCAGCAGGATTCACTGTGACATCTTTGTCACTCTGGATGTCATGATG
TGCACAGCAAGCATCTTGAACCTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCC 4 1 1  
TGCACAGCAAGCATCTTGAACCTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCC
ATGCCTATGTTGTATAACACACGCTACAGCTCCAAGCGCCGAGTTACTGTCATGATCGCC 4 7 1  
ATGCCTATGTTGTATAACACACGCTACAGCTCCAAGCGCCGAGTTACTGTCATGATCGCC
ATTGTCTGGGTCCTGTCCTTCACCATCTCTTGCCCACTGCTCTTTGGACTCAACAACACA 5 3 1  
ATTGTCTGGGTCCTGTCCTTCACCATCTCTTGCCCACTGCTCTTTGGACTCAACAACACA
GACCAGAATGAGTGTATCATTGCCAACCCTGCCTTCGTGGTCTACTCCTCCATCGTCTCG 5 9 1  
GACCAGAATGAGTGTATCATTGCCAACCCTGCCTTCGTGGTCTACTCCTCCATCGTCTCG
TTCTACGTGCCCTTCATCGTCACCCTGCTGGTCTATATCAAAATCTACATCGTTCTCCGC 6 5 1  
TTCTACGTGCCCTTCATCGTCACCCTGCTGGTCTATATCAAAATCTACATCGTTCTCCGC
AAGCGTCGGAAGCGGGTCAACACCAAGCGTAGCAGCCGAGCTTTCAGAGCCAACCTGAAG 7 1 1  
AAGC GTC GGAAGC GGGTC AAC ACC AAGC GT AGC AGC C GAGCTTTC AGAGC C AAC CTGAAG
ACACCACTCAAG.......................................................................................................................................  7 2 3
ACACCACTCAAGGGCAACTGTACCCACCCTGAGGACATGAAACTCTGCACCGTTATCATG 7 7 1
.............................................................................................................. GATGCTGCCCGCCGAGCTCAG 7 4 4
AAGTCTAATGGGAGTTTCCCAGTGAACAGGCGGAGAATGGATGCTGCCCGCCGAGCTCAG 8 3 1
GAGCTGGAAATGGAGATGCTGTCAAGCACCAGCCCCCCAGAGAGGACCCGGTATAGCCCC 8 0 4  
GAGCTGGAAATGGAGATGCTGTCAAGCACCAGCCCCCCAGAGAGGACCCGGTATAGCCCC 8 9 1
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ATCCCTCCCAGTCACCACCAGCTCACTCTCCCCGATCCATCCCACCACGGTCTACATAGC 8 6 4  
ATCCCTCCCAGTCACCACCAGCTCACTCTCCCCGATCCATCCCACCACGGTCTACATAGC 9 5 1
AACCCTGACAGTCCTGCCAAACCAGAAAAGAATGGGCATGCCAAGATTGTCAATCCCAGG 9 2 4  
AACCCTGACAGTCCTGCCAAACCAGAAAAGAATGGGCATGCCAAGATTGTCAATCCCAGG 1 0 1 1
ATTGCCAAGTTCTTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTTAAG 9 8 4  
ATTGCCAAGTTCTTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTTAAG 1 0 7 1
ACGATGAGCCGCAGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTTGCC 1 0 4 4  
ACGATGAGCCGCAGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTTGCC 1 1 3 1
ATTGTTCTTGGTGTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACGCACATCCTGAAT 1 1 0 4  
ATTGTTCTTGGTGTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACGCACATCCTGAAT 1 1 9 1
ATACACTGTGACTGCAACATCCCACCAGTCCTCTACAGCGCCTTCACATGGCTGGGCTAT 1 1 6 4  
ATACACTGTGACTGCAACATCCCACCAGTCCTCTACAGCGCCTTCACATGGCTGGGCTAT 1 2 5 1
GTCAACAGTGCCGTGAACCCCATCATCTATACCACCTTCAACATTGAGTTCCGCAAGGCC 1 2 2 4  
GTCAACAGTGCCGTGAACCCCATCATCTATACCACCTTCAACATTGAGTTCCGCAAGGCC 1 3 1 1
TTCATGAAGATCCTGCACTGCt 1 2 4 5  
TTCATGAAGATCCTGCACTGCt 1 3 3 2
Short form ORF length - 1245 bp - 87 bp shorter than E>2 l  (1332bp)
The sequences are totally homologous over their coding regions, indicating that 
the PCR derived clone of E>2 S does not contain any Taq introduced errors. The 
region spliced in the short form can clearly be seen from 723 - 810bp, this does 
not interrupt the ORF (Figure 5.221, p53a/b)
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The frequency of transformation was low and the chromogenic selection (using 
IPTG and X-Gal), failed to indicate the presence of any clones containing inserts 
(ie a white colony). However, restriction digestion of one of the apparently 
‘negative’ clones showed that it did in fact contain an insert of the correct size. 
This phenomenon could be due to the production of a fusion protein containing 
both the clone and a functional p-galactosidase protein, or possibly another start- 
site within p-galactosidase downstream from the insert site.
5.33 Sequencing
This positive clone was sequenced using the dideoxy method (Chapter 8 ). The T7 
5’ primer and U-19 3’ primer were used to obtain the terminal sequences of the 
clone, then the inner PCR primers (B1 & B2) were used to sequence further into 
the clone. To obtain the central sequence five pairs of internal primers were 
synthesised so that the entire length of the clone could be sequenced in both 
directions (Figure 5.221, p53a/b). The resulting sequence (Figure 5.331,p61) 
shows that the short isoform of the mouse D2 dopamine receptor has been cloned.
5 . 3 4  Subcloning into pcDNA3 (Invitrogen)
The EcoRI sites incorporated into the inner PCR primers were used to subclone 
the receptor into an expression vector, pcDNA3 (Invitrogen). This vector contains 
various features including the CMV (cytomegalovirus) promoter for high-level 
expression, the bovine growth hormone polyadenylation signal for 
polyadenylation of transcribed mRNAs, neomycin resistance for G418 selection 
and an EcoRI site in the polylinker. The subclone could insert in either orientation 
and therefore restriction enzymes were again used to orientate resulting clones. 
Figure 5.341 illustrates how PvuII was used to select clones in the positive 
orientation ready for expression in rat- 1 fibroblasts.
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Hindlll
Kpnl
BamHI
BstXI
EcoRI
c m v pAmp
lamHI
.Pvull
D2R
p cD N A 3
S a c lColEI
EcoRV
BstXI
Notl
Xhol
Xbal
Apal
S V 4 0  polyA
BGH p o ly A A 7 S p 6
f1 oriNeo
PvullS V 4 0  ori
Pvull
Figure 5.341 Mouse E>2 S (short isoform) dopamine receptor ligated into
pcDNA3 mammalian expression vector, 5.6kb (Lnvitrogen), using 
EcoRI sites engineered into the PCR primer 5’ ends.
From the map it can be seen that restriction with the enzyme Pvull 
allows orientation of clones so that the ORF reads forward.
Correct orientation Incorrect orientation
3284 bp 3944 bp
1410 bp 1097 bp
1097 bp 1069 bp
1069 bp 750 bp
6/4
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5 .4  Discussion
The use of cortex cDNA template was unsuccessful which was probably due to P 2 
receptors being expressed at a lower level in this region. It may also be that the 
cortex template is of a lower quality as when it was used with control primers for 
the a-subunit of the GABAa receptor (Chapter 2 ), the amount of product seen 
when using the cortex template was less than that produced from striatal template 
at the same conditions (Figure 2.62).
It was also suprising that more copies of the D2 dopamine receptor were not 
cloned as it had obviously amplified successfully. The transformation frequency 
was consistently low and of the few clones which were isolated only one gave the 
correct digest pattern. The situation was also complicated by the failure of blue 
white selection as the eventual positive clone had a blue phenotype which was 
probably caused by the fragment inserting in frame and causing a lacZ fusion 
protein or transcription restart.
It is clear that the dopamine Ebs receptor has been successfully cloned and can 
now be expressed in order to study its pharmacology.
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Pharmacological Investigation of the Mouse D2S (Short Form)
Dopamine Receptor
The cloned D2 S (short-isoform) dopamine receptor from mouse striatum was 
investigated for its ligand binding properties when expressed in rat- 1 fibroblast 
cells. The same binding assays were also carried out on rat striatal tissue 
containing both D2 S and E>2l  receptors as a comparison of pharmacological 
profiles.
A rapid membrane filtration technique was employed, along with a specific 
radioligand. This is a relatively simple method for investigating direct binding of 
compounds to receptors and is therefore frequently used for many receptor based 
systems such as neurotransmittion and hormone action.
6.1 Saturation Assay
This assay determines the amount of a radioligand specifically bound to a receptor 
species for varying concentrations of the ligand. From the graphical interpretation 
of this data the total number of binding sites (Bmax) can be calculated and also the 
ligand's dissociation constant value (K d ). K d  is defined as the concentration of 
radioligand at which 50% of the total number of receptors are labelled and is 
indicative of the affinity of the ligand for the receptor. A known quantity of 
protein (ie membrane homogenate) was incubated with a range of different 
radioligand concentrations. Disintegration per minute (dpm) of the tritium isotope 
was measured using a scintillation counter. Using the specific activity of the 
radioligand the recorded counts could be converted to radioligand concentrations 
using equation 1, therefore allowing quantitative measurement of the ligand by its 
radioactive nature.
1 Ci = 2 .1 9 7 x 1 0 ^  dpm (equation 1)
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A commercially available tritiated ligand was used, [3H]-spiperone (95 Ci/mmol) 
(DuPont) which is a selective dopamine D2 receptor antagonist. It is ideal as it 
appears to interact with the receptor in the same way as the untritiated form and has 
a long half-life of 12 years.
A saturation assay is composed of several assay forms measuring total and non­
specific binding so that the specific binding of [3H]-spiperone to D2 receptors can 
be calculated;
a) Total binding assay
This is filtered after incubation in order to collect counts representing total 
binding of radioligand to both specific (D2 receptors) and non-specific 
sites, over the range of radioligand concentrations used.
b) Non-specific binding assay (NSB)
These tubes include the drug (+)butaclamol at 10-6 M. This is a D2 
receptor specific ligand at a high concentration (1 0 0  fold excess) in order to 
ensure that it occupies all of the D2 receptor sites present preferentially over 
[3H]-spiperone. Therefore any radioligand which remains after filtration 
can be assumed to be non-specifically bound to the membrane or filter.
3) Unfiltered assay
This is identical to the total assay but remains unfiltered after incubation.
Aliquots are counted to determine the concentration of radioligand used in 
the assay.
Specific binding of the radioligand to the receptor under investigation (Eh) is 
calculated by subtraction of the counts of the NSB assay from that of the total
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binding, for each radioligand concentration. The amount of free ligand is 
calculated by subracting total bound [3H] from the unfiltered assay (ie total pH]).
When the curve is plotted for the specific binding of the radioligand, against the 
free concentration (mol I-1), for an increasing range of concentrations, binding is 
shown to increase until it reaches a steady state, indicated by a plateau on the 
curve. This is the saturation point, where all available receptor molecules are 
occupied by the radioligand, it is known as R i, representing the concentration of 
pH]-spiperone (mol I-1) required to saturate the specific binding sites (D2 
receptors). It is required to calculate the Bmax using the following equation:
Bmax -  Ri = femtomoles receptor per mg protein
2000
mg protein per tube (equation 2)
The experimental data was interpreted using the computer programme 'Ligand' 
(Munson & Rodbard, 1980), a non-linear least squares fitting programme. It 
determines 'best-fit' curves for the values obtained in the assays (see Figures 
6.412 & 6.414, p71a), therefore facilitating calculation of Kd and Bmax values.
The work of Scatchard (1949) on the graphical analysis of saturation data was 
developed by Rosenthal (1967), who showed that by plotting the specific bound 
ligand/free ligand against specific bound ligand a linear slope is produced. The 
negative reciprocal of the gradient produces the Kd value for the radioligand, 
whilst the intercept at x-axis gives the Bmax value (Figures 6.413 & 6.415, p71b). 
The drug ketanserin was included in the assays at a final saturating assay 
concentration (F.A.C.) of 1 x 10_7M. As [3H]-spiperone also has affinity for 
5 HT2 receptors, the addition of ketanserin prevents it binding at these sites.
Even though steps were taken to reduce the D2 non-specific binding of the 
radioligand, there was unavoidable binding to the membrane and filter which could
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reduce the accuracy of the assay. However, this factor was removed by 
subtraction of NSB from total binding allowing calculation of the specific binding.
6.2 Com petition Assay
This assay was used to study the relative affinities of various ligands for receptors.
As with the saturation assay a standard quantity of protein was used, however the 
concentration of radioligand was also fixed and ranges of increasing 
concentrations of various unlabelled competitor ligands were included. The 
unlabelled ligand competes with the radioligand for the receptor binding sites and 
at increasing concentrations of unlabelled competitor the binding of the radioligand 
decreases, ie the competitor is inhibiting the radioligand binding. The ability of 
each competing compound to inhibit the specific binding of the radioligand can be 
quantitatively evaluated by determining its IC50 (inhibitory concentration) value.
This is the concentration of competing ligand at which 50% of specific radioligand 
binding is inhibited. Therefore the greater the affinity of the ligand for the receptor 
the lower its IC50. It can be calculated using a curve fitting programme, or the 
following equation:
log Bi  = n logfl] - n loglCso (equation 3)
B0 -Bi
where: Bi = amount of bound
radioligand in presence of competitor
B0 = amount of bound radioligand 
in absence of competitor
I = competitor (inhibitor)
When the first half of this equation is plotted against log[I] the intercept on the x 
axis gives the IC50 value and the slope of the line, (the slope factor, /%) indicates 
whether binding is simple or complex. An value of one (unity) indicates 
binding to one site following mass action law, however a value > 1 may indicate
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positive cooperativity and < 1 can be due to multiple receptor subtypes, receptor 
states of multiple step binding.
The IC50 could then be converted to the Ki (equilibrium dissociation constant) 
value for the ligand using equation 4, derived by Cheng & Prusoff in 1973.
The negative log of this (pKO provides an index which can be used to compare the 
affinities of different ligands for a receptor.
6.21 Receptor Activation State
Dopamine receptors, like G-protein linked receptors (GPLRs) in general, can 
occur in two main dynamic states. When in complex with a G protein the receptor 
has a high affinity for agonists, which is converted to a low affinity when 
dissociated from the G protein. In normal experimental conditions there are 
receptors both in the high and low affinity states and therefore a non-hydrolysable 
analogue of GTP (Gpp(NH)p) was incorporated into the assay. This causes 
dissociation of G proteins and the convertion of all receptors to the lower affinity 
state giving a more standard binding result and shifting the competition curve for 
that drug to the right, (ie Ki increases, pKi decreases).
6.3 Protein Assay
The membrane and cell homogenates used in the binding assays were themselves 
assayed before use, using a Pierce BSA Assay Kit, to establish their protein 
concentration. This allowed standardisation of results from the saturation 
experiment, as the Bmax is corrected for assay protein concentration.
IC5Q = Ki (mol I"1)
1+ IL1 
KD
[L] = 3H-ligand conc. 
(equation 4:
Cheng-Prusoff equation)
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RESULTS
6 .4 1  Saturation Binding of [3H]-spiperone
Rat-1-fibroblast cells were stably transfected with the wild-type mouse C>2s 
dopamine receptor, binding assays were performed on membrane preparations 
from these and compared with D2 receptor preparations from rat striatal tissue.
The results from this assay show the binding of [3H]-spiperone to the D2 receptor 
population in rat stiatal tissue and to the cloned mouse D2S expressed in rat- 1 
fibroblast cells. Protocols and conditions for the assays have been determined by 
extensive research at 'Syntex' (unpublished) and are similar to other published 
conditions for these assays (Guiramand et al 1995; Leysen et al 1992), (see 
'Materials', Appendix I).
The results of the protein assay for the homogenates used in the saturation assays 
are shown in Table 6.411. The values were calculated using a standard curve 
generated using bovine serum albumin (BSA).
BSA Standard curve equation for striata homogenate y = -2.84e-3 + 0.88x 
BSA Standard curve equation for cell homogenate y = 9.273e-3 + 1.142x
Table 6.411 Membrane Homogenate Protein Concentration (mg protein/tube)
Assay Number (n) 1 2 3
Striatal Homogenate 0.164 0.158 0.145
Clone Homogenate 0.149 0.149 0.149
The curves for the binding of the D2 specific, displaceable radioligand [3H]- 
spiperone (Figures 6.412 & 6.414, p71a), show that binding is saturable, and the 
corresponding Scatchard plots (Figures 6.413 & 6.415, p71b) indicate a one site
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Figure 6.414 Saturation binding curve of f H]-spiperone
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binding model in agreement with previous studies (Woodward et al 1996; 
Guiramand etal 1995; Leysen etal 1992).
Non-specific binding to both receptor preparations was defined using (+)- 
butaclamol (10-6 M) and represented less than 30% of total binding (at Kd 
concentration of [3H]-spiperone). Saturation assays on wild-type rat-1 fibroblast 
cells showed no specific binding of the radioligand.
From this specific saturation binding data, the Bmax (quantity of receptors present) 
and the dissociation constant (K d ) of the radioligand were calculated for each 
homogenate (Table 6.416).
Table 6.416 K  o  and Bmax values fo r  striatal and cloned D2 receptors binding
[3H]-spiperone
Rat Striatal E>2 Receptors Mouse D 2S Receptor
Assay Number 
n
K D
(pM)
® m ax
(fmol/mg
protein)
K D
(pM)
K m ax
(Fmol/mg
protein)
1 21.9 176 28.0 36
2 32.0 255 25.4 25
3 38.0 218 29.6 29
Mean ± S.E.M. 3 0 .6 + 4 .7 216 ±23 2 7 .7  ± 1.2 3 0 ± 3
The dissociation constants (K d ) of both receptor preparations for [3H]-spiperone 
were very similar (ie not statistically different) in each case (Table 6.416), and 
agreed with those determined by Falardeau et al (1994), (human E>2l  = 34 ± 13 
pM; D2 S = 30 ± 12 pM) and Woodward etal (1996), (rat E>2l  = 33 ± 8 pM). Kd 
values determined by other groups range from 20-90 pM higher, which could be 
due to slight differences in assay conditions, however they were still generally in 
agreement with these values (Castro & Strange 1993; Leysen et al 1992; 
Montmayeur etal 1993).
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The Bmax value for the D2 S receptors (30 ± 3) is 7 fold lower than for the striatal 
Eh receptors (216 ± 23) (Table 6.416). Both values are lower than expected and 
significantly lower than Bmax values obtained by other groups.
6.42 Receptor Number
By using the cell count (number of transfected cells used), the specific dpm at 
saturation, the specific activity of the radioligand and 'Avagadros' Number', the 
number of cell surface expressed E>2 receptors can be calculated:
Number of cells used in saturation assay = 1.133 x 108 (ie 1/3 of total cells, p.8 ) 
Specific dpm at saturation (approx.) = 1000 Spec. Activity pH] = 95 Ci/mmol
Avagadro's number = 6.023 x 1()23
(2.197 x 1012) x95 = 2.09 x 1()14 dpm/mmol (equation 1)
2.09 x 0)14 = 208.7 dpm/fmol
specific dpm = 1000 = 4.79 fmol receptor/1.9 x 106 cells 
dpm/fmol 208.7
(4.79 x 10~15) x (6.023 x 1()23) = 1500 receptors/cell 
1.9 x 106
6.43 Competition of pH]-spiperone binding
A series of dopamine antagonists (spiperone, (+)-butaclamol & (-)-butaclamol) 
and agonists (dopamine, quinperole & 7-OH DP AT) were tested for their ability to 
inhibit radioligand binding to D2 receptors in rat striatum and also cloned D2 S 
receptors in rat-1 fibroblast cells. The agonists were tested both with and without 
the addition of Gpp(NH)p (a non-hydrolysable GTP analog). Tables 6.431 & 
6.432 (p74) show the individual drug pKi values (inhibition constant) and mean 
slope values (/2h) for the D2 receptors in rat striatum and the cloned D2 S receptor, 
respectively.
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Table 6.431 Binding o f agonist and antagonist competitors at
ratstriatalD2 receptors
pKi nH
Compound n=l n= 2 n=3 X ± SEM X ± SEM
(+)butaclamol 9.02 9.06 9.38 9.15 ±0.11 0.96 ± 0.02
(-)butaclamol 5.58 5.57 5.58 5.58 ± .003 1.14 ±0.03
spiperone 9.86 10.08 9.57 9.84 ±0.15 0.84 ±0.13
quinpirole - Gpp 6 .2 0 6.43 6.17 6.27 ± 0.08 0.69 ± 0.02
quinpirole + Gpp 5.67 5.90 5.54 5.70 ±0.10 0.63 ±0.03
7 OH DP AT -Gpp 6.73 6.79 6.48 6.67 ± 0.09 0.84 ± 0.06
7 0HDPAT + Gpp 6 .2 0 6.28 6.31 6.26 ± 0.03 0.87 ±0.06
dopamine - Gpp 
(n = 6 )
6.42
6.56
6.25
6 .6 6
6 .1 1
6.78 6.46 ±0.23 0.70 ±0.12
dopamine + Gpp 6 .0 1 5.76 5.92 5.90 ± 0.07 0.81 ± 0.08
Table 6.432 Binding o f agonist and antagonist competitor
compounds at mouse D2S receptors
pKi nH
n 1 2 3 X ± SEM X ± SEM
(+)-butaclamol 9.50 9.23 9.24 9.32 ± 0.09 0.81 ± 0 .0 2
(-)-butaclamol 5.70 5.76 5.56 5.67 ± 0.07 1.15 ± 0.16
spiperone 10.06 9.90 9.38 9.78 ±0.21 0.93 ±0.14
quinpirole - Gpp 5.74 5.66 5.83 5.74 ± 0.05 0 .8 6  ± 0.06
quinpirole +Gpp 5.13 5.13 5.34 5.20 ± 0.07 0.99 ± 0.02
7 OH DPAT - Gpp 6.61 6.26 6.56 6.48 ±0.11 0.77 ± 0.02
7 OH DP AT +Gpp 6.07 6.07 6.16 6.10 ±0.03 0.99 ± 0.04
dopamine - Gpp 
(n = 6 )
5.88
6.03
5.43
6.70
6.05
6.17 6.04 ± 0.38 0.68 ±0.09
dopamine +Gpp 5.18 5.15 5.31 5.21 ±0.05 0.89 ± 0.03
[+ Gpp = Gpp(NH)p present in assay; - Gpp = no Gpp(NH)p present]
The antagonists all produced very similar results for both mouse E>2 S and rat 
striatal E>2 receptors. Spiperone, (+) and (-)-butaclamol gave almost identical pKi 
values for each receptor preparation (» 9.8, « 9.2 & «5.6 respectively).
All agonist compounds had a lower affinity (pKi) for the cloned mouse E>2 S 
receptor than for the rat striatal D2 receptors, and the addition of Gpp(NH)p also 
reduced the pKi value for all of the agonists. The greatest difference in pKi was
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for the endogenous agonist dopamine in the presence of Gpp(NH)p. With the rat 
striatal D2 receptor, dopamine has a pKi 1 2 % higher than with the cloned D2 S 
receptor. Quinpirole also produced a pKi value 9% higher, for the rat striatal D2 
receptor.
As mentioned, the addition of the GTP analogue Gpp(NH)p to the competing 
agonist assays reduced pKi values in all cases (seen as a shift to the right in the 
binding curve). The mean pKi values for quinpirole in both striatal D2 receptor 
and cloned D2 S receptor assays were reduced by 9% each and for 7-OH DP AT by 
6 %. The largest different in pKi was for dopamine, where the addition of 
Gpp(NH)p produced a 10% reduction in its affinity for the striatal D2 receptors 
and a 16% reduction for D2 S receptors.
From the competition curves produced (Figures 6.433 & 6.434, p77a & b) it can 
be seen how the shape of the curve for agonists and antagonists varied. The 
curves were sigmoidal, with the agonists generally producing a shallower curve 
(slightly lower nH values). The nH values (slope factors) were generally close to
1 .0  (unity), consistent with one site binding, however, lower values were obtained 
for quinpirole with striatal D2 receptors (0.63), and for dopamine with both 
receptor preparations (0.68 - 0.7), (Tables 6.431 & 6.432, p74).
6.44 Statistical analysis of competition assay results
The pKi values (negative log Ki) for each competitor compound with each receptor 
preparation was used to compare binding at the mouse D2 S receptor with that at the 
rat striatal D2 receptor in order to determine whether there is a significant 
difference in pharmacological profile between the two.
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The non-parametric Mann-Whitney-Wilcoxon rank sum test was used to test the 
null hypothesis that ‘the median pK[ values of the two D2 receptor preparations are 
equal’, for each competitor compound.
Table 6.441 Mann-Whitney-Wilcoxon analysis ofpKi values between
striatal D2 and cloned D2S receptors_________
Compound P  level
(+)-butaclamol 0.30
(-)-butaclamol 0.50
spiperone 0.50
- GTP quinpirole 0.05
+ GTP quinpirole 0.05
- GTP 7 OH DPAT 0.30
+ GTP 7 OH DPAT 0.05
- GTP dopamine 0.50
+ GTP dopamine 0.05
Significance was determined at the 5% probability level (P < 0.05).
From Table 6.441 it can be seen that for the antagonists, pKj values for rat striatal 
E>2 and cloned mouse D2 S receptors are not significantly different therefore the null 
hypothesis is accepted.
The binding of the agonists however, all show significant results. In the presence 
of Gpp(NH)p, all three agonists (quinpirole, 7-OH DP AT, and dopamine) showed 
significantly different pKi values for the two D2 receptor preparations (Table 
6.441). Though, in the absence of Gpp(NH)p the situation was slightly different, 
as dopamine and 7-OH DP AT did not produce significant values.
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Table 6.442 Mann-Whitney-Wilcoxon analysis ofpKi values for  
______________ E>2s receptor in the presence and absence o f GTP
Compound P level
quinpirole 0.05
7 OH DPAT 0.05
dopamine 0.04
Table 6.443 Mann-Whitney-Wilcoxon analysis ofpKi values fo r  
____________ striatalD2 receptor in the presence and absence o f GTP
Compound P level
quinpirole 0.05
7 OH DPAT 0.05
dopamine
0 .0 2
Comparison of pKi values was also made for each agonist in the presence and 
absence of Gpp(NH)p at the same receptor (Tables 6.442 & 6.443). This analysis 
showed a significant difference for all agonists with both receptor preparations. 
The endogenous agonist dopamine produced the greatest significance for binding 
in the presence verses binding in the absence of Gpp(NH)p, with pKi values 
giving P < 0.04 for E>2 S and P  ^  0.02 for striatal D2 receptors.
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6 .5  Discussion of pharmacological results
The aim of these experiments was to examine the pharmacology of a cloned short 
isoform of the D2 dopamine receptor (E>2S) isolated from mouse striatal tissue, and 
compare this to the pharmacology of the native population of P 2 receptors in rat 
striatal tissue.
In order to do this the D2 S receptor was stably expressed in rat-1 fibroblast cells. 
This cell line was selected because it was readily available and had been regularly, 
successfully used for cellular expression of cell surface receptors by Syntex Ltd. 
Saturation assays using the radiolabel [3H]-spiperone on membrane preparations 
of the wild-type cells showed no specific binding.
Radioligand binding was performed on membrane preparations of the transfected 
cultured cell line and also, in parallel, on membrane preparations of striatal tissue 
from Sprague-Dawley rats. Allowing analysis of the pharmacological profile of 
the D2 receptor population normally expressed in this region of the rat brain.
This area of the brain was selected as it has been shown to contain the highest 
abundance of D2 receptors and would be expected to consist of approximately 
25% short isoform to 75% long isoform (Giros etal 1989).
Rat and mouse have very similar D2 receptor sequences with very few differences 
at the amino acid level (figure 5.11, p52a) and similar binding profiles making 
them useful for comparison.
Spiperone is an antagonist of D2 receptors commonly used in binding 
experiments. The tritiated nature of the drug does not affect its binding but 
provides a reasonable specific activity and a long half-life. Its  specificity is
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shown by its displacability by other Y>i receptor specific drugs, as illustrated in the 
competition assay. [125I]-iodospiperone is also sometimes used as it has a higher 
specific activity but a much shorter half-life.
6.51 Saturation binding
In figures 6.412 & 6.414 (p71a) it can be seen that the specific binding of [3H]- 
spiperone of D2 receptors is saturable in both membrane preparations. The 
Scatchard plots (figures 6.413 & 6.415, p71b) are linear indicating that the 
binding is at one site, ie one receptor type. In the case of the E>2 S receptor clone 
saturation occurs at a ligand concentration which is a factor of 10  lower than for 
the striatal receptors. The Bmax values are 10 fold lower, however the Kd values 
are the same.
The Bmax is the amount of receptor present in the preparation as femtomoles per 
microgram of protein. The values of 216 (± 23) for rat striatal tissue and 30 (± 3) 
for the expressed mouse D2 S clone were both low compared with published levels 
(Leysen etal, 1992; Montmayeurer al , 1993), possibly due to differing assay 
conditions.
Expected Bmax levels were based on results obtained by other groups. It could be 
expected that receptor density would be consistent in rat striatal tissue, however 
Leysen etal (1992) reported a level four times higher (864 ± 146 fmol/mg). The 
clone also had a very low Bmax with a value almost seven fold lower than that 
demonstrated by Montmayeur et al (1993) for a mouse D2 S receptor clone, even 
though the Kd values in each case were comparable.
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Montmayeur’s group used the eukaryotic expression vector pSG5 to transiently 
transfect JEG3 (human carcinoma) cells. Whilst in this experiment pcDNA3 was 
stably transfected into rat- 1 fibroblasts.
Could the problem be caused by the type of transfectants analysed or the use of a 
cell line from a different species? This doesn’t appear to be the case, as similar 
research performed by other groups shows the range of different expression 
methods used.
Leysen et al (1992) used stable transfectants of human D2 clones in human 
embryonic kidney cells and produced good Bmax levels. Meanwhile Castro & 
Strange (1993) obtained a high Bmax by expressing the rat D2L clone in mouse 
fibroblast cells. Therefore the result here appears not to be due to expression in a 
different species cell line or the difference between stably or transiently transfected 
lines. However, it has been shown that the same D2 receptor clone expressed in 
two different cell lines gives different binding profiles (Castro & Strange, 19932), 
therefore it is difficult to compare the results of any two groups using different 
expression systems.
A possible reason for the low expression is that the clone may require upstream 
sequences for a high level expression. The rat D2L clone used by Castro & 
Strange (1993) is a 2.5 kb cDNA containing the gene which is actually only » 1.3 
kb, whereas the cDNA expressed in this experiment is solely the ORF (open 
reading frame) of the gene.
Also the expression was stable therefore the vector construct had integrated into 
the cell genome (facilitated by the SV40 sequences of the vector). It is possible 
therefore that the insertion event had occurred at a region of suppressed expression 
such as a region of heterochromatin. However >40 transfected lines were tested 
and all gave relatively low radioligand binding, the line used in the assays had the
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highest Bmax therefore it is unlikely that all lines had suppressed expression unless 
there was a problem with the vector, which was not apparent.
The Kd value for the cloned E>2 S and striatal D2 receptors were very similar and 
agreed with those previously determined by Falardeau et al (1994), (human D2L 
= 34 ± 13 pM; D2 S = 30 ± 12 pM) and Woodward etal (1996), (rat D2L = 33 ± 8 
pM). However Kd values determined by other groups range from 20-90 pM 
higher, (Castro & Strange 1993; Leysen etal 1992; Montmayeur et al 1993) for 
various D2 and D2 S clones. The variance is probably due to slight differences in 
assay conditions, but other groups also noted the similarity of Kd between the two 
C>2 receptor isoforms (Falardeau et al, 1994; Castro & Strange, 1993)
6.52 Competition Binding
Several different agonists and antagonists were investigated for their ability to 
inhibit the specific binding of [3H]-spiperone to both the striatal and cloned D2 
receptor preparations.
For each compound at each receptor the IC50 was calculated, (concentration of 
competitor compound which causes inhibition of 50% specific radioligand 
binding). This was then converted to Ki (equilibrium dissociation constant) using 
the Cheng-Prusoff equation, allowing comparison of the pharmacology of 
competitors as it is independent of ligand concentration; and subsequently to pKj 
(negative log Kj) which provides a whole number index of relative affinity of a 
compound for a receptor sample allowing easy reference and statistical 
comparison.
The nH value (slope factor) indicates the slope of the curve which were generally 
close to 1.0 (unity), consistent with one site binding. Values less than unity 
indicate, in this case, interconverting receptor states.
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6.53 Statistical Analysis
The antagonist compounds spiperone, (-)-butaclamol and (+)-butaclamol gave pKi 
values that were not significantly different for each of the receptor preparations, 
which agrees with results from other groups (Table 6.531).
Table 6.531 Comparison of pKj values for D2 antagonist compounds
Compound
pKi (nM) 
P2Lone D2Short Reference
Spiperone 1 0 .2 1 0 .1 Montmayeur et al., 1993
1 0 .2 10.4 Castro & Strange, 1993
1 0 .8 1 1 .0 Leysen et al., 1993
(+)-Butaclamol 9.0 8.9 Grandy et al., 1989
8.4 8.4 Castro & Strange, 1993
1 0 .2 10.3 Leysen et al., 1993
(Source: Falardeau 1994)
These and other groups who have investigated antagonist binding have also not 
discovered any significant differences in binding of antagonists between the D2 
receptor isoforms, suggesting that the two forms have very similar, if not identical 
antagonist binding sites.
The agonists however, produced some interesting results. Agonist compounds as 
discussed in the introduction have their binding affinities affected by the ‘state’ of 
the receptor. The normal situation in a membrane preparation is that the receptors 
are a population of different affinity states; some are coupled to G-proteins and 
therefore in the ‘high-affinity’ state whereas others are dissociated and at ‘low- 
affmity’. The population is dynamic with constant cycling of G proteins and GTP
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hydrolysation. This complicates the analysis of binding results as ratios of states 
can differ between assays.
Therefore the addition in this experiment of excess non-hydrolysable GTP 
analogue Gpp(NH)p disrupts this equilibrium and converts all binding sites to the 
low-affmity state.
Addition of Gpp(NH)p reduced the PIC50 for each compound. This occurred the 
low affinity binding state requires a higher concentration of ligand to inhibit the 
radioligand binding (increased IC50). This can be see by the shift to the right of 
the agonists competition curves for the Gpp(NH)p assays (Figure 6.433 & 6.434, 
p77a & b). The fact that this occurs in the case of the clone, shows that the D2 S 
receptor appears to be coupling with endogenous cellular G-proteins.
This decrease in PIC50 was significant for all three agonists both for the cloned 
E>2s striatal D2 population (Tables 6.442 & 6.443, p77a & b) which indicates 
that the receptor state does influence affinity for agonists (Bimbaumer etal, 1990)
The results of the Gpp(NH)p assay were then statistically analysed to compare the 
binding of each agonist between each receptor preparation. The results show a 
difference in agonist affinity for the striatal D2 and D2 S receptor groups.
All of the agonists tested had significantly lower pICso values for the mouse E>2S 
receptor clone. The lower binding affinity of the agonists for the cloned receptor 
when compared to striatal D2 receptors agrees with the findings of Leysen et al. 
Their study revealed that dopamine and quinpirole had lower affinity for expressed 
clones of both the short and long isoform of the human D2 receptor when 
compared to rat brain tissue preparations. They discovered that “agonists showed 
an apparent lower affinity for the cloned receptor than for the striatal form” with
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IC50 values differing by up to 6  fold. PIC50 values of dopamine for the cloned 
receptor were 4- lOx lower than for striatal tissue.
Theirjustification for this was that there may be a difference in the proportion of 
coupled:uncoupled receptors in each case, ie there was less coupling in the case of 
the cloned receptor due to coupling being less efficient or the appropriate G 
proteins weren’t present in the chosen cell-line. However this does not explain the 
difference for binding in the presence of Gpp(NH)p as the point of this assay is to 
remove the influence of G protein coupling upon receptor affinity state.
It could simply be that the receptors perform better in their native situation; that 
uncoupling is not totally effective in tissue preparations because of extra material 
impeding the compounds diffusion; or that there is a genuine difference in agonist 
binding between the preparations.
Another possibility is that the difference in Bmax between the striatal receptors and 
the cloned E>2 S receptors could have affected the result. Castro & Strange (19932) 
suggest that differences in expression levels of receptors could affect results 
because of receptor/G-protein ratio in the cell. Also in this case different G-protein 
populations are likely to have been present in the membrane preparations due to the 
different cell types involved. However, these differences involving G-proteins 
should have been eliminated by the addition of Gpp(NH)p and receptor/G-protein 
dissociation.
In another study on the pharmacology of dopamine receptors, no significant 
difference in binding was found between the cloned D2 S & D2L isoforms 
(Falardeau et al, 1994). It seems to be that a difference in ligand interaction would 
not be expected, as the difference (the 29 residue spliced region in the third 
intracellular loop) is on the cytoplasmic side of the membrane and quite discrete
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from the sites implicated in ligand binding (figure 1.3, p6 a). However, Castro & 
Strange (1993) discovered that substituted benzamide antagonists had significantly 
higher affinity for E>2 s dopamine receptors and proposed that difference was due 
to an overall conformational change caused by the 29 amino acid insertion in the 
E>2l  dopamine receptors interacting with the transmembrane regions in some way.
A difference between the two isoforms which has been discovered involves the 
spliced region. This segment appears to be involved in the E>2l  selective 
recognition of a specific inhibitory G protein a-subunit (Gai2) and suggests the 
possibility of the two isoforms performing separate functions by activating 
different G-proteins and transduction pathways (Guiramand etal 1995).
6.6 Conclusion
The mouse D2S dopamine receptor has been successfully cloned and expressed 
and behaves much as expected according to previous research.
Both the D2 S receptor clone and the striatal D2 receptors showed coupling to G- 
proteins and displayed different affinity states for agonist compounds. Addition of 
a non-hydrolysable analogue of GTP shifted both receptor preparations to a 
uniform low-affinity state.
In comparison with striatal D2 receptors the D2 S clone binds antagonists with the 
same affinity but appears to have greater affinity for agonist compounds. A 
similar result was shown by Leysen et al, (1992) who also used rat striatal D2 
receptors as a comparison and discovered that cloned D2 receptors had a lower 
affinity for agonists. Unfortunately both isoforms of the D2 receptor displayed 
lower affinity than striatal D2 receptors, but the difference in affinity for agonists 
between the clones was negligible.
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This suggests that striatal material was not the best comparison to look at 
differences between the long and short isoform and ideally a E>2l  receptor clone 
should have been used (which was not available). However it does show a 
difference in binding profiles between a cloned receptor and those in their native 
environment suggesting that in isolation a receptor may behave differently from its 
native situation. This factor is important when considering the effects of drugs in 
pharmacological research.
The methods, equipment and materials (with the exception of the clone) were 
provided by and routinely used in the research laboratories of Syntex Ltd., Heriot- 
Watt Research Park, and therefore were established and validated.
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7.0 Discussion
Although, not all of the aims which were set out at the start of this project have 
been reached, much has been achieved in the time available. The ground-work 
laid during the work for Section A, proved very useful in designing and carrying 
out the research in Section B.
The dopamine receptor area has been reasonably well researched and therefore I 
had a solid foundation on which to base my research and to compair my research. 
Although the stage of creating chimeras was not reached, this is still a technique of 
great potential in investigating binding sites. Even though the D3 receptor was not 
cloned it would have still been possible to incorporate regions of D3 sequence 
within recombinant primers or by point mutations, to determine key residues. 
Unfortunately, this stage was not reached within the time, however, it is still a 
valid project.
The mouse dopamine D2 S receptor was successfully cloned and expressed, 
allowing investigation of its pharmacology and comparisons with previous 
studies. Although no significant differences were found, it was noted that there is 
a significant difference in binding profiles between a receptor when cloned and 
when in its native environment, even though experiments were carried out in 
standard physiological conditions.
The fact that in isolation a receptor may behave differently from its native situation 
is important when considering the effects of drugs in pharmacological research, as 
the ligand-binding assays used in this study tend to be standard for industrial 
research.
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If there had been time, much more work could have been carried out on the mouse 
I>2S dopamine receptor clone. At the time that I finished, work had already begun 
on designing and making mutants of the E>2 S receptor, which would have been 
pharmacologically profiled in the same way and the results compared to the wild 
type receptor.
Ultimately it was anticipated that the mouse D3 dopamine receptor would also be 
cloned and this receptor could also be profiled. My particular interest would be to 
mutate key regions shown to be involved in ligand binding on the D2 dopamine 
receptor into the corresponding residues on the D3 dopamine receptor and vice 
versa, in order to locate the exact regions/residues which differentiate each 
receptor’s individual pharmacological properties.
It would also be interesting to repeat this experiment with a E>2l  receptor clone as a 
comparison. Further ligands could be tested on the D2 S dopamine receptor, 
particularly substituted benzamide antagonists (eg raclopride and remoxipride) 
which have been reported to have a higher affinity for the D2 S receptor isoform 
over the E>2 l  receptor.
CHAPTER 8 
METHODS
Methods: Chapter 8
8.1 Introduction of plasmid DNA into E. coli
8.11 Preparation of competent cells (Hanahan, 1983)
An overnight culture of the recipient strain (grown in 2YT broth) was diluted 1 in 
100 into 10ml 2YT broth and incubated at 37°C for 90-120 minutes to a density of 
approximately 108/ml (OD^oo 0.45-0.55). The cells were harvested by 
centrifugation (12000g, 10 mins, 4), resuspended in 1ml ice cold TFB (lOmM 
MES/KOH pH 6.3; lOOmM RbCl; 45mM MnCl2; 10mM CoCl2; 3mM 
hexaminecobaltic chloride) and incubated on ice for 15 mins. Next 34pl DMF 
was added and the cells incubated on ice for 5 more minutes, then 34pl (3- 
mercaptoethanol (14.4M) and after a further 10 mins on ice another 34pl DMF. 
The cells remained on ice until use (the same day).
8.12 Transformation procedure
Transformations were carried out in sterile 1.5ml microfuge tubes. l-5pl of 
ligation mix was added to 1 0 0 -2 0 0 pl of competent cells and incubated on ice for 
45 mins. The tubes were then heat-shocked at 42°C for 3 mins and returned onto 
ice. The cells were then transferred into sterile universal tubes containing 1ml 
2xYT broth and incubated at 37°C for 30 mins. After this time, 200jxl of each cell 
suspension was plated on LB plates containing appropriate antibiotic and 
chromogenic substances and incubated at 37°C overnight.
8.13 Selection of pUC-derived recombinant clones
8.131 Antibiotic
A stock solution of ampicillin (20mg/ml in water) was added to molten agar (@ 
55T!) to a final concentration of 50pg/ml.
89
Methods: Chapter 8
8.132 Chromogenesis
Used in conjunction with IPTG this was used to identify E. coli strains containing 
pUC based vectors with inserts in their multiple cloning sites. Colonies of 
recombinants are generally white, whilst those lacking inserts are blue. From a 
stock concentration of 20mg/ml in DMF, X-gal is used at a final concentration of 
20jig/ml and IPTG from 24mg/ml in (IH2O stock is used at 50pg/ml on L-agar 
plates.
8.14 Glycerol storage of bacterial cultures
850ml of a fresh overnight culture of the strain (grown with antibiotic if 
necessary) was placed in a ‘Nunc’ tube (Gibco BRL) with 150ml sterile glycerol 
and vortexed. The tube was then labelled and quick frozen in liquid nitrogen 
before storage at -70°C. When required, the surface of the frozen culture could be 
scraped with a sterile loop, streaked onto appropriately prepared agar plates and 
incubated inverted at 37° C.
8.2 DNA Purification
8.21 Preparation of plasmid DNA
A 1.5ml aliquot of each overnight culture of the E. coli strain containing the 
transformed plasmid, was taken in a sterile 1.5ml microfuge tube. The cells were 
then pelleted by centrifugation at high speed in a microcentrifuge. The supernatant 
was removed and the cells resuspended in 2 0 0 pl of cell resuspension buffer 
(50mM Tris-HCl, pH 7.5; lOmM EDTA; lOOpg/ml RNAse A). To this 200pl of 
cell lysis solution (0.2M NaOH; 1 % SDS) was added and the tube inverted to mix 
until the suspension cleared. Then 200pl of neutralisation solution (2.55M 
KCOOH, pH 4.8) was added and the tube again inverted to mix. The tubes were 
then microcentrifuged again at high speed for 1 0  mins and the sticky pellets 
produced were removed with sterile toothpicks.
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To the clear supernatant remaining 750pl of Wizard™ Miniprep Purification Resin 
(Promega) was added and mixed by inversion. This mixture was then drawn 
through a Vac-Man™ Laboratory Vacuum Manifold (Promega) and followed by 
2ml Column Wash solution (200mM NaCl; 20mM Tris-HCl, pH 7.5; 5mM 
EDTA; dilute 1:1 with 95% ethanol). The resin was dried by continuing to draw a 
vacuum through the column for a further 2  mins then the column was transferred 
to a 1.5ml microcentrifuge tube and spun at high speed for 20 sec to remove all 
residual Column Wash solution.
The column was then transferred to a fresh sterile microcentrifuge tube and 20pl 
of lx  TE buffer (@ 70°C) applied to the top of the column. After 1 minute the 
column and tube were spun at high speed for 30 sec. This process was repeated, 
and the solution collected in the microfiige tube. The column was discarded and 
the DNA solution stored at -20°C.
Before use the samples were analysed on a 1 % agarose gel, in order to quantify 
and to check for contamination.
8.3 Dideoxy DNA Sequencing
8.31 Denaturation of double stranded DNA template
DNA was prepared as in method 8.1, then 18pl was taken in a sterile microfuge 
tube, 2pl NaOH (2M) was added and the tube incubated at 37°C for 10 mins. 
Next 50ng of the appropriate sequencing primer was added along with 6 pl 
KCOOH (2.55M, pH 4.8) and the tube vortexed to mix. 180pl of 95% ethanol 
was added and the tube vortexed, then microcentrifuged at high speed for 15 
mins. The supernatant was carefully removed and 500^1 70% ethanol added 
before recentrifuging. The supernatant was again removed and the tube dried by 
incubation at 37°C.
91
Methods: Chapter 8
8.32 Single strand DNA template production
An alternative method of producing DNA template for the sequencing reaction 
involved using the helper phage M13K07 (Promega).
The required fragment was cloned into a suitable vector containing an origin of 
single stranded replication (see cloning, method 8.7) and transformed into a F’ 
host strain.
In a sterile universal tube 1.5 ml 2YT broth (bacto-tryptone; bacto-yeast extract; 
NaCl) containing M13K07 helper phage at 107 pfu/ml and ampicillin at 200fjg/ml, 
was inoculated with a single fresh colony of the clone. This was incubated in a 
shaking incubator at 37°C for 2 hr then karu^amycin was added to 75pg/ml and the 
culture was return to the incubator for a further 18 hr.
After this time the culture was transferred to a microfuge tube and spun at 15,000 
rpm. The supernatant was transferred to a new tube, 200jul PEG solution added 
(33mM polyethylene glycol 6000; 0.5M NaCl) and vortexed before incubating at 
room temperature for 20 mins. The mixture was then spun at 15,000 rpm for 5 
mins and the PEG solution discarded. Care was taken not to dislodge the pellet 
but to totally remove the supernatant by pulse spinning the tube and removing the 
residual PEG solution by vacuum suction through a drawn out Pasteur pipette.
The phage pellet was resuspended in lOOpl lxTE (lOmM Tris-HCl, pH7.5; ImM 
EDTA), an equal volume of buffer saturated phenol added and the tube vortexed. 
After 5 mins at room temperature it was again vortexed and spun at 15,000 rpm 
for 2 mins. The upper aqueous layer was transferred to a new eppendorf tube, 
2.5 volumes ethanol and 0.1 volumes NaCOOH (3M) were added and the DNA 
precipitated at -70°C for 1 hr.
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The tube was spun at full speed again for 15 mins and the pellet washed in 95% 
ethanol. The ethanol was removed and the pellet dried before resuspending in 
30jnl lx  TE, the single stranded DNA could then be used or stored at -20°C.
8.33 Sequencing Reaction
The denatured/single stranded DNA template was resuspended in 7pl (IH2O and 
2pl annealing buffer (200mM Tris-HCl, pH7.5; lOOmM MgCfo 250mM 
NaCl), then lOng of the appropriate primer was added. This was incubated at 
37°C for 10 mins then kept on ice.
As a mixture; lp l DTT (lOOmM), 1.5pl dH2 0  and 5pCi [a35S]dATP were added 
to the tube and vortexed before replacing on ice. DNA polymerase (Sequenase 
2.0, USB) was diluted 1:8 with ice-cold enzyme dilution buffer (lOmM Tris-HCl, 
pH7.5; 5mM DTT; 0.5mg/ml BSA) to 1.5units/jil.
3 units of DNA polymerase was added to the reaction tube containing the DNA 
and annealed primer and mixed carefully. The labelling reaction was allowed to 
proceed at room temperature (15-20°C) for 2-5 mins before termination was 
begun.
Four 0.5ml microfiige tubes were incubated at 42°C. Each contained 2.5ml of one 
of the dideoxy termination mixes (80pM dGTP; 80pM dATP; 80pM dCTP; 
80pM dTTP plus 8 pM dideoxy-dNTP). After the labelling period, 3.5pl of the 
reaction was added to each of the four termination tubes and incubated at 42°C for 
2-5minutes before 4pl stop solution was added to each termination reaction. The 
sequencing reactions could then be stored at -20°C or immediately run on an 
acrylamide gel.
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8.34 Acrylamide Gel Electrophoresis
8.341 Preparation of the gel
The gel mix was made by dissolving 420g sequencing grade urea in 250ml dH2 0  
and 5xTBE, 125ml 40% bis acrylamide (19:1 Severn Biotechnology) was then 
added and dH2 0  to 1 litre. The mix was filtered through 3mm filter paper 
(Whatman) and stored at 4°C in the dark.
8.342 Electrophoresis
The gel was cast using 'Biorad' sequencing apparatus (the plates being pre- 
siliconised with dichlorodimethylsilane), and run with 0.6x TBE buffer in the 
reservoirs at 100-120W, 1900V and 50-60mA. The sequencing samples were 
heated to a temperature of 85°C for 2-3mins then placed on ice whilst the gel was 
pre-run for several minutes to heat the apparatus. Samples were loaded in a set 
order, using sharkstooth combs (3pl per well) and run for between 2-6hours 
depending on the distance of run required.
After the required running time the power was disconnected, the gel transferred to 
3mm paper and the exposed surface covered with SaranWrap. The gel was dried 
on a vacuum gel drier then exposed overnight to X-ray film, after removal of the 
SaranWrap. The sequence could then be read from the developed film.
8.4 Agarose Gel Electrophoresis
A gel was prepared according to the number and size of products to be analysed. 
Generally the larger the DNA fragments, the lower the % of agarose used. For 
example, fragments of >lkb would be best separated on a 0.7% gel, whereas for 
fragments of <0.6kb a 1.5% gel would be appropriate. Usually a 1% gel was 
used. This was made by dissolving lg agarose powder in 99ml lxTAE buffer by 
warming in a microwave, then 50pg ethidium bromide was added before pouring
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into the gel former. When set the gel was run in lxTAE .buffer. The length of 
time required for the DNA to migrate depended upon the voltage across the gel and 
its length.
After electrophoresis the DNA was visualised using a UV transilluminator. This 
allowed photographs to be taken for further reference.
8.5 DNA isolation
8.51 Activation of NA45 paper (Schleider & Schuell)
The paper was handled carefully using forceps and cut into strips of 5mm width.
These were then washed in lOmM EDTA for 10 mins and then transferred to 
0.5M NaOH for a further 5 mins. Finally the paper was rinsed rapidly in (IH2O 
and stored at 4°C submerged in (IH2O.
8.52 DNA Isolation
DNA was firstly run on an agarose gel and visualised under low wavelength UV 
(to minimise damage to DNA). A cut was made just below the band required 
using a sterile scalpel blade, and a piece of NA45 paper of the appropriate length 
inserted. The gel was reintroduced to the electrophoresis apparatus for 2 mins at a 
voltage of 100-120 then revisualised to confirm DNA transfer had occurred.
The gel was disposed of and the NA45 paper carrying the DNA was washed 
briefly 3 times in 500pl aliquots of low salt NET, then transferred to a microfuge 
tube containing 200pl high salt NET and incubated at 6 8 °C for 15 mins. This was 
repeated for 30 mins in a fresh 100pl aliquot of high salt NET, then the 2 aliquots 
of high salt NET were combined, along with lOOjul (IH2O, lOOpl ammonium 
acetate and 1ml 95% ethanol. The DNA was precipitated at -20°C and 
resuspended in 5-10pl 0.1% TE. The paper was checked under UV light to 
confirm that all of the DNA had been eluted.
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8.6 Polymerase Chain Reaction (PCR)
8.61 Oligonucliotide deprotection
The synthesised oligonuclitides required deprotection to detach them from the 
synthesis beads and prepare for use.
Firstly the synthesis column containing the oligo was carefully opened and the 
beads with the oligos attached collected in a ‘Nunc’ tube (Gibco BRL). 1ml of 
fresh 30% ammonium hydroxide was added and the tube incubated at RT for 1-2 
hours. After vortexing the tubes were quickly centrifuged and the supernatant 
transferred to a fresh Nunc tube. A further 1ml fresh 30% ammonium hydroxide 
was added to this new tube and then incubated overnight at 50°C.
The oligo was precipitated by adding 10% ammonium acetate (w/v) and 2 volumes 
of 95% ethanol and storing overnight at -20°C before resuspending in 1%TE to 
1 0 % of the original volume.
8.62 H ot-S tart Therm al Cycling
Single stranded cDNA template produced from mouse brain tissue by the reverse 
transcription method mentioned previously was used along with the appropriate 
primer pair for the reaction. In a thin-walled PCR tube (Greiner) the following 
were mixed; lOng cDNA, 200pM of each primer, 2mM each dNTP, lOx Taq 
buffer (Promega), (1.5mM MgC12; lOmM Tris-HCl, pH9 @ 25°C; 50mM KC1; 
0.1% Triton X-100) and the volume made up to 30pl with CIH2O. This mix was 
heated to 96°C for 5 mins in a Perkin-Elmer 9600 PCR machine. Meanwhile 2 
units Taq enzyme (Promega), lOx Taq buffer and dH2 0  to increase the volume to 
20jnl, were mixed and added to the PCR reaction at the end of the 5 minute hot- 
start, increasing the final volume to 50pl.
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The PCR was performed in condensation free tubes however if these tube are not 
available a wax pellet or drop of liquid paraffin should be used to seal the reaction.
The reaction then proceeded through 25-35 cycles of amplification according to the 
program used (see appendix H). The basic program involves approximately 30 
sec of denaturation > 94°C, up to 1 min at the annealing temperature 
(approximated at 5°C below the Tra of the primers), and 1-2 mins at 72°C for 
optimum nucleotide incorporation by Taq. For the specific PCR cycle program 
used in each case see that chapter or appendix II.
8.7 DNA Cloning
8.71 Ligation
A suitable vector was selected according to various factors including the function 
of the clone (ie sequencing, expression); available restriction sites; size and nature 
of insert etc. The pcDNA3 vector was used as an expression vector for the mouse 
D2S receptor clone. It was firstly cut with the restriction enzyme Eco RI which 
cuts the vector once in the polylinker (5jug vector; 10-20u Eco RI; 1 ljul dH2 0 ; 2jul 
‘React 3’ buffer (Gibco BRL) at 37°C for 90 mins, at this point 0.5pl Shrimp 
Alkaline Phosphatase (SAP), was added to the reaction and the tube was kept at 
37°C for a further 30 mins. The SAP was then deactivated by heating to 6 8 °C for 
15 mins.
8.711 ‘Ready-To-Go’ Ligation Kit (Promega)
50-250ng vector (5.4kb) was mixed with the 250ng of mouse D2 receptor 
(1.3kb), (1:4 ratio) in a Promega ‘Ready-To-Go’ ligation tube. The final volume 
was made up to 20pl using (IH2O. This was gently mixed and incubated at 16°C 
for 1 hour.
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8.72 PCR products
The pT7Blue plasmid (AMS Biotechnology) is constructed with single 3’ dT 
overhangs, specifically for the purpose of ligation to DNA amplified by DNA 
polymerase which leaves single 3' dA overhangs.
In a standard reaction 50ng pT7Blue T-vector was ligated with 0.2pmol amplified 
product in a volume of 10pl. Typically this consisted of combining, in a 1.5ml 
microfuge tube lpl lOx ligation buffer (200mM Tris-HCl, pH7; 50mM MgC^), 
0.5pl lOOmM DTT, 0.5pl lOmM ATP, lp l amplified product (~0.2pmol) in 0.1 % 
TE, 4.5pl (IH2O and finally 0.5pl (2-3 units) T4 DNA ligase. This was gently 
mixed and incubated at 16°C overnight.
A positive control was included by repeating the ligation using 5ng of a 50bp 
control insert with single 3'dA residues (AMS Biotechnology) which gave an 
insert to vector molar ratio of 5:1 .
8.721 Transformation of pT7Blue(R) constructs
Once ligated, the vector was transformed into an appropriate strain which had been 
rendered competent.
The standard transformation method (8.2) using TGI cells was generally used, 
however if a particularly high frequency was required (eg >4xl08) then NovaBlue 
competent cells (AMS Biotechnology) were used.
The cells were stored at -70°C until required, as 20pl aliquots in 1.5ml microfuge 
tubes. The cells were then thawed on ice and mixed gently to ensure even 
suspension of the cells, lpl of the overnight ligation mix was added to a 2 0 pl 
aliquot and the tube gently flicked to mix, this was repeated for lpl of the positive 
control ligation and l|ri (0.2ng) test plasmid. The tubes remained on ice for a
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further 30 mins and were then heat shocked at 42°C for 40 sec and replaced on ice 
for 2 mins. 80pl of 2YT medium at RT was added and the tubes transferred to 
incubate at 37°C, shaking at 200-250rpm for 1 hr.
After this time 50pl of each transformation was plated on LB agar plates 
containing 50pg/ml ampicillin, 15fxg/ml tetracycline (to select for F ) and IPTG/X- 
gal for chromogenic selection. The plates were inverted and incubated at 37°C 
overnight.
8.8 cDNA Synthesis
8.81 RNA extraction from brain tissue
Brain tissue had previously been dissected from freshly sacrificed mice, dissected 
and frozen to -70°C within mins of the animal’s death. Approximately lg of 
frozen brain tissue was immersed in liquid nitrogen in a DEPC treated mortar and 
a pestle used to crush the tissue to a fine powder. More liquid nitrogen was added 
as required to prevent the tissue thawing. When a powder had been achieved the 
powder was emptied into a RNAse free 50ml Falcon tube (Coming) and 2ml 
guanidinium thiocyanate solution (50jul 1M sodium citrate, 0.95g guanidinium 
thiocyanate, 0.02g Sarcosyl (Sigma)), the tube was inverted to mix. To this 
mixture 14jul b-mercaptoethanol, 2ml of 2M NaCOOH were added and mixed.
8.82 RNA Extraction
An equal volume (2ml) phenol (H2O saturated) was added to the tissue mixture 
and the tube vortexed and incubated on ice, for 20 mins. After this time it was 
spun at 5k for 10 mins and the upper, aqueous layer removed into a fresh RNAse 
free universal tube where an equal volume of chloroform/isoamyl alcohol (50:1) 
was added vortexed and the mixture again incubated on ice for 5 mins. The 5k 
spin was repeated and the upper aqueous layer again removed into a fresh RNAse
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free tube, where two volumes of isopropanol were added and the sample stored at 
-70’C until required.
When required the sample was aliquoted into 1.5ml microfuge tubes and spun at 
15k for 30 mins at 4°C, The pellet produced was washed with 70% ethanol and 
resuspended in RNAse free TE buffer, before immediate use in the synthesis of 
cDNA.
Any unused RNA could be stored at -70°C in RNAse free ethanol and NaCOOH 
( 10%).
8.82 cDNA Synthesis
Total RNA extracted from mouse brain tissue was used to produce single stranded 
cDNA by reverse transcription. 1 pg RNA in DEPC treated dH2 0  was heated to 
90°C for 5 mins and cooled quickly on ice in order to denature any secondary 
structure. To this 1.5ml microfuge tube, lOOpM random hexamers (Gibco BRL);
5mM of each dATP, dGTP, dCTP, dTTP; lx RT buffer (Promega); 20u RNAsin 
(Promega) and 5u (0.5jul) Avian Myeloblastosis Vims reverse transcriptase (AMV 
RT), (Promega), were added and the volume increased to 20pl with dH2 0 . This 
mixture was then heated to 23°C for 10 mins, then 42°C for 45 mins and finally 
95°C for 10 mins to stop the reaction. The cDNA was stored at -20°C until use.
8.9 Pharmacological Methods
8.91 Membrane Preparation of Rat Striata
Striata were dissected from whole rat brains (Sprague Dawley, Charles River UK 
Ltd.) and each pair suspended in 60 volumes (w/v) of buffer (50mM Tris HC1;
120mM NaCl; 2mM CaCl2; lmM Mg2 S04; ImM EDTA) at 4<>C on ice. The 
buffer was adjusted to pH7.4 which corresponds approximately to the
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physiological pH. A Polytron P10 tissue disrupter was washed twice with 500ml 
distilled water and then used to homogenise the tissue at setting 10, for two 10 
second periods. The homogenate was then centrifuged at 48 OOOg (SS34 rotor in 
a Du Pont RC5B centrifuge) for 15 mins to wash the membrane preparation and 
remove any endogenous neurotransmitters.
The supernatant was discarded and the pellet was resuspended in the same amount 
of fresh buffer using the Polytron P10 disrupter at setting 5 for 5 sec. The tissue 
was then recentrifuged using the same conditions. This process was repeated 
twice more.
Finally each paired striatal pellet was resuspended in 3ml buffer using the Polytron 
P10 disrupter. Care was taken to recover any homogenate adhering to the 
disrupter by washing with a small amount of buffer.
The membrane preparation was then ready to be used in assays or could be frozen 
in liquid nitrogen before storing at -70°C.
8 .9 2  Cell Culture and Membrane Preparation
Rat-1 fibroblast cells were transfected with the mammalian expression vector 
pcDNA3 (Invitrogen) containing the mouse E>2 S receptor cDNA and grown to a 
cell density of -3.4 x 108. The cell count allowed calculation of the cell number 
per assay so that receptor number per cell could be determined. The cells were 
then harvested in phosphate buffered saline (lx  PBS) containing 2mM EDTA. 
(This work was performed by Mr Bill Rowand of Syntex Research, Scotland.)
The cells were then homogenised and washed in the same way as the striatal 
preparations. These were resuspended in 6 ml buffer and 2ml (-1.1 x 108 cells) 
was used per assay. This was then diluted 1:15 with buffer (-7.5 x 106 cells/ml) 
and 250pl cells used per assay tube (-1.9 x 106 cells/tube).
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8.93 Saturation Assay
Triplicate total binding tubes, duplicate NSB tubes and duplicate total counts 
(unfiltered) tubes were used in order to reduce handling error, the experiment was 
carried out three times (n=3) and means and standard errors (S.E.M.) were 
calculated. The radioligand was diluted over a range of concentrations which was 
calculated to span from approximately 1 0  fold higher to 1 0  fold lower than the 
Kd- The highest concentration of ligand (pH]-spiperone, 95Ci/mmol, 
Amersham) was 2nM (ImM stock diluted 1:500, ie 6 pl in 3ml assay buffer) plus 
7(1:1) serial dilutions to 0.016nM.
Assays were set up in 4.9ml Sterilin assay tubes with constituents added in the 
order and quantities shown in Table 8.931.
total binding NS binding total counts
Buffer
10 0 50 1 0 0
Buffer +
lO-7 M ketanserin 10 0 1 0 0 1 0 0
[3H]-spiperone 50 50 50
Membrane
homogenate 250 250 250
(+)butaclamol (10~6m) - 50 -
TOTAL VOLUME 500pl 500pl 500pl
The assays were then vortexed and incubated at 37°C (physiological temperature) 
for 30 mins before being filtered over Whatman GF/B (glass fibre) filters. The 
total count tubes (unfiltered) were spotted onto the filters in 25pl aliquots 
(duplicated for each tube). The total binding and NSB tubes were transferred to 
filters using a Branded Cell Harvester (M24, Semat) which was washed through 
twice with distilled water and then with buffer, before suction of the cells onto a 
filter at 22mmHg vacuum pressure. Suction filtration removes any free ligand, 
leaving only bound [3H]-spiperone on the filter. The advantage of this method is 
that it is rapid therefore preventing significant receptor-radioligand dissociation.
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Once on the filter the samples were washed by drawing buffer over the filter twice 
for 5  sec to remove radioligand non-specifically bound to the filter and membrane, 
and dried for one hour in an LEEC drying oven, at full setting.
When dry, a Wallac Melt-on scintillation sheet was heat sealed to the filter, within 
a plastic cover, and the filter counted in a Wallac 1204 Betaplate BS liquid 
scintillation counter.
The disintegrations per minute (dpm) values obtained were converted into [3H]- 
spiperone concentration, to give total binding, NSB, and free radioligand 
concentration. Therefore specific binding could be calculated (total - NSB) and 
plotted against free concentration to calculate Bmax and Kd-
8.94 Com petition Assay
Duplicate total binding tubes, duplicate NSB tubes and duplicate total counts 
(unfiltered) tubes were set up (4.9ml assay tubes, Sterilin), along with twelve 
competing drug concentration duplicates. A final assay concentration (F.A.C.) of 
O.lnM [3H]spiperone was used. The F.A.C. of the cold competitive ligand 
ranged from 1 x 10-6 to 3 x 10-12 M for spiperone, (+)butaclamol, quinperole and 
7 OH-DPAT; and from 1 x 10 4 to 3 x 1 0 10 M for dopamine and (-)butaclamol. 
The drugs were weighed in powder form and then dissolved in ethanol and 
distilled water by vortexing and sonification to give lmM solutions. Constituents 
were added in the order and quantities shown in Table 8.941.
The buffer used was the same as that in the saturation assay and the drug 
ketanserin was once again added at F.A.C. 1 x 10_7M to block 5 HT2 receptors.
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Table 8.941 Competition Assay Composition
total binding NS binding total counts competitionbinding
Buffer
1 0 0 50 1 0 0 50
Buffer
(10_7M ketanserin) 1 0 0 1 0 0 1 0 0 1 0 0
pH]-spiperone 50 50 50 50
Membrane
homogenate 250 250 250 250
Test drug - - - 50
(+)butaclamol ( lO^M) - 50 - -
TOTAL VOLUME 500pl 500pl 500pl 500pl
The tubes were then vortexed and incubated at 37°C for 30 mins before being 
transferred to Whatman GF/B filters as described in the saturation assay method.
Dpm (disintegrations per minute) values were plotted against drug concentration 
and from the curve produced IC50 , and nH (Hill Coefficient) values were 
determined by a non-linear regression method. IC50 values for each cold 
competitor ligand were converted to pKi to allow comparison of results. 
Competition assays were repeated three times (n=3) for each drug tested and mean 
and standard error values were calculated.
8.942 GTP Competition Assay
The competition assay was repeated for the agonist compounds (quinpirole, 7- 
hydroxy-DPAT and dopamine) using Gpp(NH)p, a non-hydrolysable GTP 
analogue. The competition assay method was repeated for each of the agonist 
ligands with the addition of Gpp(NH)p at a F.A.C. of 1 x 10'4M
8.95 Protein Assay Method
A Pierce BSA assay kit was used to determine the protein concentrations of the 
diluted membrane homogenate used in the assays.
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Bovine serum albumin (BSA) at a stock concentration of 2mg/ml was serially 
diluted to F.A.C.S 1.0, 0 .8 ,0 .6 ,0 .4 ,0 .2  and O.lmg/ml. Then in 4.9ml Sterilin 
assay tubes, duplicate 50pl aliquots of these standard concentrations were assayed 
using the kit. Triplicate tubes of 50pl aliquots of the membrane homogenate were 
also assayed in this way.
After incubation the samples were measured for optical density (OD562nm), and a 
standard curve plotted for the BSA assays (using buffer as zero). From the mean 
CD562 of the membrane samples a protein concentration could be calculated, using 
the curve, to give the milligrams of protein per millilitre of diluted homogenate and 
therefore the mg of protein per saturation assay tube. This was calculated using 
the Apple Macintosh application 'Cricket Graph’ (Computer Associates).
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DNA Miniprep Solutions 
Cell Suspention Buffer
50mM Tris HC1, pH 7.5 
lOmM EDTA 
lOOmg/ml RNase A
Cell Lysis Solution 
0.2M NaOH(aq)
1% S.D.S.
N eutralization Solution
2.55M Potassium acetate, pH 4.8 
60ml 5M CH3COOK 
11.5ml glacial acetic acid 
28.5ml dH20
Column W ash Solution
200mM NaCl 
20mM Tris HC1, pH 7.5 
5mM EDTA 
Dilute 1:1 with 95% ethanol.
Sequencing Solutions (Sequenase USB) 
Enzyme Dilution Buffer 
lOmM Tris HC1, pH7.5 
5mM DTT 
0.5mg/ml Bovine Serum Albumin (BSA)
Prim er Annealing Buffer
200mM Tris HC1, pH7.5 
lOOmM MgCl2 
250mM NaCl
Labelling M ixture
1.5pMdTTP 
1.5pMdGTP 
1.5pM dCTP
1.5pM [a 35S] dATP (1500 Ci/mmol)
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Molecular Experimental Solutions
T ris [hydroymethyl] am inom ethane hydrochloride (Tris HC1) (1M) 
121. lg  Tris base was dissolved in 800ml (IH2O and the pH adjusted using conc. 
HC1 (pH 7.4 = 70ml; pH7.6 = 60ml; pH8.0 = 42ml). The solution was then 
autoclaved. N.B. The pH of this solution decreases with increasing temperature, 
keep at RT.
T ris I EDTA (T.E.) (lx  stock solution) 
lOmM Tris HC1, pH7.5 
ImM EDTA
Ligand Binding Buffer (pH7.4 @ 4°C)
50mM Tris HC1 (33.5g HC1; 4.85g Tris base)
120mM NaCl (34.8g)
2mM CaCl2 (1 0ml)
ImM Mg2S04 d.23g)
ImM EDTA (1.46g)
All components were dissolved in 4.5 litres CIH2O and Tris base added to adjust 
the pH to 7.4 then the volume was made up to 51itres.
Electrophoresis Buffers 
T . A .E . (50x)
242g Tris base was dissolved in 57.1ml glacial acetic acid and 100ml 0.5M EDTA 
pH 8
The working concentration of lx contains 0.04M Tris - acetate and 0.001M 
EDTA.
T.B.E. (5x)
54g Tris base and 27.5g boric acid were dissolved in 20ml 0.5M EDTA pH8 . 
The working solution of 0.5x contains 0.045M Tris - borate and 0.001M EDTA. 
N.B. If the solution precipitates on storage it should be disguarded.
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Termination Mixtures
80pM dGTP
80pM dATP
80pM dCTP
80pM dTTP
plus 8 pM dideoxy-dNTP
Stop Solution
20mM EDTA 
95% Formamide 
0.05% Bromophenol Blue 
0.05% Xylene Cyanol FF
Acrylamide Gel Solution
420g Urea (sequencing grade)
250ml dH20  
240ml 5xTBE
40% acrylamide colution (19:1 bis, Severn Biotechnology)
Make up to 11 with dH20  and filter through Whatman No. 3 paper.
Stock Solutions
E thylenediam inetetraacetic acid (E.D.T.A.) (0.5M stock solution)
186.lg disodium EDTA.2H20 was dissolved in 800ml dH20  at room temperature 
(RT) by vigorous stirring and the pH was adjusted to 8  (using approx. 20g NaOH 
pellets). The solution was then autoclaved on the standard cycle.
Sodium Dodecyl/Lauryl Sulphate (S.D.S.) (10% stock solution) 
lOOg electrophoresis grade S.D.S. was dissolved in 900ml dH20  by strring at 
6 8 oC. The a pH of 7.2 was obtained by adding conc. HC1 dropwise and dH20  
added to 11.
ATP (0.1M stock solution)
60mg ATP was dissolved in 0.8ml dH20  and the pH adjusted to 7 by dropwise 
addition of 0.1 M NaOH. The volume was increased to 1ml with dH20  and the 
solution aliquoted and stored at -70°C.
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dNTPs
Were provided as individual lOOmM stocks at pH7 (Pharmacia)
Sam ple Loading Buffer
This was used to aid loading of the sample into an agarose gel well by adding 
colour, increasing the density and to indicate the distance moved by the sample. 
Bromophenol blue dye moves towards the anode with approximately the same 
velocity as linear ds DNA of300bp length and Xylene Cyanol FF moves similarly 
with the velocity of linear ds DNA of 4kb length (in 0.5x TBE).
4g sucrose was dissolved in 6ml (IH2O along with 2.5mg bromophenol blue and 
lmg Xylene cyanol FF. The volume was increased to 10ml with dH20 and stored 
atRT.
Sodium Acetate (3M stock solution, pH7)
408. lg sodium ? .3 H2O was dissolved in 800ml dH20 and dilute acetic acid used 
to bring the pH to 7. The volume was increased to 11 with (IH2O and the solution 
autoclaved.
Ammonium acetate (10M stock solution)
770g ammonium acetate was dissolved in 800ml (IH2O and the volume made up to 
11 before filter sterilization.
D ithiothreitol (DTT)
3.09g DTT was dissolved in 20ml 0.01M sodium acetate (pH5.2), this was filter 
sterilised and stored at -20°C in 1ml aliquots.
M agnesium Chloride (MgCl2 ) (2M stock solution)
19g MgCl2 was dissolved in 90ml (IH2O, then the volume was made up to 100ml 
and autoclaved.
Na45 Paper - Activation solution
The strip of paper was taken using forceps and soaked for lOmins in lOmM 
EDTA, then transferred to 0.5M NaOH for 5mins. It was then washed quickly in 
dH20 before submerging in fresh dH20 and storing at 4°C. It was cut into 
appropriately sized strips for use and if not used disguarded after 4 months.
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Low salt NET (for use with Na45 paper) 
lOOmM NaCl(aq)
O.lmM EDTA 
20mM Tris-HCl, pH8
High salt NET (for use with Na45 paper) 
1M NaCl 
O.lmM EDTA 
20mM Tris-HCl, pH8
Microbiological solutions (prepared and used aseptically) 
Isopropylthio-b-D-galactoside (IPTG) MW 238.3 (powder at-20°C)
Stock solution at lOOmM 
0.024g dissolved in 1ml (IH2O at RT
Filter sterilize using a sterile 0.22 q,m filter unit (Sartorius, Minisart NML).
Store at 4°C. Use 4mM (40pl) per ?mm diameter petri dish.
5-bromo-4-chIoro-3-indoyl-b-D-galactopyranoside (X gal) MW 408.6 
(Store as powder in dry and dark conditions at 4°C)
Stock solution at 50mg/ml
0.0 lg dissolved in 1ml di-methyl formamide (DMF)
Store away from light at -20°C
Liquid Media 
LB
lOg bacto-tryptone 
5g bacto-yeast extract 
lOg NaCl 
950ml dH20
This was shaken till dissolved and the pH adjusted to 7 by the addition of 
approximately 0.2ml 5M NaOH solution. The volume was increased to 11 using 
dH20  and autoclaved on liquid cycle at 151b/sq in for 20mins.
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2xYT (Yeast Tryptone) Broth
16g bacto-tryptone 
lOg bacto-yeast extract 
5g NaCl 
900ml dH20
This solution was shaken until all solids were dissolved and the pH adjusted to 7 
by the addition of approximately 0.2ml 5M NaOH. The volume was increased to 
11 using dH20  and autoclaved on liquid cycle at 151b/sq in for 20mins.
SOC Media
2 0 g bacto-tryptone 
5g bacto-yeast extract 
0.5g NaCl 
950ml dH20
This solution was shaken until all solids were dissolved then 10ml 250mM KC1 
(1.8 6 g KC1 in 100ml dH20) was added. The pH was adjusted to 7 by the addition 
of approximately 0.2ml 5M NaOH and the volume was increased to 11 using 
dH20  and autoclaved on liquid cycle at 151b/sq in for 20mins. On cooling to 
60°C, 1M glucose (18g dissolved in 100ml dH20  and filter sterilized through a 
0.22 micron filter) was added to a final concentration of 20mM and 2M MgCl2 
(19g MgCl2 dissolved in 100ml dH20  and autoclaved) added to lOmM.
Solid Media 
L Agar
Bacto-agar was added to LB media at 15g/l before autoclaving. This solid media 
could then be heated till molten when required for pouring into plates.
Antibiotics
Ampicillin
Tetracyclin
Kanamycin
stock conc.
50mg/ml in dH20  
5mg/mlinEtOH 
lOmg/ml in dH20
working conc.
2 0  - 60mg/ml 
10 - 50mg/ml 
10 - 50mg/ml
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Appendix II: Sequence Alignments
Alignment of full length amino acid sequences for all neuropeptide receptors 
investigated in Chapter 3
1 50
PTH .......... .......... .......... .......... GGGRGGELGG
secretin...............................C* QSCHLLQGAA ASSLAVDLIG
calcitonin..............................CAR PHLTLRLTSP AQEMGAEA*A
somatostatin 
d-opioid 
rangiotens inll 
VIP
neuropeptide Y 
bradykinin 3 
N-formyl pep 
TRH
neurotensin
bombesin  NCSQ RDSV*DGGRK S*DKVGLILS FSSG*VSVAC
endothein ....................................................
NK-1 ....................................................
NK-3  IAVSFS FQSYLKIPAP
NK-2 AHRLGTLCTS VIWDVP*IAL REI*IQIRVC HQLPECLLLD ASFL*LSAF*
CCK ....................................................
Consensus ----------  R----Q— R- — L---L--ASSLGVEA—
51 100
PTH RRRL PRGTRP* AVAMGAARIA PSLALLLCCP VLSSAYALVD
secretin LGRS SHGLSGL GGRPGSWTTC RSLSWTQNRP PSS*R G
calcitonin PESLEPHLRT PFASIELCPA AQ*QNSRIND SH*STHFCHP RMQFSGEKIS
somatostatin ....................................................
d-opioid ....................................................
angiotensin.................................................... PA
VIP ....................................................
neuropeptide Y ....................................................
bradykinin  RRVS STVGDGVAGS R*PWTEGLPT
N-formyl pep ....................................................
TRH  E FRRV*RNCRS ED*ASAK*SS GQTDWTRFLL
neurotensin..................................................... M
bombesin *LSECTDVLL AGGVKAGTEP TSTN*ARVWN TSVCVCVCVC VCVCEFRVF*
endothelin ......KLR TGHRTPSGAG SSMQPPPSLC GRALVALVLA CGLSRIWGEE
NK-1 ....................................................
NK-3 K*PGGR EELQ RSLVLGCPWV SGRVRDCRPV AMATLPAAET
NK-2 LWCEREEPIQ RAIRMPPALR LEFEFSISKR CLNSLIGTLL PAQPDSFLPE
CCK  PQCLPRC SENGELKLPL GMAAKPTPGN
Consensus L----R— L- TG— RG-ELQ GS-MLSRR—  SSV-RLLC-P -MASR-RLP-
101 150
PTH ADDVFTKEEQ IFLLHRAQAQ CDKLLKEVLH T.AANIMESD KGWTPASTSG 
secretin QNAKGSNSGR SMLSTMRPRL SLLLLRLLLL TKAAHTVGVP PRLCDVRRVL 
calcitonin GQRDLQKSKM RFTFTSRCLA LFLLLNHPTP ILPAFSNQTY PTIEPKPFLY
somatostatin ................. DL* AAWF...*TE WKAAMEM... .SSEQLNGSQ
d-opioid ............... SKGWV PAPRAHGGDG HGGAMELVPS ARAELQSSPL
angiotensin LGGT*RSARG AGLIFDKLI* NGWVFI.*IT H*CHPRKSAP GVFDIVFATN
VIP ........................................... MDLHLFDYAE
neuropeptide Y ................. *QS DAEGLSAPVA TASGEPAVTM EGISIYTSDN
bradykinin TQNRLSREKD DPHSSLS*VQ MHCSWKRPVL LSVHEPMPTT ASLGIEMFNI
N-formyl pep ............................................PRARPQLVN
TRH QDWKLGPIST SSTRETGSVT E*RGERTTAK TNRQKGEGWK DVLESPCQRS
neurotensin HLNSSVPQGT PGEPDAQPFS GPQSEMEAT......................
bombesin REIKRLTQIS EPN*QTFSA* LKNPEVTKQH LEGAFEERSF EMAPNNCSHL
endothelin RGFPPDRA......... TPL LQTAEIMTPP TKTLWPKGSN ASLARSLAPA
NK-1 ..................................AALPAKM. DNVLPVDSDL
NK-3 WIDGGGGVGA DAVNLTASLA AGAATGAVET GWLQLLDQA. GNLSSSPSAL 
NK-2 L*AWPSGYTC LLLNRPSPLK STHRRGFLFC GNSRRNCRAR PCVPGPESVM 
CCK L...PLPAPP RQVAFGRPCD H*RRETGMSH SPARQHLVES SRMDWDSLL 
Consensus — RKLSP-GT DFL— T— L- LA-LL— P-T TKAALPM-AS D-LEIVDSDL
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151 200
PTH KPRKEKASGK FYPESKENKD VPTGSRRRGR PCLPEWUN1V CWPLGAPGEV
secretin LEERAHCLQQ LSKEKKG&LG PETAS GCEGLWENMS CWPSSAPART
calcitonin WGRKKMMDA QYK.CYDRMQ QLPAYQGEGP YCNRTWDGWL CWDDTPAGVL 
d-opioid VNLSDAFPSA FPSAGANASG SPGARSASSL .ALAIAITAL YSAVCAVGLL 
angiotensin STQVTKMILN SSTEDGIKRI QDDCPKAGRH NYIFVMIPTL YSIIFWGIF 
VIP PGNFSDISWP CNSSDCIWD TVMCPNMPNK SVLLYTLSFI YIFIFVIGMI 
neuropeptide Y YTE....EMG SGDYDSMK.. .EPCFREENA NFNKEFLPTI YSIIFLTGIV
bradykinin TTQ ALG SAHNGTFS.. EVNCPDTEWW SWLNAIQAPF LWVLFLLAAL
N-formyl peptide SPGADKMETN SSLPTNISGG TPAVSAG..Y LFLDIITYLV FAVTFVLGVL
TRH FKPLKMENDT VSEMNQTELQ PQAAVALEYQ WTILLWII C GLGIV
neurotensin FLALSLSNGS GNTSESDTAG PNSDLDVNTD IYSKVLVTAI YLALFWGTV 
bombesin NLDVDPFLSC N..DTFNQSL SPPKMDNWFH PGFIYVIPAV YGLIIVIGLI 
endothelin EVPKGDRTAG SPPRTISPP. .PCQGPIEIK ETFKYINTW SCLVFVLGII
NK-1 .FPNTSTNTS E SNQ..... FVQPT. .WQIVLWAAA YTVIWTSW
NK-3 GLPVASPAPS QPWANLTNQ..... FVQPS. .WRIALWSLA YGVWAVAVL
NK-2 GTRAIVSDAN ILSGLESNAT GVTAFSMPG. .WQLALWATA YLALVLVAVT 
CCK MNGSNITPPC EL.GLENETL FCLDQPQPSK EWQSALQILL YSIIFLLSVL 
Consensus -LPA-KMELN SS-EDL-NQG -P— FVQPR- SWLIVLIPLI Y-VIFWGVL
201 250
PTH VAVPCPDYIY DFNHK.GHAY RRCDRNGSWE WPGHNRTWA NYSECLKFMT
secretin VEVQCPKFLL MLSNKNGSLF RNCTQDGWSE TFP RP DLACGVNINN
calcitonin SYQFCPDYFP DF.DPSEKVT KYCDEKGVWF KHPENNRTWS NYTMCNAfTP 
somatostatin GNTLV. .IYV ILRYA.. .KM KTITNIYILN LAIADELFML GLPFLAMQVA 
d-opioid GNVLV..MFG IVRYT...KL KTATNIYIFN LALADALATS TLPFQSAKY. 
angiotensin GNSLV. .VIV IYFYM...KL KTVASVFLLN LALADLCFLL TLPLWAVYTA 
VIP ANSW-.VWV NIQAK...TT GYDTHCYILN LAIADLWWL TIPVWWSLV 
neuropeptide Y GNGLV..ILV MGYQK...KL RSMTDKYRLH LSVADLLFVI TLPFWAVDAV 
bradykinin ENIFV..LSV FCLHK...TN CTVAEIYLGN LAAADLILAC GLPFWAITIA 
N-formyl peptide GNGLV..IW AGFRM...T. HTVTTISYLN LAVADFCFTS TLPFFMVRKA 
TRH GNIMV. .VLV VMRTK...HM RTPTNCYLVS LAVADI/WLV AAGLPNITDS 
neurotensin GNSVT..AFT LARKKSLQSL QSTVHYHLGS LALSDLLILL LAMPVELYNF 
bombesin GNITL..IKI FCTVK...SM RNVPNLFISS LALGDLLLLV TCAPVDASKY 
endothelin GNSTL..LRI IYKNK...CM RNGPNILIAS LALGDLLHIV IDIPINVYKL 
NK-1 GNVW..IWI ILAHK...RM RTVTNYFLVN LAFAEACMAA FNTWNFTYA 
NK-3 GNLIV..IWI ILAHK.. .RM RTVTNYFLVN LAFSDASMAA FNTLVNFIYA 
NK-2 GNATV..IWI ILAHE...RM RTVTNYFIIN LALADLCMAA FNATFNFIYA 
CCK GNTLV. . ITV LIRNK...RM RTVTNIFLLS LAVSDLMLCL FCMPFNLIPN 
Consensus GNVLVPDIWV ILRHKSG— M RTVTNIFLLN LALADLLFLL TLPFWN-YYA
PTH
secretin
calcitonin
somatostatin
d-opioid
angiotensin
VIP
neuropeptide Y 
bradykinin 
N-formyl peptide 
TRH
neurotensin
bombesin
endothelin
NK-1
NK-3
NK-2
CCK
Consensus
251 300
N.ETREREVF DRLGMIYTVG YSMSLASLTV AVLILAYFRR LH.......
SFNERRHAYL LKLKVMYTVG YSSSLAMLLV ALSILCSFRR LH.......
..EKLKNAYV ..LYYLAIVG HSLSIFTLVI SLGIFVFFRK LTTIFPLNWK 
L..V.HWPFG KAICRWMTV DGINQFTSIF CLTVMSIDRY LAWHPIKSA 
L..METWPFG ELLCKAVLSI DYYNMFTSIF TLTMMSVDRY IAVCHPVKAL 
M. • EYRWPFG NYLCKIASAS VSFNLYASVF LLTCLSIDRY LAIVHPMKSR 
Q..HNQWPMG ELTCKVTHLI FSINLFSGIF FLTCMSVDRY LSITYFTNTP 
A. .N..WYFG NFLCKAVHVI YTVNLYSSVL ILAFISLDRY LAIVHATNSQ 
N..NFDWLFG EVLCRWNTM IYMNLYSSIC FLMLVSIDRY LALVKTMSMG 
M. .GGHWPFG WFLCKFLFTI VDINLFGSVF LIALIALDRC VCVLHPVWTQ 
IYG..SWVYG YVGCLCITYL QYLGINASSC SITAFTIERY IAICHPIKAQ 
IWVHHPWAFG DAGCRGYYFL RDACTYATAL NVASLSVERY LAICHPFKAK 
L. .ADRWLFG RIGCKLIPFI QLTSVGVSVF TLTALSADRY KAIVRPMDIQ 
L..AEDWPFG AEMCKLVPFI QKASVGITVL SLCALSIDRY RAVASWSRIK 
V..HNVWYYG LFYCKFHNFF PIAALFASIY SMTAVAFDRY MAIIHPLQPR 
L..HSEWYFG ANYCRFQNFF PITAVFASIY SMTAIAVDRY MAIIDPLKPR 
S..HNIWYFG RAFCYFQNLF PITAMFVSIY SMTAIAADRY MAIVHPFQPR 
L..LKDFIFG SAVCKTTTYF MGTSVSVSTF NLVAISLERY GAICRPLQSR 
L-EH-EWPFG EFLCKFVNFF P— NLFASIF SLTALS-DRY LAIVHPLKSR
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301 350
PTH .......CT RNYIHMHMFL, SFMLRAASIF VKDAVLYS.- GFTLDEAERL
secretin .......CP RNYTHMHT >I**V SFTLRALSNF 3KDAVLFSSD DVTYCDAHKV
calcitonin YRKALSLGCQ RVTLHKNMFL TYZLNSMIII IHLVEWPNG ELVRRDP...
somatostatin ........ K WRRPRTAKMI NVAVWCVSLL VTLPIMLYAG LR___SNQW
d-opioid ........D FRTPAKAKLI NICIWVLASG VGVPIMVMAV TQ___PRD.
angiotensin ........L RRTMLVAKVT CIIIWLLAGL ASLPAIIHRN V. .FFIENTN
VIP ........S SRKKMVRRW CILVWLLAFC VSLPDTYYLK T..VTSASNN
neuropeptide Y ........R PRKLLAEKW YVGVWIPALL LTIPDFIFAN V. ...SEADD
bradykinin ........R MRGVRWAKLY SLVTWSCTLL LSSPMLVFRT MKDYREEGHN
N-formyl peptide ........N HRTVSLAKKV IIGPWVMALL LTLPVIIRVT T....VPGKT
TRH ........F LCTFSRAKKI IIFVWAFTSI YCMLWFFLLD L___NISTY
neurotensin ........T IWSRSRTKKF ISAIWLASAL LAIPMLFTMG L0JRSGDGTH
bombesin ........A SHALMKICLK AALIWIVSML LAIPEAVFSD LHPFHVKDTN
endothelin ........G IGVPKWTAVE IVLIWWSW LAVPEAIGFD IITMDYKGSY
NK-1 ........L SATATKV..V IFVIWVLALL LAFPQGYYS. ....TTETMP
NK-3 ........L SATA3KI..V IGSIWILAFL LAFPQCLYS. ....KTKVMP
NK-2 ........L SAPSTKA..1 IAGIWLVALA LASPQCFYS. ....TITVDE
CCK IAATWCLSFT IMTPYPIYSN LVPPTKNNNQ
Consensus ------- CL RRTLLKAK-V IIIIWVLALL LALPEL-YSD — T-TIE-TN
351 400
PTH TRHKI.HTTAQ VPPPPAAAAV GYAGCRVAVT FFT.YFTATNY YWILVEGLYL
secretin ...GCKLVMI FFQYCIMANY AWLLVEGLYL
calcitonin FHQYMMACNY FWMLCEGIYL
somatostatin GRSSCTINWP GESG..... IIYAFILG..
d-opioid GAWCMLQFP SPSW..... KECVFLFA..
angiotensin ITVC.AFHYE SQNS..... GLTKNILG..
VIP ETYCRSFYPE HSIK..... ___EWLIGM ELVSWLG..
neuropeptide Y RYICDRFY.. .PND..... ___LWVWF QFQHIMVG..
bradykinin VTACVIVY.. • PSR..... NMT.T.NT.VG, .
N-formyl peptide GTVACTFNFS PWTNDPKERI NVAVAMLTVR GIIRFIIG.. .......FS
TRH KNAVWSCGY KISRNY___ ___YSPIYL . -MDFGVF.. .......YV
neurotensin PGGLV..CTP IVDTAT___ ___VKWIQ . .VNTFMS.. .......FL
bombesin QTFISCAPYP HSN..E___ ___LHPKTH SMASFLVF.. .......YV
endothelin LRICTiTiHPVQ KTAFMQ.... DWWLFSFY..
NK-1 SRWCMIEWP EHPNRT___ ___YEKAYH ICVTVLIY..
NK-3 grtlcfvqwp EGPKQH___ IIVIILVY..
NK-2 GATKCWAWP NDNGGK___ LWFVLIY..
CCK TANMCRFLLP SDAMQQ___ ......SWQ TFLLLILF.. .......L.
Consensus GRVCCMIYWP EP-RQT--- — AG-WP-YF IFV-FLVYNY -W-LVEGLFL
401 450
PTH HSLIFMAFFS EKKYLWGFTI FGWGLPAVFV AVWVGVRATL ANTGCWDLSS
secretin HTLLAISFFS ERKYLQAFVL LGWGSPAIFV ALWAITRHFL ENTGCWDINA
calcitonin HTLIWAVFT EKQRLRWYYL LGWGFPLVPT TIHAITRAVY FNDNCW.LSV
somatostatin VPLTIICLC. IIIKVKSSGI RVGSSKRK..
d-opioid VPILIITVC. ......YGL MLLRLRSVRL LSGSKEKD..
angiotensin FPFLIILTS. ......YTL IWKALKKAYE IQKNKPRN..
VIP VPFSIIAVF. ......YFL LARAISASSD QEKHSSR__
neuropeptide Y LPGIVILSC. ......YCI IISKLSHSKG HQKRKA___
bradykinin LPLSII.TF. ......CTV RIMQVLRNNE MKKFKEVQ..
N-formyl peptide APMSIVAVS. ......YGL IATKIHKQGL IKSSRP___
TRH VPMILATVL. ......YGF IARILFLNPI PSDPKENSKM WKNDSIHQNK
neurotensin FPMLVISIL. ......NTV IANKLTV..M VHQAAEQGRV CTVGTHNGLE
bombesin IPLAIISVY. IARNLIQSAY NLPVEGNIHV KK.......
endothelin LPLAITAFF. ......YTL MTCEMLRKKS GMQIALNDHL KQ.......
NK-1 LPLLVIGYA. ......YTV VGITLWAS.. .EIP.GDSSD
NK-3 FPLLIMGIT. ......YTI VGITLWGG.. . EIP. GDTCD
NK-2 LPLLVMFGA. ......YSV IGLTLWKR.. .AVPRHQAHG
CCK LPGIVMWA. ......YGL ISLELYQGIK FDASQKKSAK EKKPSTGSST
Consensus LPLLIIAVFS EKKYL— YTL IG-TLWAS— I-KSKERDHL K-IPCGDSSD
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451 500
PTH GHK.KWIIQV PILASWLNF ILFINIIEVL ATKLRETNAG RCDTRQQYRK
secretin NASVWWVXRG PVTLSILINF IFFINILRIL MRKLR.TQET RGSETNHYKR
calcitonin ETHLLYIIHG PVMAALWNF FFLUJIVKVL VTKMRETHEA ...ESHMYLK
somatostatin
d-opioid
angiotensin
VIP ...................K
neuropeptide Y
bradykinin
N-formyl peptide
TRH NLN.................
neurotensin HST.................
bombesin
endothelin
NK-1 RYHE................
NK-3 KYHE................
NK-2 ANLR................
CCK RYEDSDGCYL QKSRPPRKLE LQQLSSGSGG SRLNRIRSSS SAANLIAKKR
Consensus RYHE-WII-G PV-AS-V-NF -FF-NI-RVL —■—kLRETNJE— R—SQ— AK—K
PTH
secretin
calcitonin
somatostatin
d-opioid
angiotensin
VIP
neuropeptide Y 
bradykinin 
N-formyl peptide 
TRH
neurotensin
bombesin
endothelin
NK-1
NK-3
NK-2
CCK
Consensus
501
LLRSTLVLVP 
LAKSTLLLIP 
AVKATMILVP 
VTRMVSIWA 
ITRMVLVWG 
II.MAIVL.. 
II.FSYW.. 
TT.VILIL.. 
TV.LVLAVLG 
.LRVLSFVAA 
VTKMLAVWI 
GVLVLRAWI 
LAKTVLVFVG 
VAKTVFCLVL 
WKMMIWVC 
WKMMIIWM 
FVKAMVLWL 
VTRMLIVIW 
WKMM-VW-
LFGVHYTVF...........
LFGIHYIVF...........
LLGIQFWF...........
VFIFCWLPFY IFNVSSVSVA 
AFWCWAPIH IFVTVWTLVD 
FFFFSWIPHQ IFTFLDVLIQ 
VFLVCWLPYH VAVLLDIFSI 
AFFACWLPYY IGISIDSFIL 
LFVLCWFPFQ ISTFLDTLLR 
AFFLCWSPYQ WALIATVRI 
LFALLWMPYR TLVWNSFLS 
AFWCWLPYH VRRLMFCYIS 
LFAFCWLPNH VIYLYRSYHY 
VFALCWLPLH LSRILKLTLY 
TFAICWLPFH IFFLLPYIN. 
TFAICWLPYH IYFILTAIY. 
TFAICWLPYH LYFILGTFQ. 
LFFLCWMPIF SANAWRAYD. 
LFAICWLP-H IFFLL— F-Y
.MALPYTEVS
•AFSPEDAM.
.PWRPSNKHL
I...... SP
IN..... RR
LGIIR.DCRI 
LHYIPFTCRL 
LEIIKQGCEF 
LGVLS.GCWN 
RELLQGMYKE 
SPFQEN..WF 
DEQWTT..FL 
SEVDTSM... 
NQNDPNRCEL
 PDLYL
 QQLNR
 EDIYY
 TVSAE
LE-IP-DC-L
550
GTLWQIQMHY 
....EVQLFF 
GKIYDYVMH. 
TPALKGMFDF 
DPLWAALHL 
ADIVDTAMPI 
EHALFTALHV 
ENTVHKWISI 
ERAVDIVTQI 
...IGIAVDV 
LLFCRIC... 
FDFYHYFYML 
..LHFVTSIC 
LSFLLVLDYI 
KKFIQQVYLA 
WKYIQQVYLA 
HKFIQQVYLA 
KHLSGTPISF 
-KFIQIVYLI
PTH 
secretin 
calcitonin 
somatostatin 
d-opioid 
angiotens in 
VIP
neuropeptide Y 
bradykinin 
N-formyl peptide 
TRH
neurotensin
bombesin
endothelin
NK-1
NK-3
NK-2
CCK
Consensus
551 600
EMLFNSFQGF FVAIIYCFCN GEVQAEIRKS WSRWTLALDF KRKARSGSSS 
ELALGSFQGL WAVLYCFLN GEVQLEVQKK WRQWHLQ.EF PLRPVAFNNS 
..SLIHFQGF FVATIYCFCN NEVQTTVKRQ WAQFKIQWNQ RWGRRPSNRS 
WILTYANTC ANPILYAFLS DNFKKSFQNV LCLVKVSGTE DGERSDSKQD 
CIALGYANSS LNPVLYAFLD ENFKRCFRQ. LCRTPCGRQE PGSLRRPRQA 
TICIAYFNNC LNPLFYGFLG KKFKRYFLQL L...KYIPPK AKSHSN...L 
TQCLSLVHCC VNPVLYSFIN RNYR...YEL M...KAFIFK YSAKTG...L 
TEALAFFHCC LNPILYAFLG AKFKTSAQHA L...TSVSRG SSLKIL...S 
SSYVAYSNSC LNPLVYVIVG KRFRKKSREV Y...QAICRK GGCMGESVQM
TSALAFFNSC LNPMLYVFMG QDFRERLIHA L...............PASL
 IYLNSA INPVIYNLMS QKFRAAFRK........LCN CKQKPTEKAA
TNALFYVSSA INPILYNLVS ANFRQVFLST LAC LCP GWRHRRKKRP
AHLLAFTNSC VNPFALYLLS KSFRKQFNTQ L.LC.....CQPGLMNRSH
GINMASLNSC INPIALYLVS KRFKNCFKSC L.CCWCQSFE EKQSLEEKQS 
SMWLAMSSTM YNPIIYCCLN DRFRLGFKHA FRCCPFISAG DYEGLEMKST 
SFWLAMSSTM YNPIIYCCLN KRFRAGFKRA FRWCPFIKVS SYDELELKTT 
LFWLAMSSTM YNPIIYCCLN HRFRSGFRLA FRCCPWVTPT EEDRLELTHT
ILLLSYTSSC VNPIIYCFMN KRFRLGFMAT FPCCPNPGPP G........
T-WLAYFNSC LNPI-YCFLN KRFR-GF— A LRCCPFISP- DYD-LELKST
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601 650
PTH YSYGPMVSHT SVTNV...GP RAGLSLPLSP RLPPATTNGH SQLPGHAKPG
secretin FSNATNGPTH STKA..... SIPRA.... SII*
calcitonin ARAAAAAAEA GDIPIYICHQ EPRNEPANNQ GEESAEIIPL NIIEQESSA*
somatostatin KSRLNETTET QRTLLNGDLQ TSI*
d-opioid TTRERVTACT PSDGPGGGAA A*
angiotensin STKMSTLSYR PSDNVSSSTK KPAPCFEVE*
VIP .TKLIDAS.R VSETEYSALE QNAK*
neuropeptide Y KGKRGGHSSV STESESSSFH SS*
bradykinin ENSMGTLRTS ISVDRQIHKL QDWAGNKQ*
N-formyl peptide ERALTEDSTQ TSDTATNSTL PSAEVALQAK *
TRH NYSVALNYSV IKES..DRFS TELEDITVTD TYVSTTKVSF DDTCLASEN*
neurotensin TFSRKPN..S MSSN..HAFS TSATRETLY*
bombesin S..TGRSTTC MTSFKSTNPS ATFSLINRNI CHEGYV*
endothelin CLKFKANDHG YDNFRSSNKY SSS*
NK-1 RYLQT.QSSV YKVSRLETTI STWGAHEDE PEEGPKATPS SLDLTSNGSS
NK-3 RFHPNRQSSM YTVTRMESMT WFDPNDADT TRSSRKKRAT PRDPSFNGCS
NK-2 PSLSRR___ ..VNRCHTKE TLFMTGDMTH SEATNGQVGS PQDGEPAGPI
CCK . .VRGEVGEE EDGRTIRALL SRYSYSHMST SAPPP*
Consensus -YKLT-QSS- YS— RS-S— SSF— A-- T -L-SRK— PS SQDPS-NGFS
PTH
secretin
calcitonin
somatostatin
d-opioid
angiotensin
VIP
neuropeptide Y 
bradykinin 
N-formyl peptide 
TRH
neurotensin
bombesin
endothelin
NK-1
NK-3
NK-2
CCK
Consensus
651
APATETETLP VTMAVPKDDG FLNGSCSG.. ..LD..EEAS
700
GSARPPPLLQ
RSNS... 
KERNS. . 
CKAQA*
•KT MTESSSFYSN ILA*
.KS ASATSSFISS PYT SV DEYS*
R——S----K--T— SSF-S
701
PTH EEWETVM*
All sequences obtained from GenEMBL database and translated using Wisconsin
Genetics GCG program.
Database accession numbers:-
rat parathyroid hormone receptor (PTH) - M77184
rat secretin receptor -X59132 rat neurotensin receptor - P20789
human calcitonin receptor - L00587 mouse bombesin receptor - M61000
mouse somatostatin receptor - M91000 human endothelinB receptor - M74921
rat 6-opioid receptor - L07271 mouse NK-1 receptor - X62934
human angiotensin receptor - M93394 human NK-3 receptor - M89473
human neuropeptide Y receptor - M84755 rat NK-2 receptor - M3183
rat bradykinin receptor - X69681
mouse thyrotropin releasing hormone receptor (TRH) -M59811 
human vasoactive intestinal peptide receptor (VIP) - L I3288 
human N-formyl peptide receptor - M60627 
rat cholecystokmin receptor (CCK) - X01032
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Alignment of full length amino acid coding sequences for the neuropeptide
receptors in group i as assigned by peptide sequence homology in Table 2.46
1 50
PTH............. GGGRGGEL GGRR..RLPR GTRP*AVAMG AARIAPSLAL
secretin C*QSCHLLQG AAASSLAVDL IGLG..RSSH GLSGLGGRPG SWTTCRSLSW
calcitonin GRTASPPDPG RAAPRLSRTF LGWRGARRPH LAQGLESPIQ EMRAGA*VPE
Consensus — — — — G —AA——L— —L —G—R— R—PH G— GL----G ——R—— SL——
51 100
PTH LLCCFVLSS. ..AYALVDAD DVFTKEEQIF LLHRAQAQCD KLLKEVLHT.
secretin T©®PPSS*. ..R....GQN AKGSNSGRSM LSTMRPRLSL LLLRLLLLTK
calcitonin SLEPPPANDL RFH*AVPGSP VRLLQD*QDH LQKSKMRPTL TKWCLTLFIF 
Consensus -L— PP-S—  A— G— ------- Q—  L----R— L -LL-L-L-T-
101 150
PTH AANIMESDKG WTPASTSGKP RKEKASGKFY PESKENKDVP TGSRRRGRP.
secretin AAHTVGVPPR LCDVRRVLLE ERAHCLQQLS KEKKGALGPE TAS G,
calcitonin LNRPLPVLPD SADGAHTPTL EPEPFLYILG KQRMLEAQHR CYDRMQKLPP
Consensus AA V-P- — D-------E-E— L— L- KE-K------ T-SR P-
151 200
PTH  CLP EWDNIVCWPL GAPGEWAVP CPDYIYDFNH K.GHAYRRCD
secretin  CEG LWDNMSCWPS SAPARTVEVQ CPKFLLMLSN KNGSLFRNCT
calcitonin YQGEGLYCNR TWDGWSCWDD TPAGVLAEQY CPDYFPDF.D AAEKVTKYCG
Consensus ------ C--- WDN-SCWP--APG— VEV- CPDY— DF—  K-G---R-C-
201 250
PTH RNGSWEWPG HNRTWANYSE CLKFMTN.ET REREVFDRLG MIYTVGYSMS
secretin QDGWSETFP..... RPDLAC GVNINNSFNE RRHAYLLKLK VMYTVGYSSS
calcitonin EDGDWYRHPE SNISWSNYTM C NAFTP DKLQNAYILY YLAIVGHSLS
Consensus -DG-WE— P---N— W-NY—  C----N-F-- R----- L--- YTVGYS-S
251 300
PTH LASLTVAVLI LAYFRRLHCT RNYIHMHMFL SFMLRAASIF VKDAVLYS..
secretin LAMLLVALSI LCSFRRLHCT RNYIHMHLFV SFILRALSNF IKDAVLFSSD
calcitonin ILTLLISLGI FMFLRSISCQ RVTLHKNMFL TYVLNSIIII VHLWIVPNG
Consensus LA-LLVAL-I L— FRRLHCT RNYIHMHMFL SF-LRA-SIF VKDAVL-S—
301 350
PTH GFTLDEAERL TEEELHIIAQ VPPPPAAAAV GYAGCRVAVT FFLYFLATNY
secretin DVTYCDAHKV........................ GCKLVMI FFQYCIMANY
calcitonin ELVKRDP........................... PICKVLHF FHQYMMSCNY
Consensus — T— DA -----------------   GCKV------ FFQY---NY
351 400
PTH YWILVEGLYL HSLIFMAFFS EKKYLWGFTI FGWGLPAVFV AVWVGVRATL
secretin AWLLVEGLYL HTLLAISFFS ERKYLQAFVL LGWGSPAIFV ALWAITRHFL
calcitonin FWMLCEGVYL HTLIWSVFA EGQRLWWYHV LGWGFPLIPT TAHAITRAVL
Consensus -W-LVEGLYL HTLI— SFFS E-KYLW-F—  LGWG-PAIFV A-WAITRA-L
401 450
PTH ANTGCWDLSS GHK.KWIIQV PILASWLNF ILFINIIRVL ATKLRETNAG
secretin ENTGCWDINA NASVWWVIRG PVILSILINF IFFINILRIL MRKLR.TQET
calcitonin FNDNCW.LSV DTNLLYIIHG PVMAALWNF FFLLNILRVL VKKLKESQEA
Consensus -NTGCWDLS------WII-G PV-AS-V-NF IFFINILRVL — KLRETQE-
451 500
PTH RCDTRQQYRK LLRSTLVLVP LFGVHYTVFM ALPYTEVSGT LWQIQMHYEM
secretin RGSETNHYKR LAKSTLLLIP LFGIHYTVFA FSPEDAM..... EVQLFFEL
calcitonin ...ESHMYLK AVRATLILVP LLGVQFWLP WRPSTPLLGK IYDYWH...
Consensus R— E Y-K L-RSTL-LVP LFGVHY-VF- — P-T G----- Q-H-E-
501 550
PTH LFNSFQGFFV AIIYCFCNGE VQAEIRKSWS RWTLALDFKR KARSGSSSYS
secretin ALGSFQGLW AVLYCFLNGE VQLEVQKKWR QWHLQ.EFPL RPVAFNNSFS
calcitonin SLIHFQGFFV AIIYCFCNHE VQGALKRQWN QYQAQ... .R WAGRRSTRAA
Consensus -L-SFQGFFV AIIYCFCNGE VQ-E— K-W- QW-LQ— F-R -A S-S-S
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551
PTH YGPMVSHTSV TNVGPRAGLS 
secretin NflTNGPTHST KA.......S
calcitonin NAAAAIAAAA AALAETVEIP 
Consensus NA S— -A------ S
601
PTH TETLPVTMAV PKDDGFLNGS
secretin GLDI....... R*DGHLSDS
calcitonin VLEQETSA*T *RKYSIVTTE 
Consensus -L------- -R-DG-L— S
651
PTH GTRGLDCWPG HMDRWTKKPV
secretin ...... RSS RSRKRTHDLV
calcitonin IQ*IFPS....... *T*SKF
Consensus ----------  T-- V
600
LPLSPKLPPA TTNGHSQLPG HAKPGAPATE
TEQSRSIPRA SII*G CSK. .APADE
VYICHQEPRE EPAGEEPWE VEGVEVXAME 
 S P R A  G-S G — K— APA-E
650
CSGLD..EEA SGSARPPPLL QEEWETVM*L
HLVLDWLNRL VSRVRASSEI KQEETT___
SSLPGRKTNL ASKM..ISIL PGGNISFVRI 
-S-LD L -S— R— S-L — E— T---
700
FGWLSIGTGP GR*PKENGSG RSREEGRGFA
F.LVLLRRAI QQLQKGQG............
YLVLLLRETV SEWSLPLQPL *TPVNSIFHP 
F— LLLR--------K— G------------
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Alignment of full length amino acid coding sequences for the neuropeptide
receptors in group ii as assigned by peptide sequence homology in Table 2.46
1 50
NKl  ........................................  .........
NK3   IAVSFS FQSYLKTPAP
NK2 AHRLGTLCTS VIWDVP*IAL REI*IQIRVC HQLPECLLLD ASFL*LSAF* 
Consensus--------- ---------- ---------- ---------- ----------
51 100
NKl ....................................................
NK3 K*PGGR.......... EELQ RSLVLGCPWV SGKVRDCRFV AMATLPAAET
NK2 LWCEREEPIQ RATRMPPALR LEFEFSISKR CLNSLIGTLL PAQPDSFLPE
Consensus--------- ---------- ---------- ---------- — — ------
101 150
NKl  AALPAKM. DNVLPVDSDL
NK3 WIDGGGGVGA DAVNLTASLA A6AATGAVET GHLQLLDQA. GNLSSSPSAL
NK2 L*AWPSGYTC LLLNRPSPLK STHRRGFLFC GNSRRNCRAR PCVPGPESVM
Consensus ----- G------ N--- L - ---- G---  G-- L-- A- -NV--- S-L
NKl
151
•FPNTSTNTS
NK3 GLPVASPAPS
NK2 GTRAIVSDAN
Consensus G-P— S-- S
NKl
201
VWIWIILAH
NK3 LXVIWIILAH
NK2 ATVTWIILAH
Consensus — VTWIILAH
NKl
251
GLFYCKFHNF
NK3 ganycrfqnf
NK2 GRAFCYF®IL
Consensus G— YC-F®JF
NKl
301
IFVTWVLALL
NK3 IGSIWILAFL
NK2 IAGIWLVALA
Consensus I— IW-LALL
NKl
351
TVLIYFLPLL
NK3 IILVYCFPLL
NK2 FVLIYFLPLL
Consensus -VLIYFLPLL
NKl
401
MIVWCTFAI
NK3 MIIWMTFAI
NK2 MVLWLTFAI
Consensus MI-W-TFAI
NKl
451
YNPIIYCCLN
NK3 YNPIIYCCLN
NK2 YNPIIYCCLN
Consensus YNPIIYCCLN
NKl
501
YKVSRLETTI
NK3 YTVTRMESMT
NK2 ..VNRCHTKE
Consensus Y-V-R-ET—
E SNQ..... FVQPTW
QPWANLTNQ..... FVQPSW
ILSGLESNAT GVTAFSMPGW 
----- SNQ----- FVQP-W
KRMRTVTNYF LVNLAFAEAC 
KRMRTVTNYF LVNLAFSDAS 
ERMRTVTNYF UNLALADLC 
KRMRTVTNYF LVNLAFADAC
FPIAALFASI YSMTAVAFDR 
FPITAVFASI YSMTAIAVDR 
FPITAMFVSI YSMTAIAADR 
FPITA-FASI YSMTAIA-DR
LAFPQGYYST TETMPSRWC 
LAFPQCLYSK TKVMPGRTLC 
LASPQCFYST ITVDEGATKC 
LAFPQC-YST T-VMPGRT-C
VIGYAYTWG ITLWASEIP. 
IMGITYTIVG ITLWGGEIP. 
VMFGAYSVIG LTLWKRAVPR 
VMG-AYTWG ITLW— EIP-
CWLPFHIFFL LPYINPDLYL 
CWLPYHIYFI LTAIYQQLNR 
CWLPYHLYFI LGTFQEDIYY 
CWLPYHIYFI L— I— DLY-
DRFRLGFKHA FRCCPFISAG 
KRFRAGFKRA FRWCPFIKVS 
HRFRSGFRLA FRCCPWVTPT 
-RFR-GFK-A FRCCPFI--
STWGAHEDE PEEGPKATPS 
WFDPNDADT TRSSRKKRAT 
TLFMTGDMTH SEATNGQVGS 
— F-- D-D E K S
200
QIVLWAAAYT VIWTSWGN 
RIALWSLAYG VWAVAVLGN 
QLALWATAYL ALVLVAVTGN 
QIALWA-AY- V-V-VAV-GN
250
MAAFNTWNF TYAVHNVWYY 
MAAFNTLVNF IYALHSEWYF 
MAAFNATFNF IYASHNIWYF 
MAAFNT-VNF IYA-HN-WYF
300
YMAIIHPLQP RLSATATKW 
YMAIIDPLKP RLSATATKIV 
YMAIVHPFQP RLSAPSTKAI 
YMAIIHPLQP RLSATATK-V
350
MIEWPEHPNR TYEKAYHICV 
FVQWPEGPKQ HF..TYHIIV 
WAWPNDNGG KMLLLYHLW 
-V-WPE-P------- YHI-V
400
GDSSDRYHEQ VSAKRKWKM 
GDTCDKYHEQ LKAKRKWKM 
HQAHGANLRH LQAKKKFVKA 
GD— D-YHEQ L-AKRKWKM
450
KKFIQQVYLA SMWLAMSSTM 
WKYIQQVYLA SFWLAMSSTM 
HKFIQQVYLA LFWLAMSSTM 
-KFIQQVYLA SFWLAMSSTM
500
DYEGLEMKST RYLQT.QSSV 
SYDELELKTT RFHPNRQSSM
EEDRLELTHT PSLSRR___
-YD-LELK-T R-L— RQSS-
550
SLDLTSNGSS RSNS___ KT
PRDPSFNGCS RRNS___ KS
PQDGEPAGPI CKAQA*PL*E 
P-D NG-S R-NS K-
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551 600
NKl MTESSSFTSN ILA*AARHNM..............................
NK3 ASATSSFISS PYT SV DEYS*FHFLR *KI.   SVRPSWCQS.
NK2 AADGKAPT** LVPHPILQHT NRKNRMVLGM PQAIQVSTKN SEHRHLSQAI 
Consenstis A SSF-S---------- ---------- ----------  S------Q—
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Appendix U: Sequence Alignments
Alignment of full length amino acid coding sequences for the neuropeptide
receptors in group iii as assigned by peptide sequence homology in Table 2.46
1 50
TRH EFRRV*RNCR SED*ASAK*S SCQTDWTRFL LQDWKLGPIS TSSTRETGSV
neurotensin ............................... MHLNSSVPQG TPGEPDAQPF
neuropeptide Y .............................................*QSDAEGL
Consensus -------------------  :---P—  T DA--
TRH
neurotensin 
neuropeptide Y 
Consensus
51 100
TE*RGERTTA KTNRQKGEGW KDVLESPCQR SFKPLKMEND TVSEMNQTEL
SGPQSEMEAT FLALSLSNG SGNTSESDTA
SAFVAIASGE PAVTMEG ISIYTSDN YTEEMGSGDY
S-P— E---------- G----------------F— L— SN---- EM-S--
TRH
neurotensin 
neuropeptide Y 
Consensus
101 150
QP. .QAAVAL EYQWTILLV VIIC GL GIVGNIMWL WMRTK. . .H
GP..NSDLDV NTDIYSKVLV TAIYLALFW GTVGNSVTAF TLARKKSLQS 
DSMKEPCFRE ENANFNKEFE PTIYSIIFLT GIVGNGLVIL VMGYQK...K 
-P-------- E---- K-LV — IY--- F—  GIVGN— V-L V— R-K---
TRH
neurotensin 
neuropeptide Y 
Consensus
151 200
MRTPTNCYLV SLAVADLMVL VAAGLPNITD SIYG..SWVY GYVGCLCITY 
LQSTVHYHLG SLALSDLLIL LLAMPVELYN FIWVHHPWAF GDAGCRGYYF 
LRSMTDKYRL HLSVADLLFV ITLPFWAVDA VA....NWYF GNFLCKAVHV 
LRS-T— YL- SLAVADLL-L — A-------- 1----- W-F G— GC----
TRH
neurotensin 
neuropeptide Y 
Consensus
201 250
LQYLGINASS CSITAFTIER YIAICHPIKA QFLCTFSRAK KIIIFVWAFT 
LRDACTYATA LNVASLSVER YLAICHPFKA KTLMSRSRTK KFISAIWLAS
IYTVNLYSSV LILAFISLDR YLAIVHATNS Q RPR KLLAEKWYV
L YAS- L— A— S-ER YLAICHP-KA Q-L SR-K K-I W--
TRH
neurotensin 
neuropeptide Y 
Consensus
251 300
SIYCMLWFFL LDL NIS TYKNAWVSC GYKISRNYYS PIYLMD.FGV
ALLAIPMLFT MGLQNRSGDG THPGGLV..C TPIVDTATVK WIQVN.TFM 
GVWIPALLLT IPDFIFANVS EADDRYI..C DRFYPNDLW WFQFQHIMV 
-- LFT — L-------- N-S T--- V— C -----------W - Q ---- V
TRH
neurotensin 
neuropeptide Y 
Consensus
301 350
FYWPMILAT VLYGFIARIL FLNPIPSDPK ENSKMWKNDS IHQNKNLNLN 
SFLFPMLVIS ILNTVTANKL TV..MVHQAA EQGRVCTVGT HNGLEHSTFN
GLILPGIVIL SCYCIIISKL S.............................
 PMIVI--LY— IA-KL----------E------------------- N
351 400
TRH ATNRCFNSTV SSRKQVTKML AVWILFALL WMPYRTLVW NSFLSSPF. .
neurotensin MTIEP. .GRV QALRHGVLVL RAWIAFWC WLPYHVRRLM FCYISDEQ..
neuropeptide Y  HSKG HQKRKALKTT VILILAFFAC WLPYYIGISI DSFILLEIIK
Consensus -T S - V  R K-L — WIAF— C WLPY----- -SFIS-E---
TRH
neurotensin 
neuropeptide Y 
Consensus
401 450
QENWFLLFCR IC I YLNSAINFVI YNLMSQKFRA AFRK LC
WTTFLFDFYH YFYMLTNALF YVSSAINPIL YNLVSANFRQ VFLSTLACLC 
QGCEFENTVH KWISITEALA FFHCCLNPIL YAFLGAKFKT SAQHALTSVS 
Q F— F - H  T-AL- Y— SAINPIL YNL-SAKFR F L— LC
TRH
neurotensin 
neuropeptide Y 
Consensus
451 500
NCKQKPTEKA ANYSVALNYS VIKESDRFST ELEDIT..............
PGWRHRRKKR PTFSRKPN.. SMSSNHAFST SATRET*.............
RGSSLKILSR GKRGGHSSVS TESESSSFHS S*HRCKRLFF IR*ITFF*VT 
-G----- K---- S---N-S — SES— FST S— R-T--------------
501 550
TRH  VTDTYVST TKVSFDDTCL ASEN*RRP*R
neurotensin ....................................................
neuropeptide Y HFSDIKD*PI LYSFYCLLDF CLVFL*FL*S LIDLFI*IFF VSY*CVSRQD 
Consensus --------- ---------- — V----------  F-- -S--------
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Alignment of full length amino acid coding sequences for the neuropeptide
receptors in group iv as assigned by peptide sequence homology in Table 2.46
1 50
bombesin NCSQRDSV*D GGRKS*DKVG LILSFSSG*V SVAC*LSECT DVLLAGGVKA
endothlin ........................................... KLRTGHRTP
CCK ....................................................
Consensus --------- ---------- -------  — — L— G—-----
51 100
bombesin GTEPTSTN*A RVWNTSVCVC VCVCVCVCEF RVF*REZKRL TQISEPN*QT
endothlin SGAGSSMQPP PSLCGRALVA LVLACGLSRI WGEERGFPPD RA....
CCK  PQCLPR CSENGELKLP LGMAAKPTPG NLPLPAPPRQ VAFGRP_
Consensus  S— P- -S-NG V- L— A-- — FLR— PR- -A P---
101 150
bombesin FSA*LKNPEV TKQHLEGAFE ERSFEMAPNN CSHLNLDVDP FLSCN. .DTF
endothlin .TPLLQTAEI MTPPTKTLWP KGSNASLARS LAPAEVPKGD RTAGSPPRTI
CCK CDH*RRETGM SHSPARQHLV ESSRMDWDS LLMNGSNITP PCELGLENET
Consensus  L E -  P----- E-S- S L------- P -------- T-
151 200
bombesin NQSLSPPKMD NWFHPGFIYV IPAVYGLIIV IGLIGNITLI KIFCTVKSMR 
endothlin SPP. .PCQGP IEIKETFKYI NTWSCLVFV LGIIGNSTLL RIIYKNKCMR 
CCK LFCLDQPQPS KEWQSALQIL ...LYSIIFL LSVLGNTLVX TVLIRNKRMR 
Consensus  L-PPQ E F-Y VY-LIFV LG-IGN-TLI -I NK-MR
201 250
bombesin NVPNLFISSL ALGDLLLLVT CAPVDASKYL ADRWLFGRIG CKLIPFIQLT
endothlin NGPNILIASL ALGDLLHIVT DIPINVYKLL AEDWPFGAEM CKLVPFIQKA
CCK TVTNIFLLSL AVSDLMLCLF CMPFNLIPNL LKDFIFGSAV CKTTTYFMGT
Consensus NVPNIFI-SL ALGDLLL-V- C-P K-L A-DW-FG  CKL-PFIQ-T
251 300
bombesin SVGVSVFTLT ALSADRYKAI VRPMDIQASH ALMKICLKAA LIWXVSMLLA 
endothlin SVGITVLSLC ALSIDRYRAV ASWSRIKGIG VPKWTAVEIV LIWWSWLA 
CCK SVSVSTFNLV AISLERYGAI CRPLQSRVWQ TKSHALKVIA ATWCLSFTIM 
Consensus SVGVSVF-L- ALS-DRY-AI -RP— I IA LIW-VS— LA
301 350
bombesin IPEAVFSDLH PFHVKDTNQT FISCAPYPHS N..ELHPKIH SMASFLVFYV 
endothlin VPEAIGFDII TMDYKGSYLR ICLLHPVQKT AFMQFYKTAK DWWLFSFYFC 
CCK TPYPIYSNLV PFTKNNNQTA NMCRFLLPSD AMQQSWQT.. ..FLLLILFL 
Consensus -PEAI-SDL- PF— K  P A— Q----- --- LFL— F-
351 400
bombesin IPLAIISVYY YFIARNLIQ................................
endothlin LPLAITAFFY TLMTCEMLR................................
CCK LPGIVMWAY GLISLELYQG IKFDASQKKS AKEKKPSTGS STRYEDSDGC 
Consensus LPLAI— V-Y -LI— EL-Q---------------------------------
401 450
bombesin ...................  SAYNLPVEGN IHVKKQIESR KRLAKTVLVF
endothlin ................... KKSGMQIALN DHLKQ R REVAKTVFCL
CCK YLQKSRPPRK LELQQLSSGS GGSRLNRIRS SSSAANLIAK KRVIRMLIVI
Consensus ----------------------- S-L--- N -H-K---- R KRVAKTV-V-
451 500
bombesin VGLFAFCWLP NHVIYLYRSY HYSEVDTSM..... LHFVTS ICAHLLAFTN
endothlin VLVFALCWLP LHLSRILKLT LYNQNDPNRC ELLSFLLVLD YIGINMASLN
CCK WLFFLCWMP IFSANAWRAY DTVSAEKHLS GTPISFILL.......LSYTS
Consensus V-LFA-CWLP -H R-Y -Y D ----- V L - ------LAFTN
501 550
bombesin SCVNPFALYL LSKSFRKQFN TQLLC...........CQPGL MNRSHS..TG
endothlin SCINPIALYL VSKRFKNCFK SCLCC... .W CQSFEEKQSL EEKQSCLKFK
CCK SCVNPIIYCF MNKRFRLGFM ATFPCCPNPG PPGVRGEVGE EEDGRTIRAL
Consensus SCVNPIALYL -SKRFR— F- — L-C----- --------GL EE-------
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551 600
bombesin RSTTCMTSFK STNPSATFSL ZNRNICHEGY V*TKLQPCL* HNSWYCSTDV 
endothlin ANDHGYDNFR SSNKYSSS*K KNYSLYFIFF ILDRSH*NKM KHLPKQNKKL
CCK LSRYSYSHMS TSAPPP*TPP GPL........ ...................
Consensus -S--- Y— F- SSNP------- N------- ---------- -----------
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Alignment of full length amino acid coding sequences for the neuropeptide
receptors in group v as assigned by peptide sequence homology in Table Z46
1 50
angiotensin  PA LGGT*RSARG AGLIFDKLI *
bradykinin  RRVS STVGDGVAGS R*PWTEGLPT TC&SRLSREKD DPHSSLS*VQ
n-formyl peptide ....................................................
Consensus------- R—  — V------ ----- E— PA L S ---1--- I-
51 100
angiotensin NGWVFI.*IT H*CHPRKSAP GVFDIVFATN STQVIKMTLN SSTEDGIKRI
bradykinin MHCSWKRPVL LSVHEPMPTT ASLGIEMFNI TTQ ALG SAHNGTFSEV
n-formyl peptide  PRARPQLVN SPGADKMETN SSLPTNIS..
Consensus M----- I T --- H---------F-IV— TN STQ— KMAI2J SS-EDGI-RI
101 150
angiotensin QDDCPKAGRH NYIFVMIPTL ..YSIIFWG ZPGNSLWTV IYFYMKLKTV
bradykinin . .NCPDTEWW SWLNAIQAPF . .LWVLFLLA ALENIFVLSV FCLHKTNCTV
n-formyl peptide ..GGTPAVSA GYLFLDIITY LVFAVTFVLG VLGNGLVIWV AGFRMT.HTV
Consensus QDDCPKAGRH SY-FVMIPTL — YS-IFV-G I-GNSLWIV IYFYM-LKTV
angiotensin 
bradykinin 
n-formyl peptide 
Consensus
151 200
ASVFLLNLAL ADLCFLLTLP LWAVYTAMEY RWPPGNYLCK IASASVSFNL 
AEIYLGNLAA ADLILACGLP FWAITIANNF DWLFGEVLCR WNTMIYMNL 
TTISYLNLAV ADFCFTSTLP FFMVRKAMGG HWPFGWFLCK FLFTTVDINL 
AS-FLLNLAL ADLCFLLTLP -WAVYTAMEY RWPFGN-LCK IAS-SV-FNL
201 250
angiotensin YASVFLLTCL SIDRYLAIVH PMKSRLRRTM LVAKVTCIII WLLAGLASLP
bradykinin YSSICFLMLV SIDRYLALVK TMSMGRMRGV RWAKLYSLVI WSCTLLLSSP
n-formyl peptide FGSVFLIALI ALDRCVCVLH PVWTQNHRTV SLAKKVIIGP WVMALLLTLP
Consensus YASVFLLT—  SIDRYLAIVH PMKSRLRRT- LVAKVTCIII WLMA-L-SLP
251 300
angiotensin AIIHRNV..F FIENTNITVC AFHYESQNST..........  LPIGLGLTKN
bradykinin MLVFRTMKDY REEGHNVTAC VIVYPSRSWE..........  VFTNMLL..N
n-formyl peptide VIIRVTTVP. ..GKTGTVAC TFNFSPWTND PKERINVAVA MLTVRGIIRF
Consensus AIIHR-V— Y FIENTNIT-C AFHYESRNS-----------  L— GLGLTKN
angiotensin 
bradykinin 
n-formyl peptide 
Consensus
301 350
ILGFLFPFLI ILTSYTLIWK ALKKAYEIQK NKPRNDD..I FKIIMATVLF 
LVGFLLPLSI I.TFCTVRIM QVLRNNEMKK FKEVQTEKKA TVLVLAVLGL
IIGFSAPMSI VAVSYGLIAT KIHKQGLIKS SRP...... LRVLSFVAAA
I-GFLFPF-I ILTSYTLIWK A-KKAYEI-K NKPRNDD— I FRIIMA-VLF
angiotensin 
bradykinin 
n-formyl peptide 
Consensus
351 400
FFFSWIPHQI FTFLDVLIQL GIIRDCRIAD IVDTAMPITI CIAYFNNCLN 
FVLCWFPFQI STFLDTLLRL GVLSGCWNER AVDIVTQISS YVAYSNSCLN 
FFLCWSPYQV VALIATVRIR ELLQG..MYK EIGIAVDVTS ALAFFNSCLN 
FF— W-P-QI FTFLD-LIQL GV C-I-D IVD-AMPIT- CIAYFN-CLN
angiotensin 
bradykinin 
n-formyl peptide 
Consensus
401 450
PLFYGFLGKK FKRYFLQLLK YIPPKA.KSH SNLSTKMSTL SYRPSDN.-.
PLVYVIVGKR FRKKSREVYQ AICRKG.GCM GE............ SVQ. . .
PMLYVFMGQD FRERLIHALP ASLERALTED STQTSDTATN STLPSAEVAL 
PLFY-FLGKK F-KYFLQLLK -IPPKA-KSH S-LSTKMSTL SYRPSDN--
451 500
angiotensin ......... VSSSTKKPAP CFEVE*HVRN LSIK*FCERR SKRTFLCSTS
bradykinin ......... MENSMGTLRT SISVDRQIHK LQ.DWAGNKQ *TQAIGQDDC
n-formyl peptide QAK*GGSWGT LSSSQLQLRL TLS*AEHRHF LLILGLPTHQ KKKKSLCVP*
Consensus --------- MSSS-KK CF-VE— VH- L-I C SK-A-LCSD-
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Alignment o f full length amino acid coding sequences fo r  the neuropeptide
receptors in group vi as assigned by peptide sequence homology in Table 2.46
1 50
somatostatin DL* AAWF...*TE WKAAMEM...
d-opioid..........................SKGWV PAPRAHGGDG HGGAMELVPS
V I P .............................................. MDLHLF
Consensus --------- ---------- ---------- -A---------  AMEL--
51 100
somatostatin .SSEQLNGSQ VWVSSPFDLN GSLGPSNGSN ..QTEPYYDM TSNAVL___
d-opioid ARAELQSSPL VNLSDAFPSA FPSAGANASG SPGARSASSL .ALAIA...I
VIP DYAEPGNFSD ISWPC......... NSSDCI WDTVMCPNM PNKSVLLYTL
Consensus —  AE— N-S- V— S— F-------- SN-S---------- M ---AVL---
somatostatin
d-opioid
VIP
Consensus
101
TFIYFWCW 
TALYSAVCAV 
SFIYIFIFVI 
TFIY— V C W
GLCGNTLVIY
GLLGNVLVMF
GMIANSVWW
GL-GN-LV—
VILRYAKMKT
GIVRYTKLKT
VNIQAKTTGY
VI-RY-K-KT
ITNIYILNLA
ATNIYIFNLA
DTHCYILNLA
-TNIYILNLA
150
IADELFMLGL 
LADALATSTL 
IADLWWLTI 
IAD-L— LTL
151 200
somatostatin PFLAMQVALV . HWPFGKAIC RWMTVDGIN QFTSIFCLTV MSIDRYLAW
d-opioid PFQSAKY.LM ETWPFGELLC KAVLSIDYYN MFTSIFTLTM MSVDRYIAVC
VIP PVWWSLVQH NQWPMGELTC KVTHLIFSIN LFSGIFFLTC MSVDRYLSIT
Consensus PF----- L--- WPFGEL-C K W — ID-IN -FTSIF-LT- MSVDRYLAV-
201
somatostatin HPIKSAKWRR 
d-opioid HPVKALDFRT 
VIP YFTNTPSSRK 
Consensus HP-K R-
251
somatostatin NWPGESGA.. 
d-opioid QFPSPSWY.. 
VIP SFYPEHSIKE 
Consensus -FP-ES---
PRTAKMINVA VWCVSLLVIL 
PAKAKLINIC IWVLASGVGV 
KMVRRWCIL VWLLAFCVSL 
P— AK-INI- VW-LA— V-L
WYTGFIIYAF ILGFLVPLTI 
WDTVTKICVF LFAFWPILI 
WLIGMELVSV VLGFAVPFSI 
W-TG— I— F -LGF-VP— I
250
PIMLYAGLRS NQWGRSSCTI 
PIMVMAVTQP RD-GAWCML 
PDTYYLKTVT SASNNETYCR 
PIM-YA-T----- G---C—
300
ICLCYLFIII KVKSSGIRVG 
ITVCYGLMLL RLRSVRLLSG
IAVFYFLL..... ARAISAS
I— CY-L------------ G
somatostatin
d-opioid
VIP
Consensus
301
SSKRKKSEKK 
SKEKDRSLRR 
SDQEKHSSRK 
S K-S-RK
VTRMVSIWA 
ITRMVLVWG 
I. . .IFSYW 
ITRMV— W -
VFIFCWLPFY
AFWCWAPIH
VFLVCWLPYH
VF-VCWLP-H
IFNVSSVSVA 
IFVIVWTLVD 
VAVLLDIFSI 
IFV V-
350
I...... SP
IN..... RR
LHYIPFTCRL 
I------ R—
351
somatostatin TPALKGMFDF 
d-opioid DPLWAALHL 
VIP EHALFTALHV 
Consensus -PAL— ALH-
WILTYANTC ANPILYAFLS 
CIALGYANSS LNPVLYAFLD 
TQCLSLVHCC VNPVLYSFIN 
 L-YAN-C -NPVLYAFL-
400
DNFKKSFQNV LCLVKVSGTE 
ENFKRCFRQ. LCRTPCGRQE 
RNYRYELMKA FIFKYSAKTG 
-NFK— F LC----- TE
401 450
somatostatin DGERSDSKQD KSRLNETTET QRTLLNGDLQ TSI*TTQERN MHTH*PSPDS
d-opioid PGSLRRPRQA TTRERVTACT PSDGPGGGAA A*PTRPSP*T PLPSEVIQRP
VIP LTKLIDASRV SETEYSALEQ NAK..........................
Consensus -G-L-D — RE— T-ET------G------------ ----------
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Appendix III: Vectors
pT7Blue T-Vector Kit, R & D Systems
A vector specifically constructed for cloning of PCR products. Taq DNA polymerase 
leaves single 3' A-nucleotide overhangs on the reaction products (Clark eta l 1988). 
Therefore this vector contains compatible single T-nucleotide overhangs allowing 
direct ligation of the PCR product, but preventing self-ligation.
The vector comes ready prepared for ligation, by digestion with EcoRl followed by 
the addition of single 3' dT residues at each end. A positive control ligation fragment 
of 50bp with single 3’ dA end residues is provided.
pcDNA3 Mammalian Expression Vector, Invitrogen
A  5.4kb vector designed for high-level stable and transient expression in eukaryotic 
hosts. It contains the cytomegalovirus (CMV) promoter which gives high-level 
expression in a wide range of mammalian cells; a multiple cloning site polylinker; the 
bovine growth hormone (BGH) polyadenylation signal for polyadenylation of 
transcribed mRNAs; the neomycin resistance marker for the selection of stable 
transformants in the presence of G418. The vector also contains an SV40 origin and 
therefore will only replicate episomally in cell lines which express the SV40 large T 
antigen.
The positive control for transfection and expression is pcDNA3 with the 800bp 
chloramphenicol acetyl transferase (CAT) gene cloned into the Hindlll site of the 
polylinker.
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Appendix IV
Codes for nucleotide sequence degeneracy (chapter 3)
M = A or C 
K = G or T 
N = A, C, G or T 
R = A or G 
Y = C or T 
W =AorT  
S = G or C 
D = A, G or T 
H = A, C or T
Ikb Marker (Gibco BRL) (chapters 3 & 4)
abcdef g h i j k 1 m n opq r s
a 12 000 bp
b 11000 bp
c 10 000 bp
d 9 000 bp
e 8 000 bp
f 7 000 bp
g 6 000 bp
h 5 000 bp
i 4 000 bp
j 3 000 bp
k 2 000 bp
1 1 600 bp
m 1 000 bp
n 500 bp
0 400 bp
P 350 bp
q 300 bp
r 200 bp
s 100 bp
Calculation o f Standard Error o f the Mean (chapter 5)
Standard Deviation = Z (x'-X)2
n-l
Standard Error of the Mean = S.D 
(S.E.M.) n
where
n = number of saturation assays 
x'= individual value 
x = mean value
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